
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="15251A868AEED503051A8600256049B2.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361847/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Inherited Metabolic Disease">
<meta name="citation_title" content="Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases">
<meta name="citation_author" content="Sonam Gurung">
<meta name="citation_author_institution" content="Great Ormond Street Institute of Child Health, University College London, London, UK">
<meta name="citation_author_institution" content="National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK">
<meta name="citation_author" content="Dany Perocheau">
<meta name="citation_author_institution" content="Great Ormond Street Institute of Child Health, University College London, London, UK">
<meta name="citation_author" content="Roopkatha Ghosh">
<meta name="citation_author_institution" content="Great Ormond Street Institute of Child Health, University College London, London, UK">
<meta name="citation_author_institution" content="National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK">
<meta name="citation_author" content="Stephen L Hart">
<meta name="citation_author_institution" content="Great Ormond Street Institute of Child Health, University College London, London, UK">
<meta name="citation_author_institution" content="National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK">
<meta name="citation_author" content="Julien Baruteau">
<meta name="citation_author_institution" content="Great Ormond Street Institute of Child Health, University College London, London, UK">
<meta name="citation_author_institution" content="National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK">
<meta name="citation_author_institution" content="Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK">
<meta name="citation_publication_date" content="2025 Aug 18">
<meta name="citation_volume" content="48">
<meta name="citation_issue" content="5">
<meta name="citation_firstpage" content="e70078">
<meta name="citation_doi" content="10.1002/jimd.70078">
<meta name="citation_pmid" content="40826824">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361847/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361847/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361847/pdf/JIMD-48-0.pdf">
<meta name="description" content="mRNA encapsulated in lipid nanoparticles (LNPs) provides a dual revolution in the field of gene therapy. mRNA brings fleeting efficacy and the possibility to adjust the therapy to clinical needs. LNP, as a non‐viral vehicle with flexible ...">
<meta name="og:title" content="Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="mRNA encapsulated in lipid nanoparticles (LNPs) provides a dual revolution in the field of gene therapy. mRNA brings fleeting efficacy and the possibility to adjust the therapy to clinical needs. LNP, as a non‐viral vehicle with flexible ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361847/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12361847">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/jimd.70078"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/JIMD-48-0.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12361847%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12361847/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12361847/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361847/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/jimd.70078" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Inherit Metab Dis</button></div>. 2025 Aug 18;48(5):e70078. doi: <a href="https://doi.org/10.1002/jimd.70078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/jimd.70078</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Inherit%20Metab%20Dis%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Inherit%20Metab%20Dis%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Inherit%20Metab%20Dis%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Inherit%20Metab%20Dis%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gurung%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Sonam Gurung</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Sonam Gurung</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Great Ormond Street Institute of Child Health, University College London, London, UK</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gurung%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sonam Gurung</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Perocheau%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Dany Perocheau</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Dany Perocheau</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Great Ormond Street Institute of Child Health, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Perocheau%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dany Perocheau</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ghosh%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Roopkatha Ghosh</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Roopkatha Ghosh</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Great Ormond Street Institute of Child Health, University College London, London, UK</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ghosh%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Roopkatha Ghosh</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hart%20SL%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Stephen L Hart</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Stephen L Hart</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Great Ormond Street Institute of Child Health, University College London, London, UK</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hart%20SL%22%5BAuthor%5D" class="usa-link"><span class="name western">Stephen L Hart</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Baruteau%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Julien Baruteau</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Julien Baruteau</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Great Ormond Street Institute of Child Health, University College London, London, UK</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK</div>
<div class="p">
<sup>
<sup>3</sup>
</sup>Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Baruteau%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Julien Baruteau</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="jimd70078-aff-0001">
<sup>
<sup>1</sup>
</sup>Great Ormond Street Institute of Child Health, University College London, London, UK</div>
<div id="jimd70078-aff-0002">
<sup>
<sup>2</sup>
</sup>National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK</div>
<div id="jimd70078-aff-0003">
<sup>
<sup>3</sup>
</sup>Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong>
 
Julien Baruteau (<span>j.baruteau@ucl.ac.uk</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 11; Received 2025 Feb 11; Accepted 2025 Jul 30; Issue date 2025 Sep.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Journal of Inherited Metabolic Disease</em> published by John Wiley &amp; Sons Ltd on behalf of SSIEM.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12361847  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40826824/" class="usa-link">40826824</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>mRNA encapsulated in lipid nanoparticles (LNPs) provides a dual revolution in the field of gene therapy. mRNA brings fleeting efficacy and the possibility to adjust the therapy to clinical needs. LNP, as a non‐viral vehicle with flexible organ‐targeting, overcomes most immune complications of viral gene therapy. mRNA‐LNP has rapidly progressed from preventive medicine and vaccine applications to therapeutic use, especially in inherited metabolic diseases (IMDs). Given their natural tropism for liver uptake, this platform has been utilised successfully in numerous preclinical programmes. Early phase clinical trials are recruiting to assess safety and efficacy in liver IMDs. Here, we provide the latest update on mRNA and LNP technologies, preclinical studies and clinical trials targeting IMDs, safety considerations with a spotlight on infusion‐related reactions and safety modelling. We discuss the future directions of therapeutic mRNA‐LNP in IMDs and the right clinical use of this adjustable therapy, still to be defined. The versatility of this technology is appealing, with multiple clinical applications as bridge, long‐term cure, rescue, or adjuvant therapy. mRNA‐LNP for gene editing/insertion is an alternative approach for one‐off cure. Translating various successful preclinical programmes in patients remains an unsolved limitation. mRNA‐LNP can be tuned according to the patient's needs and is the next step in personalised medicine and individualised gene therapy.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> gene therapy, inherited metabolic diseases, lipid nanoparticle, liver, mRNA</p></section></section><section id="jimd70078-sec-0001"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>RNA‐based therapies exploit RNA interference (RNAi), antisense oligonucleotides (ASO) or messenger RNA (mRNA) to modify gene expression and alleviate disease phenotypes. They represent more than 400 programmes, 35 approved drug products and $60 billion in market capitalisation, a figure expected to double in the next 5 years [<a href="#jimd70078-bib-0001" class="usa-link" aria-describedby="jimd70078-bib-0001">1</a>, <a href="#jimd70078-bib-0002" class="usa-link" aria-describedby="jimd70078-bib-0002">2</a>, <a href="#jimd70078-bib-0003" class="usa-link" aria-describedby="jimd70078-bib-0003">3</a>]. Among these different RNA technologies, mRNA is the one showing the most rapidly expanding growth, targeting mainly non‐cancerous rare diseases [<a href="#jimd70078-bib-0003" class="usa-link" aria-describedby="jimd70078-bib-0003">3</a>, <a href="#jimd70078-bib-0004" class="usa-link" aria-describedby="jimd70078-bib-0004">4</a>, <a href="#jimd70078-bib-0005" class="usa-link" aria-describedby="jimd70078-bib-0005">5</a>, <a href="#jimd70078-bib-0006" class="usa-link" aria-describedby="jimd70078-bib-0006">6</a>, <a href="#jimd70078-bib-0007" class="usa-link" aria-describedby="jimd70078-bib-0007">7</a>]. One third of these mRNA programmes has now reached clinical stage [<a href="#jimd70078-bib-0001" class="usa-link" aria-describedby="jimd70078-bib-0001">1</a>]. Uplifted by the unprecedented success of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), mRNA‐based therapeutics have demonstrated their groundbreaking ability to act as an efficacious and safe technology platform for human use [<a href="#jimd70078-bib-0008" class="usa-link" aria-describedby="jimd70078-bib-0008">8</a>, <a href="#jimd70078-bib-0009" class="usa-link" aria-describedby="jimd70078-bib-0009">9</a>]. Building on decades of research since mRNA discovery in 1961, enhanced stability, safety and ribosomal translational efficacy have permitted the use of mRNA as a therapeutic modality in humans [<a href="#jimd70078-bib-0004" class="usa-link" aria-describedby="jimd70078-bib-0004">4</a>, <a href="#jimd70078-bib-0005" class="usa-link" aria-describedby="jimd70078-bib-0005">5</a>].</p>
<p>Inherited metabolic diseases (IMDs) are a group of rare monogenic disorders with a cumulative reported incidence of approximately 1 in 2000 live births, with variable incidence according to geographic locations [<a href="#jimd70078-bib-0010" class="usa-link" aria-describedby="jimd70078-bib-0010">10</a>, <a href="#jimd70078-bib-0011" class="usa-link" aria-describedby="jimd70078-bib-0011">11</a>]. In most IMDs, therapeutic strategies primarily focus on symptom management rather than addressing the underlying cause, resulting in high mortality and morbidity rates and a compromised quality of life [<a href="#jimd70078-bib-0012" class="usa-link" aria-describedby="jimd70078-bib-0012">12</a>]. For some liver IMDs, liver transplantation can be a cure at the expense of procedure‐related morbidity and lifelong immunosuppression. Liver‐directed adeno‐associated viral (AAV) gene therapy has been approved for liver monogenic diseases [<a href="#jimd70078-bib-0013" class="usa-link" aria-describedby="jimd70078-bib-0013">13</a>, <a href="#jimd70078-bib-0014" class="usa-link" aria-describedby="jimd70078-bib-0014">14</a>, <a href="#jimd70078-bib-0015" class="usa-link" aria-describedby="jimd70078-bib-0015">15</a>] and has progressed to phase III clinical trials for liver IMDs [<a href="#jimd70078-bib-0016" class="usa-link" aria-describedby="jimd70078-bib-0016">16</a>]. However, immunogenicity and transient efficacy in the paediatric liver limit its use in patients with the most unmet needs in infantile and juvenile populations [<a href="#jimd70078-bib-0017" class="usa-link" aria-describedby="jimd70078-bib-0017">17</a>]. mRNA encapsulated in lipid nanoparticle (LNP) holds promise for liver‐targeting therapies due to its absence of sustained immunogenicity and the natural tropism of some LNP for the liver, facilitated by the opsonisation of LNP by serum proteins, especially apolipoprotein E (ApoE), which mediates hepatocyte endocytosis via very low‐density lipoprotein receptor (VLDLR) [<a href="#jimd70078-bib-0018" class="usa-link" aria-describedby="jimd70078-bib-0018">18</a>, <a href="#jimd70078-bib-0019" class="usa-link" aria-describedby="jimd70078-bib-0019">19</a>]. These properties position LNP as a highly effective delivery platform for treating liver IMDs [<a href="#jimd70078-bib-0020" class="usa-link" aria-describedby="jimd70078-bib-0020">20</a>]. Building on these advantages, several preclinical in vivo proof‐of‐concept studies have explored mRNA‐LNP therapies for liver IMDs, progressing towards early phase clinical trials [<a href="#jimd70078-bib-0021" class="usa-link" aria-describedby="jimd70078-bib-0021">21</a>].</p>
<p>In this review, we discuss the latest developments of mRNA‐LNP therapy and its applications in targeting IMDs at both preclinical and clinical stages. We highlight safety considerations based on recent studies and provide insights into mRNA‐LNP in the future therapeutic landscape of IMDs, assessing their potential as a long‐term solution or bridging therapy.</p></section><section id="jimd70078-sec-0002"><h2 class="pmc_sec_title">2. The Toolbox: mRNA and LNP Technologies for Therapeutic Use</h2>
<p>The clinical development of mRNA therapies has been greatly facilitated by advancements in mRNA engineering [<a href="#jimd70078-bib-0022" class="usa-link" aria-describedby="jimd70078-bib-0022">22</a>] and in vitro transcription (IVT), enabling the production of synthetic and chemically modified mRNA that closely mimic endogenous mRNA [<a href="#jimd70078-bib-0023" class="usa-link" aria-describedby="jimd70078-bib-0023">23</a>, <a href="#jimd70078-bib-0024" class="usa-link" aria-describedby="jimd70078-bib-0024">24</a>]. IVT mRNA eliminates the need for costly protein manufacturing and allows simple and cost‐effective production [<a href="#jimd70078-bib-0024" class="usa-link" aria-describedby="jimd70078-bib-0024">24</a>]. It also overcomes key challenges of gene therapies, offering higher transfection efficiency, bypassing the need for nuclear transport and eliminating the risk of infection or insertional mutagenesis [<a href="#jimd70078-bib-0005" class="usa-link" aria-describedby="jimd70078-bib-0005">5</a>].</p>
<p>Engineered or IVT mRNA is a single‐stranded nucleic acid, which comprises: (i) a 5′ end cap, critical for mRNA stability and translation, (ii) a 5′ untranslated region (UTR), (iii) a coding sequence which starts with the Kozak sequence recognised by the ribosome to initiate translation and ends with a stop codon, (iv) a 3′UTR involved in mRNA stability and translational efficacy and (v) a poly(A) tail to protect the mRNA from degradation (Figure <a href="#jimd70078-fig-0001" class="usa-link">1</a>) [<a href="#jimd70078-bib-0025" class="usa-link" aria-describedby="jimd70078-bib-0025">25</a>]. Chemical engineering with methylation of mRNA nucleotides, such as N<sup>1</sup>‐methylpseudouridine (m<sup>1</sup>ψ) [<a href="#jimd70078-bib-0026" class="usa-link" aria-describedby="jimd70078-bib-0026">26</a>, <a href="#jimd70078-bib-0027" class="usa-link" aria-describedby="jimd70078-bib-0027">27</a>, <a href="#jimd70078-bib-0028" class="usa-link" aria-describedby="jimd70078-bib-0028">28</a>] or 5‐methylcytidine [<a href="#jimd70078-bib-0029" class="usa-link" aria-describedby="jimd70078-bib-0029">29</a>, <a href="#jimd70078-bib-0030" class="usa-link" aria-describedby="jimd70078-bib-0030">30</a>], improves stability and reduces immunogenicity. This seminal discovery led to Katalin Karikó's and Drew Weissman's Nobel Prize in Physiology or Medicine awarded in 2023 [<a href="#jimd70078-bib-0031" class="usa-link" aria-describedby="jimd70078-bib-0031">31</a>]. To limit costly production of modified nucleotides and a theoretical risk of amino acid misincorporation due to modified bases, novel approaches have been developed to synthesise IVT mRNA with unmodified bases and an additional Watson‐Crick base pairing RNA/DNA sequence. The RNA/DNA sequence called Additional Chimeric Element can modulate immunogenicity [<a href="#jimd70078-bib-0032" class="usa-link" aria-describedby="jimd70078-bib-0032">32</a>]. Beyond nucleoside chemistry, all IVT mRNA parts can be optimised to increase half‐life, ribosomal entry and protein synthesis. Eukaryotic mRNA requires a 5′‐cap, which protects mRNA from cleavage by nucleases, playing a crucial role in mRNA stability and is essential for the initiation of mRNA translation [<a href="#jimd70078-bib-0033" class="usa-link" aria-describedby="jimd70078-bib-0033">33</a>]. This is usually achieved by the incorporation of a modified guanosine nucleotide, 7‐Methylguanosine (<sup>m7</sup>G), linked to the first transcribed nucleotide by a triphosphate bridge [<a href="#jimd70078-bib-0034" class="usa-link" aria-describedby="jimd70078-bib-0034">34</a>]. This modification is known as Cap 0 (<sup>m7</sup>GpppN). A methylation of the 2′‐O position of the first cap‐proximal nucleotide forms Cap1 (<sup>m7</sup>GpppN<sub>m</sub>N), whilst a 2′‐O methylation of the next second‐cap proximal nucleotide forms Cap2 (<sup>m7</sup>GpppN<sub>m</sub>N<sub>m</sub>) [<a href="#jimd70078-bib-0033" class="usa-link" aria-describedby="jimd70078-bib-0033">33</a>]. However, the production of IVT mRNA can sometimes lead to capping errors where modified nucleosides can sometimes be erroneously incorporated not on the 5′ end but on the 3′ end [<a href="#jimd70078-bib-0035" class="usa-link" aria-describedby="jimd70078-bib-0035">35</a>]. These mRNA have shorter half‐lives. To prevent this, an anti‐reverse cap analogue (ARCA) strategy has been developed. Specific modifications of nucleotides will prevent their incorporation at the 3′ end. This is for instance the case by adding a methoxy group (OCH3) at the C3′ position of a <sup>m7</sup>G (m<sub>2</sub>
<sup>7,3′‐O</sup>GP<sub>3</sub>G), which hinders the RNA polymerase from adding the cap in the reverse direction. ARCA are essential for producing high‐quality mRNA and include various cap dinucleotides like m<sub>2</sub>
<sup>7,3′‐O</sup>GP<sub>3</sub>G (m(7)3′dGp(3)G or m(2)(7,3′‐)(O)Gp(3)G) [<a href="#jimd70078-bib-0036" class="usa-link" aria-describedby="jimd70078-bib-0036">36</a>, <a href="#jimd70078-bib-0037" class="usa-link" aria-describedby="jimd70078-bib-0037">37</a>].</p>
<figure class="fig xbox font-sm" id="jimd70078-fig-0001"><h3 class="obj_head">FIGURE 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebd/12361847/3761d938844d/JIMD-48-0-g001.jpg" loading="lazy" id="jats-graphic-1" height="351" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/jimd70078-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>mRNA‐LNP engineering. Each section of the mRNA sequence can be engineered to optimise stability, efficacy and safety. The composition of LNP through lipid chemistry, ratios, and exterior motifs can be optimised to increase targeting, half‐life, and safety. A, adenine nucleotide; LNP, lipid nanoparticle; m<sup>7</sup>G, m<sup>7</sup>methylguanosine; miRNA, microRNA; P, phosphate; PEG, polyethylene glycol; UTR, untranslated region.</p></figcaption></figure><p>mRNA stability and translation can also be improved by optimising the 5′ and 3′ UTRs. UTR sequences from highly expressed genes such as human β‐Globin [<a href="#jimd70078-bib-0038" class="usa-link" aria-describedby="jimd70078-bib-0038">38</a>] are commonly used alongside engineered synthetic sequences designed via bioinformatic tools [<a href="#jimd70078-bib-0039" class="usa-link" aria-describedby="jimd70078-bib-0039">39</a>]. Codon optimisation of the mRNA open reading frame coding sequence is crucial for transcriptional activity [<a href="#jimd70078-bib-0040" class="usa-link" aria-describedby="jimd70078-bib-0040">40</a>]. The amino acid sequence of the protein of interest can also be optimised to increase the half‐life and the catalytic efficacy of a transgenic enzyme [<a href="#jimd70078-bib-0041" class="usa-link" aria-describedby="jimd70078-bib-0041">41</a>, <a href="#jimd70078-bib-0042" class="usa-link" aria-describedby="jimd70078-bib-0042">42</a>]. The poly(A) tail, exposed to exonucleases and deadenylation, can reduce stability and translation capacity if shortened [<a href="#jimd70078-bib-0043" class="usa-link" aria-describedby="jimd70078-bib-0043">43</a>]. Poly(A) tail engineering by introducing chemical modifications, site‐specific exonucleases‐resistant modifications, or even multiple branched‐chain synthetic poly(A) tails have significantly increased half‐life [<a href="#jimd70078-bib-0044" class="usa-link" aria-describedby="jimd70078-bib-0044">44</a>, <a href="#jimd70078-bib-0045" class="usa-link" aria-describedby="jimd70078-bib-0045">45</a>]. Scalable manufacturing processes and adequate purification methods are essential to obtain translational titres, reproducible batches and non‐immunogenic mRNA‐LNP material.</p>
<p>An effective delivery system is required to encapsulate and protect the mRNA payload, enhance its bioavailability, and ensure its precise delivery [<a href="#jimd70078-bib-0005" class="usa-link" aria-describedby="jimd70078-bib-0005">5</a>, <a href="#jimd70078-bib-0023" class="usa-link" aria-describedby="jimd70078-bib-0023">23</a>]. Non‐viral vectors, particularly engineered LNP, are highly versatile delivery systems and the most widely used non‐viral platform for mRNA delivery [<a href="#jimd70078-bib-0046" class="usa-link" aria-describedby="jimd70078-bib-0046">46</a>, <a href="#jimd70078-bib-0047" class="usa-link" aria-describedby="jimd70078-bib-0047">47</a>]. LNP were used in the development of the mRNA‐based vaccines against SARS‐CoV‐2 by Pfizer‐BioNTech (Comirnaty) and Moderna (Spikevax), both of which demonstrated over 94% efficacy at preventing symptomatic disease in phase III clinical trials [<a href="#jimd70078-bib-0008" class="usa-link" aria-describedby="jimd70078-bib-0008">8</a>, <a href="#jimd70078-bib-0009" class="usa-link" aria-describedby="jimd70078-bib-0009">9</a>]. The advantages of this delivery system include simple formulation, high biocompatibility, high payload capacity, efficient delivery and quick clearance [<a href="#jimd70078-bib-0048" class="usa-link" aria-describedby="jimd70078-bib-0048">48</a>]. Advancements in LNP engineering and microfluidic technology have further enhanced their safety, efficacy and scalability and have widened their range of applications [<a href="#jimd70078-bib-0049" class="usa-link" aria-describedby="jimd70078-bib-0049">49</a>, <a href="#jimd70078-bib-0050" class="usa-link" aria-describedby="jimd70078-bib-0050">50</a>]. The first drug approvals of LNP delivering siRNA have paved the translational way of RNA‐based therapy [<a href="#jimd70078-bib-0051" class="usa-link" aria-describedby="jimd70078-bib-0051">51</a>], currently followed by a rapid expansion of programmes using mRNA as payload, broadening applications for vaccines, protein replacement therapies, or gene editing [<a href="#jimd70078-bib-0007" class="usa-link" aria-describedby="jimd70078-bib-0007">7</a>, <a href="#jimd70078-bib-0052" class="usa-link" aria-describedby="jimd70078-bib-0052">52</a>, <a href="#jimd70078-bib-0053" class="usa-link" aria-describedby="jimd70078-bib-0053">53</a>].</p>
<p>LNP have improved significantly from simple liposomes to engineered and sophisticated systems. LNP play the roles of physically protecting their cargo and delivering it into the cytosol via the endosomal pathway [<a href="#jimd70078-bib-0047" class="usa-link" aria-describedby="jimd70078-bib-0047">47</a>]. These nanoparticles, sized less than 1 μm in diameter, are formed by four main types of lipids: ionisable lipids, helper lipids, polyethylene glycol (PEG) lipids and cholesterol, and can carry various cargoes including nucleic acids. LNP are taken up by endocytosis via electrostatic fusion with the cell membrane, but also by clathrin‐mediated endocytosis and macropinocytosis [<a href="#jimd70078-bib-0054" class="usa-link" aria-describedby="jimd70078-bib-0054">54</a>, <a href="#jimd70078-bib-0055" class="usa-link" aria-describedby="jimd70078-bib-0055">55</a>, <a href="#jimd70078-bib-0056" class="usa-link" aria-describedby="jimd70078-bib-0056">56</a>].</p>
<p>The technology of lipid and polymeric nanoparticles has swiftly progressed in the past two decades. Initial nanoparticle formulations involved the use of cationic liposomes [<a href="#jimd70078-bib-0057" class="usa-link" aria-describedby="jimd70078-bib-0057">57</a>]. The development of “pH‐variable lipids” or ionisable lipids came as a breakthrough and an alternative to permanently charged cationic lipids, which were prone to rapid elimination and a toxic profile triggering immunogenicity [<a href="#jimd70078-bib-0047" class="usa-link" aria-describedby="jimd70078-bib-0047">47</a>, <a href="#jimd70078-bib-0051" class="usa-link" aria-describedby="jimd70078-bib-0051">51</a>, <a href="#jimd70078-bib-0058" class="usa-link" aria-describedby="jimd70078-bib-0058">58</a>]. Ionisable lipids are positively charged at acidic pH, allowing them to condense mRNA into LNP but are neutral at physiological pH, minimising toxicity. This neutral charge allows a reduction of the protein corona; thereby, facilitating blood clearance and pharmacokinetics, tissue biodistribution and limiting uptake by the reticuloendothelial system (RES) [<a href="#jimd70078-bib-0047" class="usa-link" aria-describedby="jimd70078-bib-0047">47</a>, <a href="#jimd70078-bib-0059" class="usa-link" aria-describedby="jimd70078-bib-0059">59</a>]. They become protonated during the acidification process of endosomes and interact with anionic endosomal phospholipids, which facilitates conformational changes, membrane fusion/disruption, endosomal escape and cargo release in the cytosol [<a href="#jimd70078-bib-0060" class="usa-link" aria-describedby="jimd70078-bib-0060">60</a>]. Ionisable lipids are recognised as essential for both the encapsulation of negatively charged mRNA and for their optimal release into the cytosol following the fusion of the LNP with the endosomal cell membrane.</p>
<p>Helper lipids are phospholipids acting as stabilisers of the lipid bilayer structure [<a href="#jimd70078-bib-0061" class="usa-link" aria-describedby="jimd70078-bib-0061">61</a>, <a href="#jimd70078-bib-0062" class="usa-link" aria-describedby="jimd70078-bib-0062">62</a>]. The two predominant phospholipids used in LNP are 1,2‐distearoyl‐sn‐glycero‐3‐phosphocholine (DSPC) and 1,2‐dioleoyl‐sn‐glycero‐3‐phosphoethanolamine (DOPE). DSPC, a saturated lipid, increases pharmacokinetics; while the unsaturated DOPE, a fusogenic lipid [<a href="#jimd70078-bib-0061" class="usa-link" aria-describedby="jimd70078-bib-0061">61</a>], facilitates endosomal escape [<a href="#jimd70078-bib-0063" class="usa-link" aria-describedby="jimd70078-bib-0063">63</a>].</p>
<p>Pegylated lipids consist of a hydrophobic lipid anchor, buried into the particle membrane and a hydrophilic PEG polymer on the LNP surface. The PEG domain acts as a shield against surface residual charges, preventing opsonisation in the bloodstream [<a href="#jimd70078-bib-0063" class="usa-link" aria-describedby="jimd70078-bib-0063">63</a>], thereby reducing LNP blood clearance [<a href="#jimd70078-bib-0061" class="usa-link" aria-describedby="jimd70078-bib-0061">61</a>].</p>
<p>Cholesterol increases pharmacokinetics by reducing the amount of surface‐bound protein and serum opsonins [<a href="#jimd70078-bib-0064" class="usa-link" aria-describedby="jimd70078-bib-0064">64</a>]. Modification of the cholesterol tail structure can enhance transfection by facilitating membrane fusion [<a href="#jimd70078-bib-0062" class="usa-link" aria-describedby="jimd70078-bib-0062">62</a>, <a href="#jimd70078-bib-0065" class="usa-link" aria-describedby="jimd70078-bib-0065">65</a>, <a href="#jimd70078-bib-0066" class="usa-link" aria-describedby="jimd70078-bib-0066">66</a>]. The biochemical formulation of each lipid component and its respective ratios will influence the LNP size, surface charge, mRNA encapsulation efficacy, tissue targeting and cytoplasmic release. Adding peptide‐targeting ligands at the LNP surface can facilitate on‐target biodistribution [<a href="#jimd70078-bib-0067" class="usa-link" aria-describedby="jimd70078-bib-0067">67</a>].</p>
<p>Using mRNA‐LNP to provide long‐term therapy for genetic diseases represents a full change of paradigm compared to the application of this technology for vaccines. If immunisations require the infrequent administration of a limited amount of a highly immunogenic antigenic epitope, treating inherited diseases requires the regular administration of a high dose of a non‐immunogenic transgenic protein. Differences in dose, route of administration and pattern of injection highlight the specificities between these different indications (Table <a href="#jimd70078-tbl-0001" class="usa-link">1</a>). Designing mRNA‐LNP constructs for human translation requires optimisation of various parameters: LNP, mRNA, transgenic protein and manufacturing (Figure <a href="#jimd70078-fig-0001" class="usa-link">1</a>). Combinatorial high‐throughput screening of these variables can now be performed at large scale [<a href="#jimd70078-bib-0068" class="usa-link" aria-describedby="jimd70078-bib-0068">68</a>].</p>
<section class="tw xbox font-sm" id="jimd70078-tbl-0001"><h3 class="obj_head">TABLE 1.</h3>
<div class="caption p"><p>Comparison of mRNA‐LNP technology used for preventive and therapeutic medicine.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="2" valign="bottom" rowspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Vaccines</th>
<th align="center" colspan="2" valign="bottom" rowspan="1">Therapeutics</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" colspan="2" valign="top" rowspan="1">Application</td>
<td align="center" valign="top" rowspan="1" colspan="1">Immune protection</td>
<td align="center" valign="top" rowspan="1" colspan="1">Enzyme replacement</td>
<td align="center" valign="top" rowspan="1" colspan="1">Editing</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top" rowspan="1">Protein expression</td>
<td align="center" valign="top" rowspan="1" colspan="1">Low</td>
<td align="center" colspan="2" valign="top" rowspan="1">High</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top" rowspan="1">Immunogenicity</td>
<td align="center" valign="top" rowspan="1" colspan="1">Required</td>
<td align="center" colspan="2" valign="top" rowspan="1">None</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top" rowspan="1">Tropism</td>
<td align="center" valign="top" rowspan="1" colspan="1">Not required</td>
<td align="center" colspan="2" valign="top" rowspan="1">Cell‐/‐tissue specific</td>
</tr>
<tr>
<td align="left" rowspan="3" valign="top" colspan="1">Delivery</td>
<td align="center" valign="top" rowspan="1" colspan="1">Route</td>
<td align="center" valign="top" rowspan="1" colspan="1">Intramuscular</td>
<td align="center" colspan="2" valign="top" rowspan="1">Direct or Systemic</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Pattern</td>
<td align="center" valign="top" rowspan="1" colspan="1">Few times</td>
<td align="center" valign="top" rowspan="1" colspan="1">Long‐term</td>
<td align="center" valign="top" rowspan="1" colspan="1">One‐off</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Dose (per injection)</td>
<td align="center" valign="top" rowspan="1" colspan="1">50–100 μg</td>
<td align="center" valign="top" rowspan="1" colspan="1">300‐900 μg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">100‐300 μg/kg</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top" rowspan="1">Optimisation</td>
<td align="center" valign="top" rowspan="1" colspan="1">Amplification</td>
<td align="center" valign="top" rowspan="1" colspan="1">Increased signal, stability, half‐life</td>
<td align="center" valign="top" rowspan="1" colspan="1">On‐target biodistribution</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/jimd70078-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>For human liver applications for IMDs, the differential expression of metabolic pathways through the hepatic lobule called metabolic zonation is of particular importance for cell‐autonomous diseases, in which protein is not secreted [<a href="#jimd70078-bib-0069" class="usa-link" aria-describedby="jimd70078-bib-0069">69</a>]. Tackling this challenge requires the transduction of as many hepatocytes as possible, preferably in the metabolic zone where the deficient protein is physiologically expressed. As an example, the urea cycle is expressed in periportal hepatocytes. Interestingly, LNP transfection has been observed either preferentially in periportal hepatocytes in arginase‐ or ornithine transcarbamylase (OTC)‐deficient mice [<a href="#jimd70078-bib-0070" class="usa-link" aria-describedby="jimd70078-bib-0070">70</a>, <a href="#jimd70078-bib-0071" class="usa-link" aria-describedby="jimd70078-bib-0071">71</a>] or homogeneously through the hepatic lobule in argininosuccinate lyase (ASL) deficient mice (Figure <a href="#jimd70078-fig-0002" class="usa-link">2</a>) [<a href="#jimd70078-bib-0072" class="usa-link" aria-describedby="jimd70078-bib-0072">72</a>], likely influenced by the LNP formulation and potentially by the pathophysiology of the underlying disease.</p>
<figure class="fig xbox font-sm" id="jimd70078-fig-0002"><h3 class="obj_head">FIGURE 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebd/12361847/90d6b36e35d6/JIMD-48-0-g003.jpg" loading="lazy" id="jats-graphic-3" height="355" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/jimd70078-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>In vivo mouse liver biodistribution of mRNA‐LNP compared to viral gene therapy. Mouse liver immunostaining against the urea cycle cytosolic enzyme argininosuccinate lyase (ASL) for (A) wild‐type and (B–F) hypomorphic ASL‐deficient <em>Asl</em>
<sup>
<em>Neo/Neo</em>
</sup> mouse either (B) untreated, (C) intravenously (IV) <em>hASL</em> mRNA‐LNP injected weekly during 7 weeks and sacrificed 48 h after the last injection, (D, E) IV AAV gene therapy injected in (D) adult mouse or newborn pup (E) mouse, or (F) IV lentiviral gene therapy injected in newborn pup. mRNA‐LNP biodistribution is homogeneous and diffuse across the hepatic lobule and liver parenchyma, in contrast with viral vectors, which show heterogeneous transduction. Scale bar: A–C 100 μm, D–F 250 μm.</p></figcaption></figure></section><section id="jimd70078-sec-0003"><h2 class="pmc_sec_title">3. Pre‐Clinical Development of mRNA‐LNP Therapy in Liver IMDs
</h2>
<p>mRNA replacement strategy using mRNA‐LNP technology has shown great promise in targeting liver monogenic disorders, encompassing a large range of pathways from organic acidemias, fatty acid oxidation disorders, carbohydrate metabolism disorders to urea cycle and amino acid disorders. Over 25 preclinical proof‐of‐concept studies targeting the liver IMDs have been published as of 2025 (Table <a href="#jimd70078-tbl-0002" class="usa-link">2</a>). First publications assessing mRNA therapy in liver IMDs started in 2016 and have gradually progressed, despite a marked stall during the COVID‐19 pandemic (Figure <a href="#jimd70078-fig-0003" class="usa-link">3</a>). These studies demonstrated sustained efficacy and phenotypic correction in vivo following repeated systemic injections with appropriate dose response, alongside an adequate safety profile. While the preclinical studies are mostly constrained to transgenic mouse models, some have extended the efficacy and safety studies to rats and larger animals such as rabbits and non‐human primates (NHPs), preceding clinical translation [<a href="#jimd70078-bib-0080" class="usa-link" aria-describedby="jimd70078-bib-0080">80</a>, <a href="#jimd70078-bib-0096" class="usa-link" aria-describedby="jimd70078-bib-0096">96</a>]. We provide an updated overview of preclinical works for liver IMDs.</p>
<section class="tw xbox font-sm" id="jimd70078-tbl-0002"><h3 class="obj_head">TABLE 2.</h3>
<div class="caption p"><p>Pre‐clinical work implementing mRNA‐LNP.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Disease</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Species</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Dose</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Markers of efficacy</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Repeated dosing</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Frequency</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Toxicity marker</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">References</th>
</tr></thead>
<tbody valign="top">
<tr><td align="left" colspan="8" valign="top" rowspan="1">Organic acidemias</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Methylmalonic acidemia (MA)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.2 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Improved survival, growth, low plasma MMA, low plasma 2‐methylcitrate, low C3/C2 carnitine ratios</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">Weekly</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALP, AST, ALT, IL‐6, Interferon‐ƴ, TNF‐α, IL‐1β</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0073" class="usa-link" aria-describedby="jimd70078-bib-0073">73</a>, <a href="#jimd70078-bib-0074" class="usa-link" aria-describedby="jimd70078-bib-0074">74</a>, <a href="#jimd70078-bib-0075" class="usa-link" aria-describedby="jimd70078-bib-0075">75</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Propionic acidemia (PA)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.5 and 2 mg/kg, 0.5 or 1 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">PCC activity, reduction in plasma primary biomarkers (2MC, 3HP, C3/C2 ratio), ammonia reduction</td>
<td align="center" valign="top" rowspan="1" colspan="1">3‐months and 6‐months studies</td>
<td align="center" valign="top" rowspan="1" colspan="1">3‐weekly (3 month study); monthly (6‐month study)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Serum ALT, AST, BUN</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0076" class="usa-link" aria-describedby="jimd70078-bib-0076">76</a>, <a href="#jimd70078-bib-0077" class="usa-link" aria-describedby="jimd70078-bib-0077">77</a>]</td>
</tr>
<tr><td align="left" colspan="8" valign="top" rowspan="1">Heme synthesis</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Acute intermittent Porphyria (AIP)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse, rat, rabbit, NHPs</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.2, 0.5 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Urinary PBG and ALT excretion, preventing acute induced porphyric attack and recurrent attacks</td>
<td align="center" valign="top" rowspan="1" colspan="1">27 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 administrations over 27 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">Serum, albumin, ALP, ALT</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0078" class="usa-link" aria-describedby="jimd70078-bib-0078">78</a>, <a href="#jimd70078-bib-0079" class="usa-link" aria-describedby="jimd70078-bib-0079">79</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Variegate porphyria (VP)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Rabbit</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.5 mg/kg single dose</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mitochondrial respiratory complex activity, hepatic heme levels, mitochondrial heme A, lipid peroxidation; Systolic blood pressure (hypertension), blood glucose, sciatic nerve amplitude</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALP, ALT</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0080" class="usa-link" aria-describedby="jimd70078-bib-0080">80</a>]</td>
</tr>
<tr><td align="left" colspan="8" valign="top" rowspan="1">Carbohydrate metabolism</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Classic galactosaemia</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.5 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Gallactose‐1‐Phosphate level (blood and tissue); plasma galactose</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 weeks</td>
<td align="center" valign="top" rowspan="1" colspan="1">Bi‐weekly</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0078" class="usa-link" aria-describedby="jimd70078-bib-0078">78</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Glycogen storage 1a (GSD1a)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.25 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Blood glucose levels</td>
<td align="center" valign="top" rowspan="1" colspan="1">52 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 doses over 52 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">IFN‐ ƴ, IL‐6, ALT, TNF‐alpha</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0081" class="usa-link" aria-describedby="jimd70078-bib-0081">81</a>]</td>
</tr>
<tr><td align="left" colspan="8" valign="top" rowspan="1">Urea cycle and amino acid disorders</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Citrin deficiency (CTLN II)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.5 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Hepatic citrulline and blood ammonia post sucrose challenge</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">Single dose</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0082" class="usa-link" aria-describedby="jimd70078-bib-0082">82</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ornithine carboxylase deficiency (OTCD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Survival, ammonia, orotic acid</td>
<td align="center" valign="top" rowspan="1" colspan="1">70 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">Weekly or bi‐weekly</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT, AST, cytokine panel</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0070" class="usa-link" aria-describedby="jimd70078-bib-0070">70</a>, <a href="#jimd70078-bib-0083" class="usa-link" aria-describedby="jimd70078-bib-0083">83</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Argininosuccinic aciduria (ASA)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Survival, plasma ammonia, ASA, citrulline levels, ureagenesis</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 months</td>
<td align="center" valign="top" rowspan="1" colspan="1">Weekly</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0072" class="usa-link" aria-describedby="jimd70078-bib-0072">72</a>, <a href="#jimd70078-bib-0084" class="usa-link" aria-describedby="jimd70078-bib-0084">84</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ASA</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.25‐3 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Survival benefits</td>
<td align="center" valign="top" rowspan="1" colspan="1">35 days from treatment</td>
<td align="center" valign="top" rowspan="1" colspan="1">Weekly or biweekly</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0085" class="usa-link" aria-describedby="jimd70078-bib-0085">85</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Arginase deficiency</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Plasma and hepatic arginine and glutamine, plasma ammonia and GAA, ureagenesis</td>
<td align="center" valign="top" rowspan="1" colspan="1">63 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">Lack of inflammatory infiltrates</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0071" class="usa-link" aria-describedby="jimd70078-bib-0071">71</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Phenylketonuria</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Plasma phenylalanine: tyrosine ratio, cholesterol, albumin:globulin ratio</td>
<td align="center" valign="top" rowspan="1" colspan="1">336 h</td>
<td align="center" valign="top" rowspan="1" colspan="1">Every 3 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALP, ALT</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0086" class="usa-link" aria-describedby="jimd70078-bib-0086">86</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Tyrosinemia I</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Normalised body weight, serum succinylacetone and Tyrosine levels 21 days post NTBC withdrawal. NTBC supplementation withdrawn 5 days prior to treatment</td>
<td align="center" valign="top" rowspan="1" colspan="1">21 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">Every 5 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALT, AST, ALP</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0087" class="usa-link" aria-describedby="jimd70078-bib-0087">87</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Maple Syrup Urine Disease (MSUD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.2, 0.5, 1 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Survival, reduction in serum leucine</td>
<td align="center" valign="top" rowspan="1" colspan="1">Up to 70 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">Weekly</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0088" class="usa-link" aria-describedby="jimd70078-bib-0088">88</a>]</td>
</tr>
<tr><td align="left" colspan="8" valign="top" rowspan="1">Fatty acid oxidation</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Very long chain acyl CoA deficiency (VLCAD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Increased tolerance to cold, reduced C16 and C18 acylcarnitines</td>
<td align="center" valign="top" rowspan="1" colspan="1">14 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 doses over 14 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">Minimal inflammatory response</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0089" class="usa-link" aria-describedby="jimd70078-bib-0089">89</a>]</td>
</tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Medium chain acyl CoA deficiency (MCAD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Reduced medium chain acylcarnitines, reduced hepatic steatosis, reduced glucose after cold stress</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 doses</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0090" class="usa-link" aria-describedby="jimd70078-bib-0090">90</a>]</td>
</tr>
<tr><td align="left" colspan="8" valign="top" rowspan="1">Oxalate metabolism</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Primary hyperoxaluria type I</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse, rat and NHP</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.5–2 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Reduction in urinary oxalate</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">Weekly (for toxicology analysis)</td>
<td align="center" valign="top" rowspan="1" colspan="1">IL‐6, CXCL1, ALT, AST, TBIL, CK, C3 and C4</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0091" class="usa-link" aria-describedby="jimd70078-bib-0091">91</a>]</td>
</tr>
<tr><td align="left" colspan="8" valign="top" rowspan="1">Bilirubin metabolism</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Crigler Najjar syndrome</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.2 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Neonatal lethality restored with single dose</p>
<p>Repeated dosing restored bilirubin levels in adults (neonatal lethality restored with phototherapy)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Up to 154 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">Every 2 or 3 or 4 weeks</td>
<td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0092" class="usa-link" aria-describedby="jimd70078-bib-0092">92</a>]</td>
</tr>
<tr><td align="left" colspan="8" valign="top" rowspan="1">Secreted</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">α1‐Anti‐trypsin (AAT) deficiency</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.5 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Reduction in elastase activity, detection of modified human AAT mRNA in liver via in situ hybridisation</td>
<td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="top" rowspan="1" colspan="1">ALP, AST, CK, GGT and albumin</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0093" class="usa-link" aria-describedby="jimd70078-bib-0093">93</a>]</td>
</tr>
<tr><td align="left" colspan="8" valign="top" rowspan="1">Membrane</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Progressive familial intrahepatic cholestasis III (PFICIII)</td>
<td align="center" valign="top" rowspan="1" colspan="1">mouse</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Restoration of biliary phospholipids secretion, improved hepatomegaly and livery injury, prevents liver fibrosis progression</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">twice a week</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0094" class="usa-link" aria-describedby="jimd70078-bib-0094">94</a>]</td>
</tr>
<tr><td align="left" colspan="8" valign="top" rowspan="1">Lysosomal</td></tr>
<tr>
<td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Fabry disease</td>
<td align="center" valign="top" rowspan="1" colspan="1">Mouse, NHP (safety)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.2 or 0.5 mg/kg</td>
<td align="center" valign="top" rowspan="1" colspan="1">Restoration of α‐Galactose A (Gal A) activity in heart and liver globotriaosylsphingosine (Lyso‐Gb3) reduction in plasma, heart, kidney, liver and spleen.</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 months</td>
<td align="center" valign="top" rowspan="1" colspan="1">Every two weeks or monthly</td>
<td align="center" valign="top" rowspan="1" colspan="1">Serum albumin, AST, ALP, ALT, GGT, TBIL and TPROT levels in NHPs</td>
<td align="center" valign="top" rowspan="1" colspan="1">[<a href="#jimd70078-bib-0095" class="usa-link" aria-describedby="jimd70078-bib-0095">95</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/jimd70078-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="jimd70078-note-0003"><p>Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; GGT, gamma‐glutamyl transpeptidase; IL, interleukin; NHP, nonhuman primates; TBIL, total bilirubin; TNF, tumour necrosis factor; TPROT, total protein test.</p></div></div></section><figure class="fig xbox font-sm" id="jimd70078-fig-0003"><h3 class="obj_head">FIGURE 3.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebd/12361847/44abf3466862/JIMD-48-0-g004.jpg" loading="lazy" id="jats-graphic-5" height="334" width="669" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/jimd70078-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Disclosed targeted inherited metabolic diseases for mRNA‐LNP therapy. The graph represents publications or disclosed reports of mRNA‐LNP therapy for inherited metabolic diseases over time. The first preclinical proof of concept was published in 2016, followed by gradual increase of indications and success, transiently halted during the COVID‐19 pandemic. The first interim results of a phase I/II clinical trial were published in 2024. IMD, inherited metabolic diseases; POC, proof of concept. Data obtained from a Pubmed search using the MeSH terms “mRNA” AND “inherited metabolic diseases” on 15th January 2025.</p></figcaption></figure><section id="jimd70078-sec-0004"><h3 class="pmc_sec_title">3.1. Organic Acidemias</h3>
<p>The first proof‐of‐concept study using mRNA replacement strategy in liver IMDs was demonstrated for methylmalonic acidemia (MMA) [<a href="#jimd70078-bib-0073" class="usa-link" aria-describedby="jimd70078-bib-0073">73</a>, <a href="#jimd70078-bib-0074" class="usa-link" aria-describedby="jimd70078-bib-0074">74</a>]. mRNA‐LNP encoding codon‐optimised human methylmalonyl‐CoA mutase (<em>hMUT</em>) showed robust hepatic protein expression for at least 7 days after single systemic administration. Long‐term efficacy with repeated administrations was achieved in two MMA murine models, the <em>Mut</em>
<sup>
<em>−/−</em>
</sup>
<em>; Tg</em>
<sup>
<em>INS‐Mck‐Mut</em>
</sup> mouse with the <em>Mut</em> gene under the transcriptional control of a muscle‐specific creatine kinase (<em>MCK</em>) promoter and the <em>Mut</em>
<sup>
<em>−/−</em>
</sup>
<em>; Tg</em>
<sup>
<em>INS‐CBA‐G715V</em>
</sup> mouse, a hypomorphic model ubiquitously expressing a mouse orthologous mutation (p.G715V) of an MMA patient mutation (p.G717V). The study demonstrated increased hepatic MUT activity, improved growth, survival and reduced disease‐associated plasma metabolites in both models. Lack of increased toxicity and inflammation markers following repeated dosing demonstrated safety [<a href="#jimd70078-bib-0073" class="usa-link" aria-describedby="jimd70078-bib-0073">73</a>, <a href="#jimd70078-bib-0074" class="usa-link" aria-describedby="jimd70078-bib-0074">74</a>]. This programme has been translated into a phase I/II clinical trial (<a href="https://clinicaltrials.gov/ct2/show/NCT04899310" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04899310</a>).</p>
<p>Similarly, mRNA replacement therapy was successful in propionic acidemia (PA) [<a href="#jimd70078-bib-0076" class="usa-link" aria-describedby="jimd70078-bib-0076">76</a>]. This work highlighted the long‐term therapeutic effect of a combined mRNA therapy. PA is an IMD caused by propionyl‐CoA carboxylase (PCC) deficiency localised in the mitochondrial matrix. PCC is a large heterododecamer enzyme composed of α‐ and β‐subunits (PCCA and PCCB). Although patients have pathogenic mutations in either the PCCA or PCCB subunit, the alternative subunit cannot compensate as two functional subunits are required for a functional PCC enzyme. LNP encapsulating an equimolar ratio of <em>hPCCA</em> and <em>hPCCB</em> mRNAs was successfully tested in a hypomorphic PA murine model (<em>Pcca</em>
<sup>
<em>−/−</em>
</sup> (A138T) mice). Single IV dosing of 1 mg/kg mRNA resulted in therapeutically relevant protein expression of both PCCA and PCCB subunits, comparable to endogenous protein levels in human liver [<a href="#jimd70078-bib-0076" class="usa-link" aria-describedby="jimd70078-bib-0076">76</a>]. Long‐term repeated dosing for up to 6 months demonstrated sustained efficacy and tolerability. This therapeutic candidate was taken forward for a phase I/II clinical trial (<a href="https://clinicaltrials.gov/ct2/show/NCT04159103" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04159103</a>; <a href="https://clinicaltrials.gov/ct2/show/NCT05130437" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05130437</a>) with interim data published in April 2024 and detailed in the next section [<a href="#jimd70078-bib-0021" class="usa-link" aria-describedby="jimd70078-bib-0021">21</a>].</p></section><section id="jimd70078-sec-0005"><h3 class="pmc_sec_title">3.2. Urea Cycle Disorders (UCDs)</h3>
<p>Several independent preclinical studies have demonstrated the efficacy and safety of mRNA‐LNP to replace defective enzymes involved in the urea cycle pathway, such as citrin deficiency [<a href="#jimd70078-bib-0082" class="usa-link" aria-describedby="jimd70078-bib-0082">82</a>], ornithine transcarbamylase deficiency (OTCD) [<a href="#jimd70078-bib-0070" class="usa-link" aria-describedby="jimd70078-bib-0070">70</a>, <a href="#jimd70078-bib-0083" class="usa-link" aria-describedby="jimd70078-bib-0083">83</a>, <a href="#jimd70078-bib-0097" class="usa-link" aria-describedby="jimd70078-bib-0097">97</a>], argininosuccinic aciduria (ASA) (resulting from argininosuccinate lyase (ASL) deficiency) [<a href="#jimd70078-bib-0072" class="usa-link" aria-describedby="jimd70078-bib-0072">72</a>, <a href="#jimd70078-bib-0085" class="usa-link" aria-describedby="jimd70078-bib-0085">85</a>] and arginase deficiency [<a href="#jimd70078-bib-0071" class="usa-link" aria-describedby="jimd70078-bib-0071">71</a>, <a href="#jimd70078-bib-0098" class="usa-link" aria-describedby="jimd70078-bib-0098">98</a>]. The LNP encapsulating OTC‐mRNA (LUNAR‐OTC) to target OTCD is currently undergoing Phase II clinical trials [<a href="#jimd70078-bib-0097" class="usa-link" aria-describedby="jimd70078-bib-0097">97</a>]. A study in a hypomorphic mouse model of ASA not only showed correction of survival, disease biomarkers and restoration of ureagenesis but also correction of the global liver metabolic dysfunction, including dysregulation of glutathione metabolism [<a href="#jimd70078-bib-0072" class="usa-link" aria-describedby="jimd70078-bib-0072">72</a>]. Sustained phenotypic correction was observed following neonatal initiation of therapy. Rescue of juvenile ASL‐deficient mice demonstrated the ability for mRNA‐LNP to reverse a severe pre‐dying phenotype [<a href="#jimd70078-bib-0072" class="usa-link" aria-describedby="jimd70078-bib-0072">72</a>]. Indication of neurological advantage following normalised ureagenesis with mRNA‐LNP therapy was also evident, albeit indirectly, in the ASA hypomorphic mouse model with the absence of abnormal neuroimaging findings [<a href="#jimd70078-bib-0084" class="usa-link" aria-describedby="jimd70078-bib-0084">84</a>] and in precision‐cut liver slices [<a href="#jimd70078-bib-0099" class="usa-link" aria-describedby="jimd70078-bib-0099">99</a>]. mRNA‐LNP corrected ureagenesis and the liver metabolic phenotype in arginase deficiency [<a href="#jimd70078-bib-0071" class="usa-link" aria-describedby="jimd70078-bib-0071">71</a>] This enabled subsequent therapeutic benefit on the neuropathology, as observed with myelination improvement preventing leukodystrophy and oligodendrocyte dysfunction in vivo [<a href="#jimd70078-bib-0098" class="usa-link" aria-describedby="jimd70078-bib-0098">98</a>]. mRNA‐LNP showed an improved phenotype, particularly in behavioural changes, in a hypomorphic mouse model of citrin deficiency with improved sucrose aversion [<a href="#jimd70078-bib-0082" class="usa-link" aria-describedby="jimd70078-bib-0082">82</a>].</p></section><section id="jimd70078-sec-0006"><h3 class="pmc_sec_title">3.3. Aminoacidopathies</h3>
<p>Similarly, multiple independent proof‐of‐concepts of mRNA‐LNP therapy have been shown for phenylketonuria [<a href="#jimd70078-bib-0077" class="usa-link" aria-describedby="jimd70078-bib-0077">77</a>, <a href="#jimd70078-bib-0086" class="usa-link" aria-describedby="jimd70078-bib-0086">86</a>], tyrosinemia type I [<a href="#jimd70078-bib-0087" class="usa-link" aria-describedby="jimd70078-bib-0087">87</a>, <a href="#jimd70078-bib-0100" class="usa-link" aria-describedby="jimd70078-bib-0100">100</a>] and Maple Syrup Urine Disease (MSUD) with correction of the clinical and biological phenotypes [<a href="#jimd70078-bib-0088" class="usa-link" aria-describedby="jimd70078-bib-0088">88</a>].</p></section><section id="jimd70078-sec-0007"><h3 class="pmc_sec_title">3.4. Porphyrias</h3>
<p>Porphyrias are a group of IMDs resulting from a defect in enzymes in the heme biosynthetic pathway [<a href="#jimd70078-bib-0101" class="usa-link" aria-describedby="jimd70078-bib-0101">101</a>]. Porphobilinogen deaminase (PBGD) is the third enzyme in this pathway, and its hepatic deficiency results in acute intermittent porphyria (AIP). Patients predominantly display acute neurovisceral attacks due to high production of neurotoxic porphyrin precursors and additional heterogeneous symptoms [<a href="#jimd70078-bib-0102" class="usa-link" aria-describedby="jimd70078-bib-0102">102</a>]. The therapeutic benefit of <em>PBGD</em> encoding mRNA was demonstrated by the rescue of acute porphyric attacks and prolonged repeated dosing prospectively preventing attacks in AIP mice. The therapeutic efficacy was further demonstrated in a chemically induced porphyrin precursor rabbit model. Importantly, this study showed the translatability of the administration dose from the mouse model (0.5 mg/kg) to rats and larger animals such as rabbits and NHPs, achieving up to 80% of endogenous activity within 24 h post‐dosing with minimal toxicity [<a href="#jimd70078-bib-0103" class="usa-link" aria-describedby="jimd70078-bib-0103">103</a>]. The sustained efficacy and tolerability during repeated administration tested successfully in all species demonstrated the therapeutic benefit of mRNA‐LNP. Interestingly, another study in a novel rabbit model of chemically induced Variegate Porphyria (VP) evaluated the therapeutic efficacy of systemic administration of LNP encapsulating <em>PBGD</em> mRNA. While VP is resultant from haploinsufficiency of protoporphyrinogen oxidase (PPOX), the seventh enzyme in the heme biosynthesis pathway, <em>PBGD</em> mRNA showed efficacy in preventing acute attacks [<a href="#jimd70078-bib-0080" class="usa-link" aria-describedby="jimd70078-bib-0080">80</a>].</p></section><section id="jimd70078-sec-0008"><h3 class="pmc_sec_title">3.5. Energy‐Related Disorders</h3>
<p>mRNA replacement strategy has also been successfully implemented in fatty acid oxidation disorders such as very‐long‐chain acyl‐CoA dehydrogenase deficiency (VLCADD) [<a href="#jimd70078-bib-0089" class="usa-link" aria-describedby="jimd70078-bib-0089">89</a>] and medium‐chain acyl‐CoA dehydrogenase deficiency (MCADD) [<a href="#jimd70078-bib-0090" class="usa-link" aria-describedby="jimd70078-bib-0090">90</a>] carbohydrate metabolism disorders such as classic galactosemia [<a href="#jimd70078-bib-0078" class="usa-link" aria-describedby="jimd70078-bib-0078">78</a>] and glycogen storage disease 1a (GSD1a) [<a href="#jimd70078-bib-0081" class="usa-link" aria-describedby="jimd70078-bib-0081">81</a>, <a href="#jimd70078-bib-0104" class="usa-link" aria-describedby="jimd70078-bib-0104">104</a>]. Proof‐of‐concept study in a GSD1a mouse model showed efficacy of mRNA therapy in addressing both life‐threatening acute hypoglycemia and chronic risk of hepatocellular adenoma and carcinoma (HCA/HCC) associated with the disease [<a href="#jimd70078-bib-0081" class="usa-link" aria-describedby="jimd70078-bib-0081">81</a>]. This GSD1a programme has been translated into a phase I/II clinical trial (<a href="https://clinicaltrials.gov/ct2/show/NCT05095727" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05095727</a>).</p></section><section id="jimd70078-sec-0009"><h3 class="pmc_sec_title">3.6. Lysosomal Disorders</h3>
<p>Fabry disease is the most common lysosomal storage disease resulting from lack of functional alpha galactosidase A (α‐GalA) activity causing accumulation of glycosphingolipids. Preclinical study of mRNA replacement strategy demonstrated efficacy in a Fabry disease mouse model and safety in non‐human primates (NHPs). Bi‐weekly administration of up to 4 doses in NHPs showed sustained secreted functional α‐GalA protein and absence of immunogenicity [<a href="#jimd70078-bib-0095" class="usa-link" aria-describedby="jimd70078-bib-0095">95</a>]. Preliminary work in Niemann‐Pick disease Type C (NPC‐1) has shown proof of concept with restoration of functional protein expression and reversal of disease pathology in NPC‐1 patient fibroblasts [<a href="#jimd70078-bib-0105" class="usa-link" aria-describedby="jimd70078-bib-0105">105</a>].</p></section><section id="jimd70078-sec-0010"><h3 class="pmc_sec_title">3.7. Oxalate Metabolism</h3>
<p>Primary hyperoxaluria type I is a liver IMD where lack of function of alanine glyoxylate aminotransferase (AGT) causes accumulation of glyoxylate, a metabolite converted into oxalate. Oxalate accumulation results in deposition of oxalate crystals causing a severe systemic disease affecting various organs, such as kidney with stones and causing progressive renal failure, bone, heart, skin and retina [<a href="#jimd70078-bib-0106" class="usa-link" aria-describedby="jimd70078-bib-0106">106</a>]. Single injection of sequence‐optimised human <em>AGT</em> mRNA resulted in AGT protein expression for up to 48 h, and a single dose of 2 mg/kg <em>hAGT</em>mRNA‐LNP therapy in a rat model of AGT deficiency, WT mice and Cynomolgus monkeys [<a href="#jimd70078-bib-0091" class="usa-link" aria-describedby="jimd70078-bib-0091">91</a>]. Significant reduction in urinary oxalate &gt; 70% was observed in AGT‐deficient mice and rats within 48–72 h with minimal toxic profile at up to 2 mg/kg dose [<a href="#jimd70078-bib-0091" class="usa-link" aria-describedby="jimd70078-bib-0091">91</a>].</p>
<p>Other conditions include Alpha 1‐antitrypsin (AAT) deficiency where levels of circulating AAT are significantly lowered due to aberrant protein folding and aggregation in the rough endoplasmic reticulum of hepatocytes [<a href="#jimd70078-bib-0093" class="usa-link" aria-describedby="jimd70078-bib-0093">93</a>]. Systemic administration of mRNA therapy in a transgenic mouse model of AAT deficiency led to hepatic uptake and translation into effective protein in mice; with phenotypic improvement [<a href="#jimd70078-bib-0107" class="usa-link" aria-describedby="jimd70078-bib-0107">107</a>].</p></section></section><section id="jimd70078-sec-0011"><h2 class="pmc_sec_title">4. Clinical Trials of mRNA‐LNP Therapy in Liver IMDs
</h2>
<p>Following the successes of mRNA‐LNP technology in preclinical models, various phase I/II clinical trials have been announced targeting liver IMDs (Table <a href="#jimd70078-tbl-0003" class="usa-link">3</a>).</p>
<section class="tw xbox font-sm" id="jimd70078-tbl-0003"><h3 class="obj_head">TABLE 3.</h3>
<div class="caption p"><p>mRNA‐LNP clinical trials for liver IMDs.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Condition</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Sponsor</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Phase</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Drug</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Status</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Clinical trial number</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Propionic acidemia (PA)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Moderna</td>
<td align="center" valign="top" rowspan="1" colspan="1">Phase I/II</td>
<td align="center" valign="top" rowspan="1" colspan="1">mRNA‐3927</td>
<td align="center" valign="top" rowspan="1" colspan="1">Recruiting</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p><a href="https://clinicaltrials.gov/ct2/show/NCT04159103" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04159103</a></p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT05130437" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05130437</a></p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Methylmalonic acidemia (MMA)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Moderna</td>
<td align="center" valign="top" rowspan="1" colspan="1">Phase I/II</td>
<td align="center" valign="top" rowspan="1" colspan="1">mRNA‐3705</td>
<td align="center" valign="top" rowspan="1" colspan="1">Recruiting</td>
<td align="center" valign="top" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04899310" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04899310</a></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Ornithine transcarbamylase deficiency (OTCD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Arcturus</td>
<td align="center" valign="top" rowspan="1" colspan="1">Phase I/II</td>
<td align="center" valign="top" rowspan="1" colspan="1">ARCT‐810</td>
<td align="center" valign="top" rowspan="1" colspan="1">Recruiting/completed</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<a href="https://clinicaltrials.gov/ct2/show/NCT06488313" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06488313</a>/<a href="https://clinicaltrials.gov/ct2/show/NCT04442347" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04442347</a>/N CT04416126</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Glycogen storage disease 1a (GSD1a)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Moderna</td>
<td align="center" valign="top" rowspan="1" colspan="1">Phase I/II</td>
<td align="center" valign="top" rowspan="1" colspan="1">mRNA‐3745</td>
<td align="center" valign="top" rowspan="1" colspan="1">Recruiting</td>
<td align="center" valign="top" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT05095727" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05095727</a></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Phenylketonuria (PKU)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Moderna</td>
<td align="center" valign="top" rowspan="1" colspan="1">Phase I/II</td>
<td align="center" valign="top" rowspan="1" colspan="1">mRNA‐320</td>
<td align="center" valign="top" rowspan="1" colspan="1">Recruitment complete</td>
<td align="center" valign="top" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT06147856" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06147856</a></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Crigler–Najjar disease</td>
<td align="center" valign="top" rowspan="1" colspan="1">Moderna</td>
<td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">No updates</td>
<td align="center" valign="top" rowspan="1" colspan="1">Preclinical</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/jimd70078-tbl-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>The interim data of the first‐in‐human phase I/II mRNA dose optimisation and extension study trial for PA sponsored by Moderna Inc. (<a href="https://clinicaltrials.gov/ct2/show/NCT04159103" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04159103</a>; <a href="https://clinicaltrials.gov/ct2/show/NCT05130437" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05130437</a>) were recently published, showing promising results [<a href="#jimd70078-bib-0021" class="usa-link" aria-describedby="jimd70078-bib-0021">21</a>]. The study evaluated the safety and efficacy of mRNA‐3927, a dual mRNA‐LNP therapy encoding mRNA for <em>hPCCA</em> and <em>hPCCB</em> delivered systemically [<a href="#jimd70078-bib-0076" class="usa-link" aria-describedby="jimd70078-bib-0076">76</a>]. Sixteen participants were allocated to five different cohorts. Cohort 1 received a dose of 0.3 mg/kg every 3 weeks, while cohorts 2–5 received treatment every 2 weeks at doses of 0.3, 0.45, 0.6 and 0.9 mg/kg respectively. A total of 321 doses had been administered at the data cut‐off. Safety data showed no dose‐limiting toxicity, with the mRNA injections being generally well‐tolerated, with treatment‐related adverse events reported in 15/16 patients and serious adverse events in 8/16 patients. The severe adverse events were not attributable to the drug itself, especially a grade 3 pancreatitis attributed to the underlying genetic disease by the Data Safety Monitoring Committee. Infusion‐related reactions (IRRs) were a common finding observed in 5/16 (31.3%) patients and in 18/346 (5.2%) doses. These IRR manifestations were essentially grade 1 and 2 rashes occurring during the first few doses, then disappearing in most cases in line with a tachyphylaxis effect previously described with liposomal drugs. The IRR manifestation resulted in the withdrawal of one patient from the trial.</p>
<p>A preliminary trend of increased pharmacokinetics with dose escalation was observed from the serum analysis of <em>hPCCA</em> mRNA. A 70% reduction in relative risk of metabolic decompensation events (RR 0.3 with 95% CI 0.066–1.315; <em>p</em> = 0.0927) showed an encouraging trend, despite limitations from a limited study cohort, lack of a control arm and 2‐year follow‐up completed only for 2 patients from the lowest dose cohort. Another consideration linked to the pathophysiology of this multisystemic disease is that a liver‐targeting mRNA‐LNP can provide a significant but still partial correction of the disease. As illustrated by liver‐transplanted PA patients, a significant production of toxic metabolites from extrahepatic organs still persists, and the risk of acute metabolic decompensations and extrahepatic organ complications, although decreased, remains [<a href="#jimd70078-bib-0108" class="usa-link" aria-describedby="jimd70078-bib-0108">108</a>]. Hence, results at study completion will be closely scrutinised. A follow‐up phase III clinical trial will assess the long‐term safety and clinical activity (<a href="https://clinicaltrials.gov/ct2/show/NCT04159103" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04159103</a>) and will be key in determining the clinical translational potential of mRNA‐LNP in PA.</p>
<p>Additional clinical trial data have been disclosed in non‐peer reviewed communications. A phase I/II clinical trial on patients diagnosed with isolated MMA using mRNA‐3705 (<a href="https://clinicaltrials.gov/ct2/show/NCT04899310" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04899310</a>) and sponsored by Moderna Inc. is recruiting, assessing safety, pharmacokinetics and dynamics with two phases of dose optimisation and dose expansion. <em>Corporate press releases have disclosed</em> encouraging initial pharmacodynamics [<a href="#jimd70078-bib-0109" class="usa-link" aria-describedby="jimd70078-bib-0109">109</a>], following the dosing of 11 participants and a total of 221 doses administered intravenously. The treatment was reported as well tolerated, with dose‐dependent reduction in metabolite in MMA in certain cohorts, decrease of yearly metabolic decompensation events, and MMA related hospitalisations [<a href="#jimd70078-bib-0109" class="usa-link" aria-describedby="jimd70078-bib-0109">109</a>, <a href="#jimd70078-bib-0110" class="usa-link" aria-describedby="jimd70078-bib-0110">110</a>]. <em>No peer‐reviewed data have been published, and the disclosed information should be interpreted with caution</em>. A follow‐up extension trial was announced to evaluate long‐term safety, including treatment and follow‐up periods (<a href="https://clinicaltrials.gov/ct2/show/NCT05295433" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05295433</a>).</p>
<p>Arcturus therapeutics also reported on phase IA single ascending dose (SAD) study for ARCT‐810, an mRNA therapeutic candidate for OTCD [<a href="#jimd70078-bib-0111" class="usa-link" aria-describedby="jimd70078-bib-0111">111</a>]. Thirty healthy adults were enrolled and randomised 2:1 to receive ARCT‐810 at multiple ascending doses or placebo intravenously (<a href="https://clinicaltrials.gov/ct2/show/NCT04416126" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04416126</a>). This was followed by a phase 1B SAD study which enrolled 16 adults with metabolically well‐controlled OTCD, randomised 3:1 to receive single doses of the therapeutic candidate or placebo (<a href="https://clinicaltrials.gov/ct2/show/NCT04442347" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04442347</a>). An ongoing phase II study has been initiated in OTCD adolescents and adults, with subjects randomised to receive 5 doses or placebo every 14 days (<a href="https://clinicaltrials.gov/ct2/show/NCT06488313" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06488313</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT05526066" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05526066</a>) [<a href="#jimd70078-bib-0111" class="usa-link" aria-describedby="jimd70078-bib-0111">111</a>].</p>
<p>Additional clinical trials announced through press releases include phase I/II clinical trial for GSD1a (<a href="https://clinicaltrials.gov/ct2/show/NCT05095727" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05095727</a>) with mRNA‐3745 (actively recruiting) [<a href="#jimd70078-bib-0111" class="usa-link" aria-describedby="jimd70078-bib-0111">111</a>], PKU with mRNA‐3210 (<a href="https://clinicaltrials.gov/ct2/show/NCT06147856" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06147856</a>) (withdrawn) [<a href="#jimd70078-bib-0109" class="usa-link" aria-describedby="jimd70078-bib-0109">109</a>, <a href="#jimd70078-bib-0111" class="usa-link" aria-describedby="jimd70078-bib-0111">111</a>], mRNA‐3139 for OTCD and mRNA‐3351 for Crigler‐Najjar Syndrome (CN‐1) [<a href="#jimd70078-bib-0112" class="usa-link" aria-describedby="jimd70078-bib-0112">112</a>].</p>
<p>Overall, various early phase clinical trials are ongoing for liver IMDs, with limited interim results published thus far. First interim results support safety despite a high rate of infusion‐related reactions [<a href="#jimd70078-bib-0021" class="usa-link" aria-describedby="jimd70078-bib-0021">21</a>]. A trend for efficacy has been reported but requires study completion to confirm the therapeutic value and its extent.</p>
<p>Interestingly, a bioinformatic model has been published validating this approach to efficiently assist with extrapolation of minimally effective dosing while translating mRNA‐LNP from preclinical animal models into patients [<a href="#jimd70078-bib-0077" class="usa-link" aria-describedby="jimd70078-bib-0077">77</a>, <a href="#jimd70078-bib-0113" class="usa-link" aria-describedby="jimd70078-bib-0113">113</a>]. This is of particular interest as each liver IMD is expected to have a different therapeutic threshold of transgenic protein expression.</p></section><section id="jimd70078-sec-0012"><h2 class="pmc_sec_title">5. Safety and Immunogenicity of mRNA‐LNP
</h2>
<p>Ensuring long‐term safety for a therapy, which requires lifelong administration, is key. As the technology is gradually being translated to patients, disclosed safety data are currently limited to a few patients who have received mRNA‐LNP for a maximum of 2 years [<a href="#jimd70078-bib-0021" class="usa-link" aria-describedby="jimd70078-bib-0021">21</a>]. In the PA trial sponsored by Moderna (<a href="https://clinicaltrials.gov/ct2/show/NCT04159103" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04159103</a>; <a href="https://clinicaltrials.gov/ct2/show/NCT05130437" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05130437</a>), no dose‐limiting toxicity was observed at the highest dose of 0.9 mg/kg mRNA administered every 2 weeks; although the duration of follow‐up data disclosed remained limited to 6 months maximum in this high‐dose cohort [<a href="#jimd70078-bib-0021" class="usa-link" aria-describedby="jimd70078-bib-0021">21</a>].</p>
<p>The immune response described against mRNA‐LNP is mainly based on innate immune response or anaphylactic reactions mediated by either IgE or IgM‐complement. To study mRNA‐LNP related immunogenicity, in vitro (e.g., cell viability assays, incubation with immune cells) and in vivo (e.g., small and large animals) models have been used. Innate immune response can target either mRNA, LNP, or the combination mRNA‐LNP. In clinical trials for IMDs, this innate immune response has not been reported.</p>
<p>Synthetic mRNA can be recognised by multiple endosomal (Toll‐like receptors (TLR) 7,8,9) and cytosolic protein kinase RNA‐activated (PKR), retinoic acid‐inducible gene I protein (RIG‐I), melanoma differentiation‐associated protein 5 (MDA5) and 2′–5′‐oligoadenylate synthase (OAS) innate immunity sensors. These sensors can be triggered by single‐stranded (via TLR7, 8) or double‐stranded (via TLR3) mRNA or LNP. Upon activation, they initiate an inflammatory cascade through myeloid differentiation primary response protein 88 (Myd88)/NFKB (nuclear factor‐κB)—CREB (cAMP response element‐binding protein), interferon regulatory factor (IRF) activating type 1 interferon response [<a href="#jimd70078-bib-0114" class="usa-link" aria-describedby="jimd70078-bib-0114">114</a>], chemokines (CXCL1 and CXCL2), cytokines‐mediated response (IL‐6, IL‐10, IL‐12β and IL‐1β), and leucocyte recruitment [<a href="#jimd70078-bib-0115" class="usa-link" aria-describedby="jimd70078-bib-0115">115</a>]. Incorporation of naturally occurring modified nucleosides such as (N1‐methyl)pseudouridine, 2‐thiouridine, 5‐methyluridine, 5‐methylcytidine, or N6‐methyladenosine prevents mRNA recognition by TLR3, 7, 8 and precludes the associated innate immune response [<a href="#jimd70078-bib-0113" class="usa-link" aria-describedby="jimd70078-bib-0113">113</a>].</p>
<p>Strong evidence has been generated that lipid‐based carriers, especially LNP, participate and trigger the quality and the intensity of the innate immune response, mediated by the NLRP3 inflammasome, IL‐1 and IL‐1 receptor antagonist (IL‐1ra) [<a href="#jimd70078-bib-0116" class="usa-link" aria-describedby="jimd70078-bib-0116">116</a>, <a href="#jimd70078-bib-0117" class="usa-link" aria-describedby="jimd70078-bib-0117">117</a>] or IL‐6 [<a href="#jimd70078-bib-0118" class="usa-link" aria-describedby="jimd70078-bib-0118">118</a>]. This adjuvant role of LNP in triggering innate immunogenicity has been well documented in mRNA vaccines, particularly with ionizable lipids like SM‐102 from Moderna's vaccine, with species‐specific responses [<a href="#jimd70078-bib-0116" class="usa-link" aria-describedby="jimd70078-bib-0116">116</a>, <a href="#jimd70078-bib-0117" class="usa-link" aria-describedby="jimd70078-bib-0117">117</a>].</p>
<p>Hence, both LNP and mRNA, independently or in combination, can trigger innate immune response [<a href="#jimd70078-bib-0116" class="usa-link" aria-describedby="jimd70078-bib-0116">116</a>]. Interactions between ionisable lipids and pattern recognition sensors are complex and multifactorial. Further research is required to better unravel these mechanisms and develop safer lipid‐based particles.</p>
<p>In the PA trial (<a href="https://clinicaltrials.gov/ct2/show/NCT04159103" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04159103</a>; <a href="https://clinicaltrials.gov/ct2/show/NCT05130437" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05130437</a>), infusion‐related reactions were a prominent adverse event reported in 31.3% of patients, essentially during the first administrations. These reactions are analogous to what has been described with other liposomal drugs such as oncolytics, for example, doxorubicin [<a href="#jimd70078-bib-0119" class="usa-link" aria-describedby="jimd70078-bib-0119">119</a>], and other RNA‐based therapies, for example, mRNA vaccines [<a href="#jimd70078-bib-0120" class="usa-link" aria-describedby="jimd70078-bib-0120">120</a>, <a href="#jimd70078-bib-0121" class="usa-link" aria-describedby="jimd70078-bib-0121">121</a>] or small interfering RNA (siRNA) [<a href="#jimd70078-bib-0122" class="usa-link" aria-describedby="jimd70078-bib-0122">122</a>].</p>
<p>A limited number of LNP drugs has been approved so far [<a href="#jimd70078-bib-0051" class="usa-link" aria-describedby="jimd70078-bib-0051">51</a>]. In those, the lipid composition and additional conjugated motifs such as PEG retain physicochemical features and biological activity, which enable improved pharmacokinetics and liver‐targeting. However, PEG‐related immune‐induced adverse events are not uncommon and include hypersensitivity, complement activation related pseudo allergy (CARPA) and occasionally anaphylaxis [<a href="#jimd70078-bib-0123" class="usa-link" aria-describedby="jimd70078-bib-0123">123</a>]. Those events have been reported with mRNA‐LNP vaccines and LNP‐based RNA therapies.</p>
<p>The immune reactions of hypersensitivity (i.e., rash, dyspnea, chills, chest pain, tachycardia, hypotension, hypertension) and anaphylaxis observed with the COVID‐19 vaccines have been reported with greater incidence compared to traditional vaccines, with an estimated anaphylaxis event of 2.5–5/1,000,000 vaccine doses [<a href="#jimd70078-bib-0120" class="usa-link" aria-describedby="jimd70078-bib-0120">120</a>, <a href="#jimd70078-bib-0124" class="usa-link" aria-describedby="jimd70078-bib-0124">124</a>]. This risk was 5000 times higher in known allergic patients [<a href="#jimd70078-bib-0121" class="usa-link" aria-describedby="jimd70078-bib-0121">121</a>].</p>
<p>Patisiran (Onpattro) produced by Alnylam, is a double‐stranded siRNA encapsulated in LNP and approved for the treatment of hereditary transthyretin amyloidosis. Hereditary transthyretin amyloidosis is a genetic, progressively fatal disease, causing neuropathy and cardiomyopathy due to the accumulation of amyloid fibrils composed of misfolded transthyretin aggregates. Patisiran, administered intravenously every 3 weeks, acts by inhibiting the synthesis of the transthyretin protein in hepatocytes. Patisiran was approved in 2018 by the FDA, becoming the first type of drug developed with LNP encapsulation of nucleic acids. The most common adverse reactions associated with patisiran are upper respiratory tract infections and infusion‐related reactions, with flushing, abdominal pain, nausea, respiratory symptoms, headache, rash, tachycardia and/or changes in blood pressure. All patients are required to receive premedication based on corticosteroids, acetaminophen and anti‐histamines (H1 and H2 blockers) [<a href="#jimd70078-bib-0125" class="usa-link" aria-describedby="jimd70078-bib-0125">125</a>]. In clinical trials, infusion‐related reactions were observed in 19% of patients versus 9% in placebo controls, with 79% occurring during the first 2 infusions and frequency decreasing over time. These reactions led to infusion interruption and permanent treatment discontinuation in 5% and &lt; 1% of patients, respectively [<a href="#jimd70078-bib-0122" class="usa-link" aria-describedby="jimd70078-bib-0122">122</a>].</p>
<p>LNP‐mediated hypersensitivity or anaphylaxis adverse events described in populations treated by mRNA‐LNP based vaccines can be triggered by IgE‐mediated classical pathway or IgM‐mediated (IgE independent) reactions. In IgE‐mediated reactions, IgE binds to the mast cells and basophilic granulocytes and will cause the release of histamine, prostaglandins, leukotrienes and tryptase. This can be triggered by anti‐PEG IgE antibodies, for example [<a href="#jimd70078-bib-0126" class="usa-link" aria-describedby="jimd70078-bib-0126">126</a>]. Another mechanism is CARPA, where anti‐PEG IgM binds to the LNP and activates the classical complement pathway, with the generation of complement products C3a, C4a, C5a, which act as anaphylatoxins, potentially causing anaphylactic reactions [<a href="#jimd70078-bib-0126" class="usa-link" aria-describedby="jimd70078-bib-0126">126</a>]. CARPA reactions can be reproduced in piglets following the injection of PEGylated liposomes or mRNA‐LNP vaccines. This causes anaphylactic shock and pulmonary hypertension, thereby enabling close monitoring of PEG‐triggered hypersensitivity reactions and complement activation in a large animal model [<a href="#jimd70078-bib-0127" class="usa-link" aria-describedby="jimd70078-bib-0127">127</a>, <a href="#jimd70078-bib-0128" class="usa-link" aria-describedby="jimd70078-bib-0128">128</a>]. Therefore, current enrolment criteria for clinical trials targeting IMDs can exclude patients with a severe allergic reaction to liposomal or PEG‐containing products, like for the OTC deficiency trial (<a href="https://clinicaltrials.gov/ct2/show/NCT05526066" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05526066</a>, terminated as of April 2025) [<a href="#jimd70078-bib-0111" class="usa-link" aria-describedby="jimd70078-bib-0111">111</a>].</p>
<p>Autoimmune reactivity, which has been observed in mRNA‐LNP vaccination, has not been described in IMD‐treated patients [<a href="#jimd70078-bib-0115" class="usa-link" aria-describedby="jimd70078-bib-0115">115</a>].</p></section><section id="jimd70078-sec-0013"><h2 class="pmc_sec_title">6. Perspectives on Translational Use of mRNA‐LNP as Therapy for IMD: Bridge or Long‐Term Cure?</h2>
<p>With a rapidly growing number of successful preclinical studies and emerging clinical data in liver IMDs, the therapeutic promise of mRNA therapy for these conditions cannot be disputed. Interestingly, its versatility with transient effect and possible modifications of dose or injection frequency provides flexibility in its use, which had not been conceptually envisaged when gene therapy was initially considered and developed as a one‐off cure. This adaptability opens opportunities for liver IMDs.</p>
<p>AAV gene replacement therapy is currently the leading gene therapy technology for liver IMDs with hundreds of clinical trials reported in monogenic diseases [<a href="#jimd70078-bib-0013" class="usa-link" aria-describedby="jimd70078-bib-0013">13</a>, <a href="#jimd70078-bib-0015" class="usa-link" aria-describedby="jimd70078-bib-0015">15</a>, <a href="#jimd70078-bib-0129" class="usa-link" aria-describedby="jimd70078-bib-0129">129</a>]. However, major limitations persist such as pre‐existing immunogenicity to AAV capsids resulting in exclusion of patient cohorts, innate and adaptive immune reactions post‐dosing, inability to re‐dose, limited sustained efficacy in the growing paediatric liver, limited transgene packaging capacity and high production costs [<a href="#jimd70078-bib-0013" class="usa-link" aria-describedby="jimd70078-bib-0013">13</a>, <a href="#jimd70078-bib-0129" class="usa-link" aria-describedby="jimd70078-bib-0129">129</a>, <a href="#jimd70078-bib-0130" class="usa-link" aria-describedby="jimd70078-bib-0130">130</a>]. Emerging research using integrating vectors such as lentiviral vectors or nuclease‐mediated integration strategies could enable long‐lasting expression due to integration of the therapeutic transgene in the host genome. Additionally, lentiviral vectors have increased payload capacity up to 15 kilobases [<a href="#jimd70078-bib-0131" class="usa-link" aria-describedby="jimd70078-bib-0131">131</a>]. But uncertainty remains regarding the long‐term efficacy and safety, with risks of insertional mutagenesis from off‐target integrations [<a href="#jimd70078-bib-0130" class="usa-link" aria-describedby="jimd70078-bib-0130">130</a>].</p>
<p>Protein/enzyme replacement therapy allows direct protein delivery bypassing complex cellular transcription and translation. This has been applied in diseases requiring substitution of hormones, enzymes, blood clotting factors and interferons. But protein instability and short half‐life, potential immunogenicity favoured by peak and trough alternations [<a href="#jimd70078-bib-0132" class="usa-link" aria-describedby="jimd70078-bib-0132">132</a>] and limited uptake, unless mediated by mannose 6‐phosphate receptor for lysosomal targeting, have prevented wide implementation of this strategy. Furthermore, this strategy may be difficult to implement for transcriptional factors and other regulatory molecules [<a href="#jimd70078-bib-0133" class="usa-link" aria-describedby="jimd70078-bib-0133">133</a>, <a href="#jimd70078-bib-0134" class="usa-link" aria-describedby="jimd70078-bib-0134">134</a>].</p>
<p>In contrast, mRNA therapy for protein replacement bypasses most limitations of the viral gene therapies (Table <a href="#jimd70078-tbl-0004" class="usa-link">4</a>). The advances in mRNA design and production have enabled longer half‐life and greater efficacy, achieving high levels of expression, while its transient nature provides greater control [<a href="#jimd70078-bib-0005" class="usa-link" aria-describedby="jimd70078-bib-0005">5</a>]. Larger transgenes can be targeted due to the large packaging capacity of LNP [<a href="#jimd70078-bib-0047" class="usa-link" aria-describedby="jimd70078-bib-0047">47</a>]. Developments in the field of LNP have resulted in their increased safety, which enables continued re‐dosing with acceptable safety and no noticeable immunogenicity against the transgenic protein [<a href="#jimd70078-bib-0005" class="usa-link" aria-describedby="jimd70078-bib-0005">5</a>, <a href="#jimd70078-bib-0047" class="usa-link" aria-describedby="jimd70078-bib-0047">47</a>]. Although long‐term follow‐up studies are required to assess the benefit–risk ratio, the lack of permanent genetic alteration will be highly favourable.</p>
<section class="tw xbox font-sm" id="jimd70078-tbl-0004"><h3 class="obj_head">TABLE 4.</h3>
<div class="caption p"><p>Comparing lead viral and non‐viral technologies for in vivo gene delivery.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">AAV</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">mRNA</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Lentivirus</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="2" valign="top" colspan="1">Technology</td>
<td align="center" valign="top" rowspan="1" colspan="1">Large Transgene</td>
<td align="center" valign="top" rowspan="1" colspan="1">No</td>
<td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
<td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Time for efficacy</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–2 days</td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; 2–6 h</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–3 days</td>
</tr>
<tr>
<td align="left" rowspan="2" valign="top" colspan="1">Manufacturing</td>
<td align="center" valign="top" rowspan="1" colspan="1">Cost</td>
<td align="center" valign="top" rowspan="1" colspan="1">High</td>
<td align="center" valign="top" rowspan="1" colspan="1">Moderate</td>
<td align="center" valign="top" rowspan="1" colspan="1">High</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Pre‐immunisation issues</td>
<td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
<td align="center" valign="top" rowspan="1" colspan="1">No</td>
<td align="center" valign="top" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="5" valign="top" colspan="1">Safety in humans</td>
<td align="center" valign="top" rowspan="1" colspan="1">Innate immune response</td>
<td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
<td align="center" valign="top" rowspan="1" colspan="1">Not observed in humans</td>
<td align="center" valign="top" rowspan="1" colspan="1">Not tested in humans</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Liver toxicity</td>
<td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
<td align="center" valign="top" rowspan="1" colspan="1">Not observed in humans</td>
<td align="center" valign="top" rowspan="1" colspan="1">Not tested in humans</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Transient Immunosuppression</td>
<td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
<td align="center" valign="top" rowspan="1" colspan="1">No</td>
<td align="center" valign="top" rowspan="1" colspan="1">Not tested in humans</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Integration</td>
<td align="center" valign="top" rowspan="1" colspan="1">Yes (low rate)</td>
<td align="center" valign="top" rowspan="1" colspan="1">No</td>
<td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Re‐injection required</td>
<td align="center" valign="top" rowspan="1" colspan="1">No</td>
<td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
<td align="center" valign="top" rowspan="1" colspan="1">No</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/jimd70078-tbl-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>The transient nature of mRNA is a double‐edged sword, providing flexibility and safety but requiring repeated dosing. Long‐term safety implications from repeated mRNA‐LNP administrations remain unknown in the absence of clinical data. Notwithstanding, lifelong dependency on this therapy presents inherent complexity. Economically, viral gene therapies incur large upfront costs, with annual spending on gene therapies predicted to reach $20.4 billion annually [<a href="#jimd70078-bib-0135" class="usa-link" aria-describedby="jimd70078-bib-0135">135</a>]. However, these costs are expected to be a one‐off payment for a lifelong therapy. mRNA‐LNP therapy will require sustained expenses over the patient's lifetime [<a href="#jimd70078-bib-0136" class="usa-link" aria-describedby="jimd70078-bib-0136">136</a>]. Manufacturing and delivery costs will need to be considered, and there is no guarantee that mRNA therapies could be marketed at a cheaper cost than expensive enzyme replacement therapies [<a href="#jimd70078-bib-0137" class="usa-link" aria-describedby="jimd70078-bib-0137">137</a>], especially in targeting rare diseases [<a href="#jimd70078-bib-0138" class="usa-link" aria-describedby="jimd70078-bib-0138">138</a>]. Repeated intravenous administrations might become a significant constraint over time.</p>
<p>Altogether, mRNA‐LNP could be used through various therapeutic modes:
</p>
<ul id="jimd70078-list-0001" class="list" style="list-style-type:none">
<li id="jimd70078-li-0001">
<span class="label">–</span><p class="display-inline">A long‐term cure with lifelong repeated administrations would be appropriate for many liver IMDs, avoiding the need for liver transplantation or viral gene therapy. This might be an option favoured particularly for patients with anti‐AAV neutralising antibodies.</p>
</li>
<li id="jimd70078-li-0002">
<span class="label">–</span><p class="display-inline">Using mRNA‐LNP as a rescue therapy during acute metabolic decompensation of certain IMDs (e.g., UCDs, MSUD, organic acidemias, porphyrias) is attractive due to the early peak of plasma mRNA observed in humans and the rapid expression of the transgenic protein in preclinical models. Both parameters are seen as early as 2 h post‐dosing; probably explained by the bypass of the nuclear gene expression machinery [<a href="#jimd70078-bib-0021" class="usa-link" aria-describedby="jimd70078-bib-0021">21</a>, <a href="#jimd70078-bib-0072" class="usa-link" aria-describedby="jimd70078-bib-0072">72</a>]. The transient effect will enable return to baseline therapy following recovery. This requires rapid access to therapy and might be a logistical challenge.</p>
</li>
<li id="jimd70078-li-0003">
<span class="label">–</span><p class="display-inline">mRNA therapy could be used as a bridge to stabilise and prepare the patient for a one‐off curative approach, for example, reaching a weight threshold for a safer liver transplantation or preventing a damaging chronic liver disease as a complication of the underlying genetic IMD for AAV gene replacement or integration/editing. Depending on the context, this transient period could last from a few weeks to many years.</p>
</li>
<li id="jimd70078-li-0004">
<span class="label">–</span><p class="display-inline">mRNA‐LNP could be used as a transient therapy to control symptomatic phases of liver IMDs, which have a natural history with age‐related clinical presentation. This therapy could then be stopped when the disease is metabolically well‐controlled and re‐initiated again according to the patient's needs. An example could be citrin deficiency, which presents with an initial symptomatic neonatal presentation with neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), which could require transient mRNA therapy especially for severe cases. NICCD is followed by a post‐NICCD period when most patients are asymptomatic with strong diet specificities such as preference for protein‐ and/or lipid‐enriched food and aversion for carbohydrates [<a href="#jimd70078-bib-0139" class="usa-link" aria-describedby="jimd70078-bib-0139">139</a>]. These patients are unlikely to require mRNA therapy unless they present with failure to thrive and dyslipidemia in citrin deficiency (FTTDCD) or develop a damaging chronic liver disease with liver fibrosis/cirrhosis [<a href="#jimd70078-bib-0139" class="usa-link" aria-describedby="jimd70078-bib-0139">139</a>]. The incidence of adolescent and adult citrin deficiency (AACD) with hyperammonemic coma and neuropsychiatric complications is &lt;10% [<a href="#jimd70078-bib-0140" class="usa-link" aria-describedby="jimd70078-bib-0140">140</a>]. Liver cirrhosis or pancreatitis might be observed too. These AACD complications would require mRNA‐LNP therapy.</p>
</li>
<li id="jimd70078-li-0005">
<span class="label">–</span><p class="display-inline">mRNA therapy could be used as a time‐limited adjuvant to existing therapy. This could be to correct poor metabolic control at a critical age for neurodevelopment, like in infants with phenylketonuria and prolonged inadequate control of phenylalanine levels, or pregnant women with phenylketonuria to prevent foetal complications. Equally, this could be considered when a patient is at a transient higher risk of severe acute decompensation, like in the peripartum for pregnant women affected by UCDs.</p>
</li>
</ul>
<p>Whether mRNA therapy will become preferentially used as a long‐term cure or bridging approach is difficult to predict, especially as, in the diverse landscape of liver IMDs, each disease has specificities, and each patient may have a different perception. Options will need to be explored on a case‐by‐case basis, further guided by future clinical safety and efficacy outcomes.</p>
<p>Considering the prolonged journey of drug development for rare diseases, the increasing number of proof‐of‐concept studies contrasts with the limited number of clinical trials. This bottleneck needs to be addressed so that as many patients as possible could benefit from these therapies. However, the resources in setting up these complex first‐in‐human clinical trials with worldwide recruitment are limited, requiring a stagger of these clinical programmes.</p>
<p>Additionally, the advantages of mRNA‐LNP are being rapidly developed to mediate genome editing whereby the mRNA is encoding the editing enzyme [<a href="#jimd70078-bib-0053" class="usa-link" aria-describedby="jimd70078-bib-0053">53</a>]. This could result in lifelong cure with gene alteration or insertion, potentially at a specific “safe harbour” genetic locus, while the transient expression of the editing enzyme increases safety by reducing off‐target toxicity. This rapidly emerging field would provide an appealing perspective to provide lifelong cure using mRNA‐LNP. Different approaches have recently been successfully reported. A combinatorial approach with a sleeping beauty transposase delivered by mRNA‐LNP alongside an AAV‐delivered OTC transgene treated an OTC‐deficient mouse model and showed safety in non‐human primates [<a href="#jimd70078-bib-0141" class="usa-link" aria-describedby="jimd70078-bib-0141">141</a>]. CRISPR adenine base editor mRNA and single‐guide RNA encapsulated in LNP have cured induced pluripotent stem cell derived hepatocytes harbouring the Finnish founder ASL mutation c.1153C&gt;T causing argininosuccinic aciduria [<a href="#jimd70078-bib-0142" class="usa-link" aria-describedby="jimd70078-bib-0142">142</a>]. This approach has been successfully reported in a patient with neonatal‐onset of carbamoyl‐phosphate synthetase 1 (CPS1) deficiency, a compound heterozygote mutation in the CPS1 gene. An academic team designed a personalised “<em>n</em> = 1” clinical trial with an adenosine base editor to edit one missense mutation and alleviate the clinical phenotype, allowing them to stop the protein restricted diet, halve the ammonia scavenger dose and prevent hyperammonaemia during 2 following episodes of viral infections. The base editor was delivered by 2 consecutive doses of mRNA‐LNP administered at 0.1 mg/kg/dose, with no safety‐related issue. This first‐in‐human approach was achieved within groundbreaking timelines of 7 months from the patient's diagnosis and CPS1 sequencing to first dosing [<a href="#jimd70078-bib-0143" class="usa-link" aria-describedby="jimd70078-bib-0143">143</a>]. Prime editing was successfully tested in a mouse model of phenylketonuria, delivering the prime editing guide RNA (pegRNA) via AAV vector and the prime editor via mRNA‐LNP. This enabled a 4% editing rate, sufficient to restore therapeutically relevant phenylalanine levels [<a href="#jimd70078-bib-0144" class="usa-link" aria-describedby="jimd70078-bib-0144">144</a>].</p>
<p>Overcoming the natural hepatic tropism of LNP is gradually becoming a key challenge alongside the needs to target extrahepatic organs. Many proof‐of‐concept studies have shown the use of targeted mRNA‐LNP technology for delivery to other organs such as bone marrow, skeletal muscle, heart, lung, adipose tissue, pancreas, placenta, brain and retina [<a href="#jimd70078-bib-0019" class="usa-link" aria-describedby="jimd70078-bib-0019">19</a>, <a href="#jimd70078-bib-0067" class="usa-link" aria-describedby="jimd70078-bib-0067">67</a>, <a href="#jimd70078-bib-0145" class="usa-link" aria-describedby="jimd70078-bib-0145">145</a>, <a href="#jimd70078-bib-0146" class="usa-link" aria-describedby="jimd70078-bib-0146">146</a>, <a href="#jimd70078-bib-0147" class="usa-link" aria-describedby="jimd70078-bib-0147">147</a>, <a href="#jimd70078-bib-0148" class="usa-link" aria-describedby="jimd70078-bib-0148">148</a>, <a href="#jimd70078-bib-0149" class="usa-link" aria-describedby="jimd70078-bib-0149">149</a>, <a href="#jimd70078-bib-0150" class="usa-link" aria-describedby="jimd70078-bib-0150">150</a>, <a href="#jimd70078-bib-0151" class="usa-link" aria-describedby="jimd70078-bib-0151">151</a>, <a href="#jimd70078-bib-0152" class="usa-link" aria-describedby="jimd70078-bib-0152">152</a>, <a href="#jimd70078-bib-0153" class="usa-link" aria-describedby="jimd70078-bib-0153">153</a>, <a href="#jimd70078-bib-0154" class="usa-link" aria-describedby="jimd70078-bib-0154">154</a>, <a href="#jimd70078-bib-0155" class="usa-link" aria-describedby="jimd70078-bib-0155">155</a>, <a href="#jimd70078-bib-0156" class="usa-link" aria-describedby="jimd70078-bib-0156">156</a>, <a href="#jimd70078-bib-0157" class="usa-link" aria-describedby="jimd70078-bib-0157">157</a>, <a href="#jimd70078-bib-0158" class="usa-link" aria-describedby="jimd70078-bib-0158">158</a>, <a href="#jimd70078-bib-0159" class="usa-link" aria-describedby="jimd70078-bib-0159">159</a>, <a href="#jimd70078-bib-0160" class="usa-link" aria-describedby="jimd70078-bib-0160">160</a>, <a href="#jimd70078-bib-0161" class="usa-link" aria-describedby="jimd70078-bib-0161">161</a>] (Figure <a href="#jimd70078-fig-0004" class="usa-link">4</a>). Specific targeting includes the incorporation of specific ligands (active targeting) or modifying lipid compositions (passive targeting) to enhance specificity to desired tissues and cells, delivered systemically and/or combined with site‐specific injections [<a href="#jimd70078-bib-0048" class="usa-link" aria-describedby="jimd70078-bib-0048">48</a>, <a href="#jimd70078-bib-0162" class="usa-link" aria-describedby="jimd70078-bib-0162">162</a>] Active targeting includes the addition of specific ligands, peptides, or antibodies to the LNP surface while passive targeting relies on LNP physicochemical properties such as size, charge and lipid composition. Novel technologies such as nanoprimers have been developed to block liver uptake and avoid natural liver accumulation [<a href="#jimd70078-bib-0163" class="usa-link" aria-describedby="jimd70078-bib-0163">163</a>]. This approach uses liposomes called Nanoprimer as a decoy to limit the uptake of mRNA‐LNP of interest administered secondarily. Such potential of targeted LNP will expand the toolbox of mRNA‐LNP to applications well beyond liver IMDs.</p>
<figure class="fig xbox font-sm" id="jimd70078-fig-0004"><h3 class="obj_head">FIGURE 4.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ebd/12361847/7014460735d8/JIMD-48-0-g002.jpg" loading="lazy" id="jats-graphic-7" height="714" width="709" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/jimd70078-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Schematic illustrating the surface functionalizations of lipid nanoparticles to enhance organ‐specific delivery. Lipid nanoparticles (LNPs) have a natural affinity for the liver due to their interactions with serum apolipoprotein E (ApoE), which facilitates hepatocyte uptake [<a href="#jimd70078-bib-0019" class="usa-link" aria-describedby="jimd70078-bib-0019">19</a>]. Ligands such as mannose have been used to target liver sinusoidal epithelial cells [<a href="#jimd70078-bib-0152" class="usa-link" aria-describedby="jimd70078-bib-0152">152</a>]. Haematopoietic stem cells (HSCs) have been reprogrammed in the bone marrow by mRNA‐LNPs decorated with the anti‐CD117 ligand [<a href="#jimd70078-bib-0147" class="usa-link" aria-describedby="jimd70078-bib-0147">147</a>], and in the foetal liver with anti‐CD45‐coated mRNA‐LNPs [<a href="#jimd70078-bib-0153" class="usa-link" aria-describedby="jimd70078-bib-0153">153</a>]. Brain‐targeted LNPs primarily employ strategies to overcome the blood–brain barrier (BBB), such as functionalization with low‐density lipoprotein receptor‐related protein 1 (LRP1)‐binding peptide angiopep‐2 [<a href="#jimd70078-bib-0154" class="usa-link" aria-describedby="jimd70078-bib-0154">154</a>] or anti‐transferrin receptor ligands [<a href="#jimd70078-bib-0155" class="usa-link" aria-describedby="jimd70078-bib-0155">155</a>], which engage receptor‐mediated transcytosis in brain endothelial cells to significantly improve brain uptake. Novel organ‐targeting peptides have been identified by phage‐display peptide screening, including a prohibitin‐binding peptide that drives selective adipocyte uptake and the MH42 peptide that directs LNPs to the retina [<a href="#jimd70078-bib-0067" class="usa-link" aria-describedby="jimd70078-bib-0067">67</a>, <a href="#jimd70078-bib-0156" class="usa-link" aria-describedby="jimd70078-bib-0156">156</a>]. Further, chemically synthesised peptides such as the placental chondroitin sulphate A‐binding peptide were shown to enhance placental drug delivery [<a href="#jimd70078-bib-0157" class="usa-link" aria-describedby="jimd70078-bib-0157">157</a>]. The addition of vitamin D3 analogs to liver‐targeting LNPs markedly improves pancreatic targeting [<a href="#jimd70078-bib-0161" class="usa-link" aria-describedby="jimd70078-bib-0161">161</a>]. In the lungs, vitronectin‐ and anti‐PV1‐coated LNPs show selective targeting [<a href="#jimd70078-bib-0158" class="usa-link" aria-describedby="jimd70078-bib-0158">158</a>, <a href="#jimd70078-bib-0159" class="usa-link" aria-describedby="jimd70078-bib-0159">159</a>], while muscle‐specific delivery has been achieved using specialised ionizable lipids such as D‐Lin and TCL053 [<a href="#jimd70078-bib-0148" class="usa-link" aria-describedby="jimd70078-bib-0148">148</a>, <a href="#jimd70078-bib-0160" class="usa-link" aria-describedby="jimd70078-bib-0160">160</a>].</p></figcaption></figure></section><section id="jimd70078-sec-0014"><h2 class="pmc_sec_title">7. Conclusion</h2>
<p>mRNA‐LNP is an appealing technology for rare diseases. Its prominent efficacy in preclinical models and early safety data in clinical trials provide hope that therapeutic mRNA will become a significant step‐change for patients with IMDs. Questions on the safety and viability of therapeutic mRNA as a lifelong therapy will gradually be answered by ongoing clinical trials. Improving understanding and prevention of infusion‐related reactions is another avenue of research. However, limited resources and the necessity of global trials to target cohorts of patients with IMDs remain the bottleneck to translating numerous proof‐of‐concept preclinical studies. How this impediment will be addressed in the near future is unclear. As time elapses and experience grows, the versatility of therapeutic mRNA should become a pivotal asset for clinicians, with multiple combinations of clinical use as bridge, long‐term cure, rescue, or adjuvant therapy. The rapid development of mRNA‐LNP for gene editing/insertion should provide an alternative and potentially safer approach for a one‐off cure. Ultimately, mRNA‐LNP therapy is poised to generate a significant therapeutic impact within the landscape of liver IMDs.</p></section><section id="jimd70078-sec-0017"><h2 class="pmc_sec_title">Disclosure</h2>
<p>All authors have seen and approved the manuscript. This manuscript has not been accepted or published elsewhere.</p></section><section id="jimd70078-sec-0016"><h2 class="pmc_sec_title">Ethics Statement</h2>
<p>The authors have nothing to report.</p></section><section id="jimd70078-sec-0015"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>S.G. and J.B. are in receipt of research funding from Moderna Inc.</p></section><section id="notes1"><p>

Gurung S., Perocheau D., Ghosh R., Hart S. L., and Baruteau J., “Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases,” Journal of Inherited Metabolic Disease
48, no. 5 (2025): e70078, 10.1002/jimd.70078.
</p>
<section id="jimd70078-ntgp-0001" class="fn-group"><div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="jimd70078-note-0001"><p>
<strong>Communicating Editor:</strong> Johannes Häberle</p></div>
<div class="fn p" id="jimd70078-note-0002"><p>
<strong>Funding:</strong> This work was supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre (S.G., S.L.H., J.B.), a Medical Research Council Clinician Scientist Fellowship MR/T008024/1, MR/Z504154/1 (J.B.), Great Ormond Street Hospital Charity VS2508 (S.G., J.B.), the Citrin Foundation RG24002 (J.B.) and a research grant from Moderna Inc. (S.G., J.B.). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.</p></div>
</div></section></section><section id="jimd70078-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="jimd70078-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="jimd70078-bib-0001">
<span class="label">1.</span><cite>
“Gene, Cell, &amp; RNA Therapy Landscape Report Q4 2024 Quarterly Data Report,” (2024), <a href="https://www.asgct.org/global/documents/asgct-citeline-q4-2024-report.aspx" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.asgct.org/global/documents/asgct‐citeline‐q4‐2024‐report.aspx</a>.</cite>
</li>
<li id="jimd70078-bib-0002">
<span class="label">2.</span><cite>
Wang F., Zuroske T., and Watts J. K., “RNA Therapeutics on the Rise,” Nature Reviews. Drug Discovery
19 (2020): 441–442, 10.1038/d41573-020-00078-0.</cite> [<a href="https://doi.org/10.1038/d41573-020-00078-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32341501/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews.%20Drug%20Discovery&amp;title=RNA%20Therapeutics%20on%20the%20Rise&amp;author=F.%20Wang&amp;author=T.%20Zuroske&amp;author=J.%20K.%20Watts&amp;volume=19&amp;publication_year=2020&amp;pages=441-442&amp;pmid=32341501&amp;doi=10.1038/d41573-020-00078-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0003">
<span class="label">3.</span><cite>
Androsavich J. R., “Frameworks for Transformational Breakthroughs in RNA‐Based Medicines,” Nature Reviews. Drug Discovery
23 (2024): 421–444, 10.1038/s41573-024-00943-2.
</cite> [<a href="https://doi.org/10.1038/s41573-024-00943-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38740953/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews.%20Drug%20Discovery&amp;title=Frameworks%20for%20Transformational%20Breakthroughs%20in%20RNA%E2%80%90Based%20Medicines&amp;author=J.%20R.%20Androsavich&amp;volume=23&amp;publication_year=2024&amp;pages=421-444&amp;pmid=38740953&amp;doi=10.1038/s41573-024-00943-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0004">
<span class="label">4.</span><cite>
Chaudhary N., Weissman D., and Whitehead K. A., “mRNA Vaccines for Infectious Diseases: Principles, Delivery and Clinical Translation,” Nature Reviews. Drug Discovery
20, no. 11 (2021): 817–838, 10.1038/s41573-021-00283-5.
</cite> [<a href="https://doi.org/10.1038/s41573-021-00283-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8386155/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34433919/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews.%20Drug%20Discovery&amp;title=mRNA%20Vaccines%20for%20Infectious%20Diseases:%20Principles,%20Delivery%20and%20Clinical%20Translation&amp;author=N.%20Chaudhary&amp;author=D.%20Weissman&amp;author=K.%20A.%20Whitehead&amp;volume=20&amp;issue=11&amp;publication_year=2021&amp;pages=817-838&amp;pmid=34433919&amp;doi=10.1038/s41573-021-00283-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0005">
<span class="label">5.</span><cite>
Qin S., Tang X., Chen Y., et al., “mRNA‐Based Therapeutics: Powerful and Versatile Tools to Combat Diseases,” Signal Transduction and Targeted Therapy
7, no. 1 (2022): 166, 10.1038/s41392-022-01007-w.
</cite> [<a href="https://doi.org/10.1038/s41392-022-01007-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9123296/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35597779/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Signal%20Transduction%20and%20Targeted%20Therapy&amp;title=mRNA%E2%80%90Based%20Therapeutics:%20Powerful%20and%20Versatile%20Tools%20to%20Combat%20Diseases&amp;author=S.%20Qin&amp;author=X.%20Tang&amp;author=Y.%20Chen&amp;volume=7&amp;issue=1&amp;publication_year=2022&amp;pages=166&amp;pmid=35597779&amp;doi=10.1038/s41392-022-01007-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0006">
<span class="label">6.</span><cite>
Kon E., Ad‐El N., Hazan‐Halevy I., Stotsky‐Oterin L., and Peer D., “Targeting Cancer With mRNA–Lipid Nanoparticles: Key Considerations and Future Prospects,” Nature Reviews. Clinical Oncology
20, no. 11 (2023): 739–754, 10.1038/s41571-023-00811-9.</cite> [<a href="https://doi.org/10.1038/s41571-023-00811-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37587254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews.%20Clinical%20Oncology&amp;title=Targeting%20Cancer%20With%20mRNA%E2%80%93Lipid%20Nanoparticles:%20Key%20Considerations%20and%20Future%20Prospects&amp;author=E.%20Kon&amp;author=N.%20Ad%E2%80%90El&amp;author=I.%20Hazan%E2%80%90Halevy&amp;author=L.%20Stotsky%E2%80%90Oterin&amp;author=D.%20Peer&amp;volume=20&amp;issue=11&amp;publication_year=2023&amp;pages=739-754&amp;pmid=37587254&amp;doi=10.1038/s41571-023-00811-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0007">
<span class="label">7.</span><cite>
Berraondo P., Martini P. G. V., Avila M. A., and Fontanellas A., “Messenger RNA Therapy for Rare Genetic Metabolic Diseases,” Gut
68, no. 7 (2019): 1323–1330, 10.1136/gutjnl-2019-318269.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2019-318269" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30796097/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=Messenger%20RNA%20Therapy%20for%20Rare%20Genetic%20Metabolic%20Diseases&amp;author=P.%20Berraondo&amp;author=P.%20G.%20V.%20Martini&amp;author=M.%20A.%20Avila&amp;author=A.%20Fontanellas&amp;volume=68&amp;issue=7&amp;publication_year=2019&amp;pages=1323-1330&amp;pmid=30796097&amp;doi=10.1136/gutjnl-2019-318269&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0008">
<span class="label">8.</span><cite>
Baden L. R., El Sahly H. M., Essink B., et al., “Efficacy and Safety of the mRNA‐1273 SARS‐CoV‐2 Vaccine,” New England Journal of Medicine
384 (2021): 403–416, 10.1056/nejmoa2035389.
</cite> [<a href="https://doi.org/10.1056/nejmoa2035389" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7787219/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33378609/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Efficacy%20and%20Safety%20of%20the%20mRNA%E2%80%901273%20SARS%E2%80%90CoV%E2%80%902%20Vaccine&amp;author=L.%20R.%20Baden&amp;author=H.%20M.%20El%20Sahly&amp;author=B.%20Essink&amp;volume=384&amp;publication_year=2021&amp;pages=403-416&amp;pmid=33378609&amp;doi=10.1056/nejmoa2035389&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0009">
<span class="label">9.</span><cite>
Polack F. P., Thomas S. J., Kitchin N., et al., “Safety and Efficacy of the BNT162b2 mRNA Covid‐19 Vaccine,” New England Journal of Medicine
383 (2020): 2603–2615, 10.1056/nejmoa2034577.
</cite> [<a href="https://doi.org/10.1056/nejmoa2034577" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7745181/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33301246/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Safety%20and%20Efficacy%20of%20the%20BNT162b2%20mRNA%20Covid%E2%80%9019%20Vaccine&amp;author=F.%20P.%20Polack&amp;author=S.%20J.%20Thomas&amp;author=N.%20Kitchin&amp;volume=383&amp;publication_year=2020&amp;pages=2603-2615&amp;pmid=33301246&amp;doi=10.1056/nejmoa2034577&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0010">
<span class="label">10.</span><cite>
Ezgu F., “Inborn Errors of Metabolism,” Advances in Clinical Chemistry
73 (2016): 195–250, 10.1016/BS.ACC.2015.12.001.
</cite> [<a href="https://doi.org/10.1016/BS.ACC.2015.12.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26975974/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advances%20in%20Clinical%20Chemistry&amp;title=Inborn%20Errors%20of%20Metabolism&amp;author=F.%20Ezgu&amp;volume=73&amp;publication_year=2016&amp;pages=195-250&amp;pmid=26975974&amp;doi=10.1016/BS.ACC.2015.12.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0011">
<span class="label">11.</span><cite>
Waters D., Adeloye D., Woolham D., Wastnedge E., Patel S., and Rudan I., “Global Birth Prevalence and Mortality From Inborn Errors of Metabolism: A Systematic Analysis of the Evidence,” Journal of Global Health
8, no. 2 (2018): 021102, 10.7189/jogh.08.021102.
</cite> [<a href="https://doi.org/10.7189/jogh.08.021102" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6237105/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30479748/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Global%20Health&amp;title=Global%20Birth%20Prevalence%20and%20Mortality%20From%20Inborn%20Errors%20of%20Metabolism:%20A%20Systematic%20Analysis%20of%20the%20Evidence&amp;author=D.%20Waters&amp;author=D.%20Adeloye&amp;author=D.%20Woolham&amp;author=E.%20Wastnedge&amp;author=S.%20Patel&amp;volume=8&amp;issue=2&amp;publication_year=2018&amp;pages=021102&amp;pmid=30479748&amp;doi=10.7189/jogh.08.021102&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0012">
<span class="label">12.</span><cite>
de Boer L., Cambi A., Verhagen L. M., et al., “Clinical and Biochemical Footprints of Inherited Metabolic Diseases. XII. Immunological Defects,” Molecular Genetics and Metabolism
139, no. 1 (2023): 107582, 10.1016/J.YMGME.2023.107582.
</cite> [<a href="https://doi.org/10.1016/J.YMGME.2023.107582" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10182388/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37087816/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Genetics%20and%20Metabolism&amp;title=Clinical%20and%20Biochemical%20Footprints%20of%20Inherited%20Metabolic%20Diseases.%20XII.%20Immunological%20Defects&amp;author=L.%20de%20Boer&amp;author=A.%20Cambi&amp;author=L.%20M.%20Verhagen&amp;volume=139&amp;issue=1&amp;publication_year=2023&amp;pages=107582&amp;pmid=37087816&amp;doi=10.1016/J.YMGME.2023.107582&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0013">
<span class="label">13.</span><cite>
Kuzmin D. A., Shutova M. V., Johnston N. R., et al., “The Clinical Landscape for AAV Gene Therapies,” Nature Reviews. Drug Discovery
20, no. 3 (2021): 173–174, 10.1038/d41573-021-00017-7.
</cite> [<a href="https://doi.org/10.1038/d41573-021-00017-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33495615/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews.%20Drug%20Discovery&amp;title=The%20Clinical%20Landscape%20for%20AAV%20Gene%20Therapies&amp;author=D.%20A.%20Kuzmin&amp;author=M.%20V.%20Shutova&amp;author=N.%20R.%20Johnston&amp;volume=20&amp;issue=3&amp;publication_year=2021&amp;pages=173-174&amp;pmid=33495615&amp;doi=10.1038/d41573-021-00017-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0014">
<span class="label">14.</span><cite>
Mendell J. R., Al‐Zaidy S. A., Rodino‐Klapac L. R., et al., “Current Clinical Applications of Gene Therapy With AAVs,” Molecular Therapy
29 (2021): 464–488, 10.1016/j.ymthe.2020.12.007.
</cite> [<a href="https://doi.org/10.1016/j.ymthe.2020.12.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7854298/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33309881/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy&amp;title=Current%20Clinical%20Applications%20of%20Gene%20Therapy%20With%20AAVs&amp;author=J.%20R.%20Mendell&amp;author=S.%20A.%20Al%E2%80%90Zaidy&amp;author=L.%20R.%20Rodino%E2%80%90Klapac&amp;volume=29&amp;publication_year=2021&amp;pages=464-488&amp;pmid=33309881&amp;doi=10.1016/j.ymthe.2020.12.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0015">
<span class="label">15.</span><cite>
Ginn S. L., Mandwie M., Alexander I. E., Edelstein M., and Abedi M. R., “Gene Therapy Clinical Trials Worldwide to 2023—An Update,” Journal of Gene Medicine
26, no. 8 (2024): e3721, 10.1002/jgm.3721.
</cite> [<a href="https://doi.org/10.1002/jgm.3721" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39114903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Gene%20Medicine&amp;title=Gene%20Therapy%20Clinical%20Trials%20Worldwide%20to%202023%E2%80%94An%20Update&amp;author=S.%20L.%20Ginn&amp;author=M.%20Mandwie&amp;author=I.%20E.%20Alexander&amp;author=M.%20Edelstein&amp;author=M.%20R.%20Abedi&amp;volume=26&amp;issue=8&amp;publication_year=2024&amp;pages=e3721&amp;pmid=39114903&amp;doi=10.1002/jgm.3721&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0016">
<span class="label">16.</span><cite>
Chuecos M. A. and Lagor W. R., “Liver Directed Adeno‐Associated Viral Vectors to Treat Metabolic Disease,” Journal of Inherited Metabolic Disease
47, no. 1 (2024): 22–40, 10.1002/jimd.12637.
</cite> [<a href="https://doi.org/10.1002/jimd.12637" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10687323/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37254440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Inherited%20Metabolic%20Disease&amp;title=Liver%20Directed%20Adeno%E2%80%90Associated%20Viral%20Vectors%20to%20Treat%20Metabolic%20Disease&amp;author=M.%20A.%20Chuecos&amp;author=W.%20R.%20Lagor&amp;volume=47&amp;issue=1&amp;publication_year=2024&amp;pages=22-40&amp;pmid=37254440&amp;doi=10.1002/jimd.12637&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0017">
<span class="label">17.</span><cite>
Baruteau J., Brunetti‐Pierri N., and Gissen P., “Liver‐Directed Gene Therapy for Inherited Metabolic Diseases,” Journal of Inherited Metabolic Disease
47, no. 1 (2024): 9–21, 10.1002/jimd.12709.
</cite> [<a href="https://doi.org/10.1002/jimd.12709" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38171926/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Inherited%20Metabolic%20Disease&amp;title=Liver%E2%80%90Directed%20Gene%20Therapy%20for%20Inherited%20Metabolic%20Diseases&amp;author=J.%20Baruteau&amp;author=N.%20Brunetti%E2%80%90Pierri&amp;author=P.%20Gissen&amp;volume=47&amp;issue=1&amp;publication_year=2024&amp;pages=9-21&amp;pmid=38171926&amp;doi=10.1002/jimd.12709&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0018">
<span class="label">18.</span><cite>
Akinc A., Querbes W., De S., et al., “Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand‐Based Mechanisms,” Molecular Therapy
18, no. 7 (2010): 1357–1364, 10.1038/mt.2010.85.
</cite> [<a href="https://doi.org/10.1038/mt.2010.85" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2911264/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20461061/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy&amp;title=Targeted%20Delivery%20of%20RNAi%20Therapeutics%20With%20Endogenous%20and%20Exogenous%20Ligand%E2%80%90Based%20Mechanisms&amp;author=A.%20Akinc&amp;author=W.%20Querbes&amp;author=S.%20De&amp;volume=18&amp;issue=7&amp;publication_year=2010&amp;pages=1357-1364&amp;pmid=20461061&amp;doi=10.1038/mt.2010.85&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0019">
<span class="label">19.</span><cite>
Hosseini‐Kharat M., Bremmell K. E., and Prestidge C. A., “Why Do Lipid Nanoparticles Target the Liver? Understanding of Biodistribution and Liver‐Specific Tropism,” Molecular Therapy ‐ Methods &amp; Clinical Development
33, no. 1 (2025): 101436, 10.1016/J.OMTM.2025.101436.
</cite> [<a href="https://doi.org/10.1016/J.OMTM.2025.101436" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11919328/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40104152/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy%20%E2%80%90%20Methods%20&amp;%20Clinical%20Development&amp;title=Why%20Do%20Lipid%20Nanoparticles%20Target%20the%20Liver?%20Understanding%20of%20Biodistribution%20and%20Liver%E2%80%90Specific%20Tropism&amp;author=M.%20Hosseini%E2%80%90Kharat&amp;author=K.%20E.%20Bremmell&amp;author=C.%20A.%20Prestidge&amp;volume=33&amp;issue=1&amp;publication_year=2025&amp;pages=101436&amp;pmid=40104152&amp;doi=10.1016/J.OMTM.2025.101436&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0020">
<span class="label">20.</span><cite>
Zhang Y. N., Poon W., Tavares A. J., McGilvray I. D., and Chan W. C. W., “Nanoparticle–Liver Interactions: Cellular Uptake and Hepatobiliary Elimination,” Journal of Controlled Release
240 (2016): 332–348, 10.1016/j.jconrel.2016.01.020.
</cite> [<a href="https://doi.org/10.1016/j.jconrel.2016.01.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26774224/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Controlled%20Release&amp;title=Nanoparticle%E2%80%93Liver%20Interactions:%20Cellular%20Uptake%20and%20Hepatobiliary%20Elimination&amp;author=Y.%20N.%20Zhang&amp;author=W.%20Poon&amp;author=A.%20J.%20Tavares&amp;author=I.%20D.%20McGilvray&amp;author=W.%20C.%20W.%20Chan&amp;volume=240&amp;publication_year=2016&amp;pages=332-348&amp;pmid=26774224&amp;doi=10.1016/j.jconrel.2016.01.020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0021">
<span class="label">21.</span><cite>
Koeberl D., Schulze A., Sondheimer N., et al., “Interim Analyses of a First‐In‐Human Phase 1/2 mRNA Trial for Propionic Acidaemia,” Nature
628 (2024): 872–877, 10.1038/s41586-024-07266-7.
</cite> [<a href="https://doi.org/10.1038/s41586-024-07266-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11156579/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38570682/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Interim%20Analyses%20of%20a%20First%E2%80%90In%E2%80%90Human%20Phase%201/2%20mRNA%20Trial%20for%20Propionic%20Acidaemia&amp;author=D.%20Koeberl&amp;author=A.%20Schulze&amp;author=N.%20Sondheimer&amp;volume=628&amp;publication_year=2024&amp;pages=872-877&amp;pmid=38570682&amp;doi=10.1038/s41586-024-07266-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0022">
<span class="label">22.</span><cite>
Burrows C., Helm M., and Zhou X., “Modulating RNA With Chemical Modifications,” Accounts of Chemical Research
57, no. 2 (2024): 175–176, 10.1021/acs.accounts.3c00770.
</cite> [<a href="https://doi.org/10.1021/acs.accounts.3c00770" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38225909/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Accounts%20of%20Chemical%20Research&amp;title=Modulating%20RNA%20With%20Chemical%20Modifications&amp;author=C.%20Burrows&amp;author=M.%20Helm&amp;author=X.%20Zhou&amp;volume=57&amp;issue=2&amp;publication_year=2024&amp;pages=175-176&amp;pmid=38225909&amp;doi=10.1021/acs.accounts.3c00770&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0023">
<span class="label">23.</span><cite>
Sahin U., Karikó K., and Türeci Ö., “mRNA‐Based Therapeutics – Developing a New Class of Drugs,” Nature Reviews. Drug Discovery
13 (2014): 759–780, 10.1038/nrd4278.
</cite> [<a href="https://doi.org/10.1038/nrd4278" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25233993/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews.%20Drug%20Discovery&amp;title=mRNA%E2%80%90Based%20Therapeutics%20%E2%80%93%20Developing%20a%20New%20Class%20of%20Drugs&amp;author=U.%20Sahin&amp;author=K.%20Karik%C3%B3&amp;author=%C3%96.%20T%C3%BCreci&amp;volume=13&amp;publication_year=2014&amp;pages=759-780&amp;pmid=25233993&amp;doi=10.1038/nrd4278&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0024">
<span class="label">24.</span><cite>
Kang D. D., Li H., and Dong Y., “Advancements of In Vitro Transcribed mRNA (IVT mRNA) to Enable Translation Into the Clinics,” Advanced Drug Delivery Reviews
199 (2023): 114961, 10.1016/j.addr.2023.114961.
</cite> [<a href="https://doi.org/10.1016/j.addr.2023.114961" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10264168/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37321375/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advanced%20Drug%20Delivery%20Reviews&amp;title=Advancements%20of%20In%C2%A0Vitro%20Transcribed%20mRNA%20(IVT%20mRNA)%20to%20Enable%20Translation%20Into%20the%20Clinics&amp;author=D.%20D.%20Kang&amp;author=H.%20Li&amp;author=Y.%20Dong&amp;volume=199&amp;publication_year=2023&amp;pages=114961&amp;pmid=37321375&amp;doi=10.1016/j.addr.2023.114961&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0025">
<span class="label">25.</span><cite>
Jia L. and Qian S. B., “Therapeutic mRNA Engineering From Head to Tail,” Accounts of Chemical Research
54, no. 23 (2021): 4272–4282, 10.1021/acs.accounts.1c00541.
</cite> [<a href="https://doi.org/10.1021/acs.accounts.1c00541" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34756012/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Accounts%20of%20Chemical%20Research&amp;title=Therapeutic%20mRNA%20Engineering%20From%20Head%20to%20Tail&amp;author=L.%20Jia&amp;author=S.%20B.%20Qian&amp;volume=54&amp;issue=23&amp;publication_year=2021&amp;pages=4272-4282&amp;pmid=34756012&amp;doi=10.1021/acs.accounts.1c00541&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0026">
<span class="label">26.</span><cite>
Nance K. D. and Meier J. L., “Modifications in an Emergency: The Role of N1‐Methylpseudouridine in COVID‐19 Vaccines,” ACS Central Science
7, no. 5 (2021): 748–756, 10.1021/acscentsci.1c00197.
</cite> [<a href="https://doi.org/10.1021/acscentsci.1c00197" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8043204/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34075344/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ACS%20Central%20Science&amp;title=Modifications%20in%20an%20Emergency:%20The%20Role%20of%20N1%E2%80%90Methylpseudouridine%20in%20COVID%E2%80%9019%20Vaccines&amp;author=K.%20D.%20Nance&amp;author=J.%20L.%20Meier&amp;volume=7&amp;issue=5&amp;publication_year=2021&amp;pages=748-756&amp;pmid=34075344&amp;doi=10.1021/acscentsci.1c00197&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0027">
<span class="label">27.</span><cite>
Andries O., Mc Cafferty S., De Smedt S. C., Weiss R., Sanders N. N., and Kitada T., “N1‐Methylpseudouridine‐Incorporated mRNA Outperforms Pseudouridine‐Incorporated mRNA by Providing Enhanced Protein Expression and Reduced Immunogenicity in Mammalian Cell Lines and Mice,” Journal of Controlled Release
217 (2015): 337–344.
</cite> [<a href="https://doi.org/10.1016/j.jconrel.2015.08.051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26342664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Controlled%20Release&amp;title=N1%E2%80%90Methylpseudouridine%E2%80%90Incorporated%20mRNA%20Outperforms%20Pseudouridine%E2%80%90Incorporated%20mRNA%20by%20Providing%20Enhanced%20Protein%20Expression%20and%20Reduced%20Immunogenicity%20in%20Mammalian%20Cell%20Lines%20and%20Mice&amp;author=O.%20Andries&amp;author=S.%20Mc%20Cafferty&amp;author=S.%20C.%20De%20Smedt&amp;author=R.%20Weiss&amp;author=N.%20N.%20Sanders&amp;volume=217&amp;publication_year=2015&amp;pages=337-344&amp;pmid=26342664&amp;doi=10.1016/j.jconrel.2015.08.051&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0028">
<span class="label">28.</span><cite>
Karikó K., Muramatsu H., Welsh F. A., et al., “Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability,” Molecular Therapy
16, no. 11 (2008): 1833–1840, 10.1038/mt.2008.200.
</cite> [<a href="https://doi.org/10.1038/mt.2008.200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2775451/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18797453/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy&amp;title=Incorporation%20of%20Pseudouridine%20Into%20mRNA%20Yields%20Superior%20Nonimmunogenic%20Vector%20With%20Increased%20Translational%20Capacity%20and%20Biological%20Stability&amp;author=K.%20Karik%C3%B3&amp;author=H.%20Muramatsu&amp;author=F.%20A.%20Welsh&amp;volume=16&amp;issue=11&amp;publication_year=2008&amp;pages=1833-1840&amp;pmid=18797453&amp;doi=10.1038/mt.2008.200&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0029">
<span class="label">29.</span><cite>
Komori M., Morey A. L., Quiñones‐Molina A. A., et al., “Incorporation of 5 Methylcytidine Alleviates Innate Immune Response to Self‐Amplifying RNA Vaccine,” bioRxiv, (2023), 11.01.565056, 10.1101/2023.11.01.565056.</cite> [<a href="https://doi.org/10.1101/2023.11.01.565056" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>]</li>
<li id="jimd70078-bib-0030">
<span class="label">30.</span><cite>
Zhang Y., Zhang L. S., Dai Q., et al., “5‐Methylcytosine (m5C) RNA Modification Controls the Innate Immune Response to Virus Infection by Regulating Type I Interferons,” Proceedings of the National Academy of Sciences of the United States of America
119, no. 42 (2022): e2123338119, 10.1073/pnas.2123338119.
</cite> [<a href="https://doi.org/10.1073/pnas.2123338119" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9586267/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36240321/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20of%20the%20United%20States%20of%20America&amp;title=5%E2%80%90Methylcytosine%20(m5C)%20RNA%20Modification%20Controls%20the%20Innate%20Immune%20Response%20to%20Virus%20Infection%20by%20Regulating%20Type%20I%20Interferons&amp;author=Y.%20Zhang&amp;author=L.%20S.%20Zhang&amp;author=Q.%20Dai&amp;volume=119&amp;issue=42&amp;publication_year=2022&amp;pages=e2123338119&amp;pmid=36240321&amp;doi=10.1073/pnas.2123338119&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0031">
<span class="label">31.</span><cite>
Bansal A., “From Rejection to the Nobel Prize: Karikó and Weissman's Pioneering Work on mRNA Vaccines, and the Need for Diversity and Inclusion in Translational Immunology,” Frontiers in Immunology
14 (2023): 1306025, 10.3389/fimmu.2023.1306025.
</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1306025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10663363/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38022662/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Immunology&amp;title=From%20Rejection%20to%20the%20Nobel%20Prize:%20Karik%C3%B3%20and%20Weissman's%20Pioneering%20Work%20on%20mRNA%20Vaccines,%20and%20the%20Need%20for%20Diversity%20and%20Inclusion%20in%20Translational%20Immunology&amp;author=A.%20Bansal&amp;volume=14&amp;publication_year=2023&amp;pages=1306025&amp;pmid=38022662&amp;doi=10.3389/fimmu.2023.1306025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0032">
<span class="label">32.</span><cite>
Son S., Park M., Kim J., and Lee K., “ACE mRNA (Additional Chimeric Element Incorporated IVT mRNA) for Enhancing Protein Expression by Modulating Immunogenicity,” Advanced Science
11 (2024): e2307541, 10.1002/advs.202307541.
</cite> [<a href="https://doi.org/10.1002/advs.202307541" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11095206/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38447169/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advanced%20Science&amp;title=ACE%20mRNA%20(Additional%20Chimeric%20Element%20Incorporated%20IVT%20mRNA)%20for%20Enhancing%20Protein%20Expression%20by%20Modulating%20Immunogenicity&amp;author=S.%20Son&amp;author=M.%20Park&amp;author=J.%20Kim&amp;author=K.%20Lee&amp;volume=11&amp;publication_year=2024&amp;pages=e2307541&amp;pmid=38447169&amp;doi=10.1002/advs.202307541&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0033">
<span class="label">33.</span><cite>
Ramanathan A., Robb G. B., and Chan S. H., “mRNA Capping: Biological Functions and Applications,” Nucleic Acids Research
44, no. 16 (2016): 7511–7526, 10.1093/nar/gkw551.
</cite> [<a href="https://doi.org/10.1093/nar/gkw551" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5027499/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27317694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Research&amp;title=mRNA%20Capping:%20Biological%20Functions%20and%20Applications&amp;author=A.%20Ramanathan&amp;author=G.%20B.%20Robb&amp;author=S.%20H.%20Chan&amp;volume=44&amp;issue=16&amp;publication_year=2016&amp;pages=7511-7526&amp;pmid=27317694&amp;doi=10.1093/nar/gkw551&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0034">
<span class="label">34.</span><cite>
Drazkowska K., Tomecki R., Warminski M., et al., “2′‐O‐Methylation of the Second Transcribed Nucleotide Within the mRNA 5′ Cap Impacts the Protein Production Level in a Cell‐Specific Manner and Contributes to RNA Immune Evasion,” Nucleic Acids Research
50, no. 16 (2022): 9051–9071, 10.1093/nar/gkac722.
</cite> [<a href="https://doi.org/10.1093/nar/gkac722" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9458431/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36018811/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Research&amp;title=2%E2%80%B2%E2%80%90O%E2%80%90Methylation%20of%20the%20Second%20Transcribed%20Nucleotide%20Within%20the%20mRNA%205%E2%80%B2%20Cap%20Impacts%20the%20Protein%20Production%20Level%20in%20a%20Cell%E2%80%90Specific%20Manner%20and%20Contributes%20to%20RNA%20Immune%20Evasion&amp;author=K.%20Drazkowska&amp;author=R.%20Tomecki&amp;author=M.%20Warminski&amp;volume=50&amp;issue=16&amp;publication_year=2022&amp;pages=9051-9071&amp;pmid=36018811&amp;doi=10.1093/nar/gkac722&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0035">
<span class="label">35.</span><cite>
Pasquinelli A. E., Dahlberg J. E., and Lund E., “Reverse 5′ Caps in RNAs Made In Vitro by Phage RNA Polymerases,” RNA
1, no. 9 (1995): 957–967.
</cite> [<a href="/articles/PMC1369344/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8548660/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RNA&amp;title=Reverse%205%E2%80%B2%20Caps%20in%20RNAs%20Made%20In%C2%A0Vitro%20by%20Phage%20RNA%20Polymerases&amp;author=A.%20E.%20Pasquinelli&amp;author=J.%20E.%20Dahlberg&amp;author=E.%20Lund&amp;volume=1&amp;issue=9&amp;publication_year=1995&amp;pages=957-967&amp;pmid=8548660&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0036">
<span class="label">36.</span><cite>
Stepinski J., Waddell C., Stolarski R., Darzynkiewicz E., and Rhoads R. E., “Synthesis and Properties of mRNAs Containing the Novel ‘Anti‐Reverse’ Cap Analogs 7‐Methyl(3′‐O‐Methyl)GpppG and 7‐Methyl(3′‐Deoxy)GpppG,” RNA
7, no. 10 (2001): 1486–1495.
</cite> [<a href="/articles/PMC1370192/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11680853/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RNA&amp;title=Synthesis%20and%20Properties%20of%20mRNAs%20Containing%20the%20Novel%20%E2%80%98Anti%E2%80%90Reverse%E2%80%99%20Cap%20Analogs%207%E2%80%90Methyl(3%E2%80%B2%E2%80%90O%E2%80%90Methyl)GpppG%20and%207%E2%80%90Methyl(3%E2%80%B2%E2%80%90Deoxy)GpppG&amp;author=J.%20Stepinski&amp;author=C.%20Waddell&amp;author=R.%20Stolarski&amp;author=E.%20Darzynkiewicz&amp;author=R.%20E.%20Rhoads&amp;volume=7&amp;issue=10&amp;publication_year=2001&amp;pages=1486-1495&amp;pmid=11680853&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0037">
<span class="label">37.</span><cite>
Jemielity J., Fowler T., Zuberek J., et al., “Novel “Anti‐Reverse” Cap Analogs With Superior Translational Properties,” RNA
9, no. 9 (2003): 1108–1122, 10.1261/rna.5430403.
</cite> [<a href="https://doi.org/10.1261/rna.5430403" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1370475/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12923259/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RNA&amp;title=Novel%20%E2%80%9CAnti%E2%80%90Reverse%E2%80%9D%20Cap%20Analogs%20With%20Superior%20Translational%20Properties&amp;author=J.%20Jemielity&amp;author=T.%20Fowler&amp;author=J.%20Zuberek&amp;volume=9&amp;issue=9&amp;publication_year=2003&amp;pages=1108-1122&amp;pmid=12923259&amp;doi=10.1261/rna.5430403&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0038">
<span class="label">38.</span><cite>
Ross J. and Sullivan T. D., “Half‐Lives of Beta and Gamma Globin Messenger RNAs and of Protein Synthetic Capacity in Cultured Human Reticulocytes,” Blood
66, no. 5 (1985): 1149–1154, <a href="https://www.ncbi.nlm.nih.gov/pubmed/4052630" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/4052630</a>.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/4052630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Half%E2%80%90Lives%20of%20Beta%20and%20Gamma%20Globin%20Messenger%20RNAs%20and%20of%20Protein%20Synthetic%20Capacity%20in%20Cultured%20Human%20Reticulocytes&amp;author=J.%20Ross&amp;author=T.%20D.%20Sullivan&amp;volume=66&amp;issue=5&amp;publication_year=1985&amp;pages=1149-1154&amp;pmid=4052630&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0039">
<span class="label">39.</span><cite>
Cao J., Novoa E. M., Zhang Z., et al., “High‐Throughput 5′ UTR Engineering for Enhanced Protein Production in Non‐Viral Gene Therapies,” Nature Communications
12, no. 1 (2021): 4138, 10.1038/s41467-021-24436-7.</cite> [<a href="https://doi.org/10.1038/s41467-021-24436-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8260622/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34230498/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=High%E2%80%90Throughput%205%E2%80%B2%20UTR%20Engineering%20for%20Enhanced%20Protein%20Production%20in%20Non%E2%80%90Viral%20Gene%20Therapies&amp;author=J.%20Cao&amp;author=E.%20M.%20Novoa&amp;author=Z.%20Zhang&amp;volume=12&amp;issue=1&amp;publication_year=2021&amp;pages=4138&amp;pmid=34230498&amp;doi=10.1038/s41467-021-24436-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0040">
<span class="label">40.</span><cite>
Bae H. and Coller J., “Codon Optimality‐Mediated mRNA Degradation: Linking Translational Elongation to mRNA Stability,” Molecular Cell
82, no. 8 (2022): 1467–1476, 10.1016/j.molcel.2022.03.032.
</cite> [<a href="https://doi.org/10.1016/j.molcel.2022.03.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10111967/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35452615/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cell&amp;title=Codon%20Optimality%E2%80%90Mediated%20mRNA%20Degradation:%20Linking%20Translational%20Elongation%20to%20mRNA%20Stability&amp;author=H.%20Bae&amp;author=J.%20Coller&amp;volume=82&amp;issue=8&amp;publication_year=2022&amp;pages=1467-1476&amp;pmid=35452615&amp;doi=10.1016/j.molcel.2022.03.032&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0041">
<span class="label">41.</span><cite>
Pokorna S., Khersonsky O., Lipsh‐Sokolik R., et al., “Design of a Stable Human Acid‐β‐Glucosidase: Towards Improved Gaucher Disease Therapy and Mutation Classification,” FEBS Journal
290, no. 13 (2023): 3383–3393, 10.1111/febs.16758.
</cite> [<a href="https://doi.org/10.1111/febs.16758" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36808692/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FEBS%20Journal&amp;title=Design%20of%20a%20Stable%20Human%20Acid%E2%80%90%CE%B2%E2%80%90Glucosidase:%20Towards%20Improved%20Gaucher%20Disease%20Therapy%20and%20Mutation%20Classification&amp;author=S.%20Pokorna&amp;author=O.%20Khersonsky&amp;author=R.%20Lipsh%E2%80%90Sokolik&amp;volume=290&amp;issue=13&amp;publication_year=2023&amp;pages=3383-3393&amp;pmid=36808692&amp;doi=10.1111/febs.16758&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0042">
<span class="label">42.</span><cite>
Fabrizio C., I‐Mei Y., Kalcheva P., et al., “Generation of β‐Glucocerebrosidase Variants With Increased Half‐Life in Human Plasma for Liver Directed AAV Gene Therapy for the Treatment of Type 1 Gaucher Disease,” Molecular Genetics and Metabolism
132, no. 2 (2021): S27–S28, 10.1016/j.ymgme.2020.12.047.</cite> [<a href="https://doi.org/10.1016/j.ymgme.2020.12.047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Genetics%20and%20Metabolism&amp;title=Generation%20of%20%CE%B2%E2%80%90Glucocerebrosidase%20Variants%20With%20Increased%20Half%E2%80%90Life%20in%20Human%20Plasma%20for%20Liver%20Directed%20AAV%20Gene%20Therapy%20for%20the%20Treatment%20of%20Type%201%20Gaucher%20Disease&amp;author=C.%20Fabrizio&amp;author=Y.%20I%E2%80%90Mei&amp;author=P.%20Kalcheva&amp;volume=132&amp;issue=2&amp;publication_year=2021&amp;pages=S27-S28&amp;doi=10.1016/j.ymgme.2020.12.047&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0043">
<span class="label">43.</span><cite>
Aditham A., Shi H., Guo J., et al., “Chemically Modified mocRNAs for Highly Efficient Protein Expression in Mammalian Cells,” ACS Chemical Biology
17, no. 12 (2022): 3352–3366, 10.1021/acschembio.1c00569.
</cite> [<a href="https://doi.org/10.1021/acschembio.1c00569" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34995053/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ACS%20Chemical%20Biology&amp;title=Chemically%20Modified%20mocRNAs%20for%20Highly%20Efficient%20Protein%20Expression%20in%20Mammalian%20Cells&amp;author=A.%20Aditham&amp;author=H.%20Shi&amp;author=J.%20Guo&amp;volume=17&amp;issue=12&amp;publication_year=2022&amp;pages=3352-3366&amp;pmid=34995053&amp;doi=10.1021/acschembio.1c00569&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0044">
<span class="label">44.</span><cite>
Chen H., Liu D., Guo J., et al., “Branched Chemically Modified Poly(A) Tails Enhance the Translation Capacity of mRNA,” Nature Biotechnology
43 (2024): 194–203, 10.1038/s41587-024-02174-7.</cite> [<a href="https://doi.org/10.1038/s41587-024-02174-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11416571/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38519719/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Biotechnology&amp;title=Branched%20Chemically%20Modified%20Poly(A)%20Tails%20Enhance%20the%20Translation%20Capacity%20of%20mRNA&amp;author=H.%20Chen&amp;author=D.%20Liu&amp;author=J.%20Guo&amp;volume=43&amp;publication_year=2024&amp;pages=194-203&amp;pmid=38519719&amp;doi=10.1038/s41587-024-02174-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0045">
<span class="label">45.</span><cite>
Strzelecka D., Smietanski M., Sikorski P. J., Warminski M., Kowalska J., and Jemielity J., “Phosphodiester Modifications in mRNA Poly(A) Tail Prevent Deadenylation Without Compromising Protein Expression,” RNA
26, no. 12 (2020): 1815–1837, 10.1261/RNA.077099.120.
</cite> [<a href="https://doi.org/10.1261/RNA.077099.120" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7668260/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32820035/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RNA&amp;title=Phosphodiester%20Modifications%20in%20mRNA%20Poly(A)%20Tail%20Prevent%20Deadenylation%20Without%20Compromising%20Protein%20Expression&amp;author=D.%20Strzelecka&amp;author=M.%20Smietanski&amp;author=P.%20J.%20Sikorski&amp;author=M.%20Warminski&amp;author=J.%20Kowalska&amp;volume=26&amp;issue=12&amp;publication_year=2020&amp;pages=1815-1837&amp;pmid=32820035&amp;doi=10.1261/RNA.077099.120&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0046">
<span class="label">46.</span><cite>
Haghighi E., Abolmaali S. S., Dehshahri A., Mousavi Shaegh S. A., Azarpira N., and Tamaddon A. M., “Navigating the Intricate In‐Vivo Journey of Lipid Nanoparticles Tailored for the Targeted Delivery of RNA Therapeutics: A Quality‐By‐Design Approach,” Journal of Nanobiotechnology
22, no. 1 (2024): 710, 10.1186/s12951-024-02972-w.
</cite> [<a href="https://doi.org/10.1186/s12951-024-02972-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11566655/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39543630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Nanobiotechnology&amp;title=Navigating%20the%20Intricate%20In%E2%80%90Vivo%20Journey%20of%20Lipid%20Nanoparticles%20Tailored%20for%20the%20Targeted%20Delivery%20of%20RNA%20Therapeutics:%20A%20Quality%E2%80%90By%E2%80%90Design%20Approach&amp;author=E.%20Haghighi&amp;author=S.%20S.%20Abolmaali&amp;author=A.%20Dehshahri&amp;author=S.%20A.%20Mousavi%20Shaegh&amp;author=N.%20Azarpira&amp;volume=22&amp;issue=1&amp;publication_year=2024&amp;pages=710&amp;pmid=39543630&amp;doi=10.1186/s12951-024-02972-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0047">
<span class="label">47.</span><cite>
Hou X., Zaks T., Langer R., and Dong Y., “Lipid Nanoparticles for mRNA Delivery,” Nature Reviews Materials
6, no. 12 (2021): 1078–1094, 10.1038/s41578-021-00358-0.
</cite> [<a href="https://doi.org/10.1038/s41578-021-00358-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8353930/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34394960/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Materials&amp;title=Lipid%20Nanoparticles%20for%20mRNA%20Delivery&amp;author=X.%20Hou&amp;author=T.%20Zaks&amp;author=R.%20Langer&amp;author=Y.%20Dong&amp;volume=6&amp;issue=12&amp;publication_year=2021&amp;pages=1078-1094&amp;pmid=34394960&amp;doi=10.1038/s41578-021-00358-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0048">
<span class="label">48.</span><cite>
Liu Y., Huang Y., He G., Guo C., Dong J., and Wu L., “Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects,” International Journal of Molecular Sciences
25, no. 18 (2024): 10166, 10.3390/ijms251810166.
</cite> [<a href="https://doi.org/10.3390/ijms251810166" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11432440/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39337651/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Molecular%20Sciences&amp;title=Development%20of%20mRNA%20Lipid%20Nanoparticles:%20Targeting%20and%20Therapeutic%20Aspects&amp;author=Y.%20Liu&amp;author=Y.%20Huang&amp;author=G.%20He&amp;author=C.%20Guo&amp;author=J.%20Dong&amp;volume=25&amp;issue=18&amp;publication_year=2024&amp;pages=10166&amp;pmid=39337651&amp;doi=10.3390/ijms251810166&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0049">
<span class="label">49.</span><cite>
Zhang Y., Sun C., Wang C., Jankovic K. E., and Dong Y., “Lipids and Lipid Derivatives for RNA Delivery,” Chemical Reviews
121, no. 20 (2021): 12181–12277, 10.1021/acs.chemrev.1c00244.
</cite> [<a href="https://doi.org/10.1021/acs.chemrev.1c00244" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10088400/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34279087/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chemical%20Reviews&amp;title=Lipids%20and%20Lipid%20Derivatives%20for%20RNA%20Delivery&amp;author=Y.%20Zhang&amp;author=C.%20Sun&amp;author=C.%20Wang&amp;author=K.%20E.%20Jankovic&amp;author=Y.%20Dong&amp;volume=121&amp;issue=20&amp;publication_year=2021&amp;pages=12181-12277&amp;pmid=34279087&amp;doi=10.1021/acs.chemrev.1c00244&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0050">
<span class="label">50.</span><cite>
Carvalho B. G., Ceccato B. T., Michelon M., Han S. W., and de la Torre L. G., “Advanced Microfluidic Technologies for Lipid Nano‐Microsystems From Synthesis to Biological Application,” Pharmaceutics
14, no. 1 (2022): 141, 10.3390/pharmaceutics14010141.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics14010141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8781930/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35057037/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceutics&amp;title=Advanced%20Microfluidic%20Technologies%20for%20Lipid%20Nano%E2%80%90Microsystems%20From%20Synthesis%20to%20Biological%20Application&amp;author=B.%20G.%20Carvalho&amp;author=B.%20T.%20Ceccato&amp;author=M.%20Michelon&amp;author=S.%20W.%20Han&amp;author=L.%20G.%20de%20la%20Torre&amp;volume=14&amp;issue=1&amp;publication_year=2022&amp;pages=141&amp;pmid=35057037&amp;doi=10.3390/pharmaceutics14010141&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0051">
<span class="label">51.</span><cite>
Akinc A., Maier M. A., Manoharan M., et al., “The Onpattro Story and the Clinical Translation of Nanomedicines Containing Nucleic Acid‐Based Drugs,” Nature Nanotechnology
14, no. 12 (2019): 1084–1087, 10.1038/s41565-019-0591-y.</cite> [<a href="https://doi.org/10.1038/s41565-019-0591-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31802031/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Nanotechnology&amp;title=The%20Onpattro%20Story%20and%20the%20Clinical%20Translation%20of%20Nanomedicines%20Containing%20Nucleic%20Acid%E2%80%90Based%20Drugs&amp;author=A.%20Akinc&amp;author=M.%20A.%20Maier&amp;author=M.%20Manoharan&amp;volume=14&amp;issue=12&amp;publication_year=2019&amp;pages=1084-1087&amp;pmid=31802031&amp;doi=10.1038/s41565-019-0591-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0052">
<span class="label">52.</span><cite>
Li D., Liu C., Li Y., et al., “Messenger RNA‐Based Therapeutics and Vaccines: What's Beyond COVID‐19?,” ACS Pharmacology &amp; Translational Science
6, no. 7 (2023): 943–969, 10.1021/acsptsci.3c00047.
</cite> [<a href="https://doi.org/10.1021/acsptsci.3c00047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10353067/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37470024/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ACS%20Pharmacology%20&amp;%20Translational%20Science&amp;title=Messenger%20RNA%E2%80%90Based%20Therapeutics%20and%20Vaccines:%20What's%20Beyond%20COVID%E2%80%9019?&amp;author=D.%20Li&amp;author=C.%20Liu&amp;author=Y.%20Li&amp;volume=6&amp;issue=7&amp;publication_year=2023&amp;pages=943-969&amp;pmid=37470024&amp;doi=10.1021/acsptsci.3c00047&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0053">
<span class="label">53.</span><cite>
Popovitz J., Sharma R., Hoshyar R., Soo Kim B., Murthy N., and Lee K., “Gene Editing Therapeutics Based on mRNA Delivery,” Advanced Drug Delivery Reviews
200 (2023): 115026, 10.1016/j.addr.2023.115026.
</cite> [<a href="https://doi.org/10.1016/j.addr.2023.115026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37516409/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advanced%20Drug%20Delivery%20Reviews&amp;title=Gene%20Editing%20Therapeutics%20Based%20on%20mRNA%20Delivery&amp;author=J.%20Popovitz&amp;author=R.%20Sharma&amp;author=R.%20Hoshyar&amp;author=B.%20Soo%20Kim&amp;author=N.%20Murthy&amp;volume=200&amp;publication_year=2023&amp;pages=115026&amp;pmid=37516409&amp;doi=10.1016/j.addr.2023.115026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0054">
<span class="label">54.</span><cite>
Chatterjee S., Kon E., Sharma P., and Peer D., “Endosomal Escape: A Bottleneck for LNP‐Mediated Therapeutics,” Proceedings of the National Academy of Sciences of the United States of America
121, no. 11 (2024): e2307800120, 10.1073/pnas.2307800120.
</cite> [<a href="https://doi.org/10.1073/pnas.2307800120" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10945858/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38437552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20of%20the%20United%20States%20of%20America&amp;title=Endosomal%20Escape:%20A%20Bottleneck%20for%20LNP%E2%80%90Mediated%20Therapeutics&amp;author=S.%20Chatterjee&amp;author=E.%20Kon&amp;author=P.%20Sharma&amp;author=D.%20Peer&amp;volume=121&amp;issue=11&amp;publication_year=2024&amp;pages=e2307800120&amp;pmid=38437552&amp;doi=10.1073/pnas.2307800120&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0055">
<span class="label">55.</span><cite>
Sahay G., Querbes W., Alabi C., et al., “Efficiency of siRNA Delivery by Lipid Nanoparticles Is Limited by Endocytic Recycling,” Nature Biotechnology
31, no. 7 (2013): 653–658, 10.1038/nbt.2614.</cite> [<a href="https://doi.org/10.1038/nbt.2614" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3814166/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23792629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Biotechnology&amp;title=Efficiency%20of%20siRNA%20Delivery%20by%20Lipid%20Nanoparticles%20Is%20Limited%20by%20Endocytic%20Recycling&amp;author=G.%20Sahay&amp;author=W.%20Querbes&amp;author=C.%20Alabi&amp;volume=31&amp;issue=7&amp;publication_year=2013&amp;pages=653-658&amp;pmid=23792629&amp;doi=10.1038/nbt.2614&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0056">
<span class="label">56.</span><cite>
Gilleron J., Querbes W., Zeigerer A., et al., “Image‐Based Analysis of Lipid Nanoparticle‐Mediated siRNA Delivery, Intracellular Trafficking and Endosomal Escape,” Nature Biotechnology
31, no. 7 (2013): 638–646, 10.1038/nbt.2612.</cite> [<a href="https://doi.org/10.1038/nbt.2612" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23792630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Biotechnology&amp;title=Image%E2%80%90Based%20Analysis%20of%20Lipid%20Nanoparticle%E2%80%90Mediated%20siRNA%20Delivery,%20Intracellular%20Trafficking%20and%20Endosomal%20Escape&amp;author=J.%20Gilleron&amp;author=W.%20Querbes&amp;author=A.%20Zeigerer&amp;volume=31&amp;issue=7&amp;publication_year=2013&amp;pages=638-646&amp;pmid=23792630&amp;doi=10.1038/nbt.2612&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0057">
<span class="label">57.</span><cite>
Dhaliwal H. K., Fan Y., Kim J., and Amiji M. M., “Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes,” Molecular Pharmaceutics
17, no. 6 (2020): 1996–2005, 10.3390/pharmaceutics13060877.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics13060877" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32365295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Pharmaceutics&amp;title=Intranasal%20Delivery%20and%20Transfection%20of%20mRNA%20Therapeutics%20in%20the%20Brain%20Using%20Cationic%20Liposomes&amp;author=H.%20K.%20Dhaliwal&amp;author=Y.%20Fan&amp;author=J.%20Kim&amp;author=M.%20M.%20Amiji&amp;volume=17&amp;issue=6&amp;publication_year=2020&amp;pages=1996-2005&amp;pmid=32365295&amp;doi=10.3390/pharmaceutics13060877&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0058">
<span class="label">58.</span><cite>
Vangasseri D. P., Cui Z., Chen W., Hokey D. A., Falo L. D., and Huang L., “Immunostimulation of Dendritic Cells by Cationic Liposomes,” Molecular Membrane Biology
23, no. 5 (2006): 385–395, 10.1080/09687860600790537.
</cite> [<a href="https://doi.org/10.1080/09687860600790537" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17060156/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Membrane%20Biology&amp;title=Immunostimulation%20of%20Dendritic%20Cells%20by%20Cationic%20Liposomes&amp;author=D.%20P.%20Vangasseri&amp;author=Z.%20Cui&amp;author=W.%20Chen&amp;author=D.%20A.%20Hokey&amp;author=L.%20D.%20Falo&amp;volume=23&amp;issue=5&amp;publication_year=2006&amp;pages=385-395&amp;pmid=17060156&amp;doi=10.1080/09687860600790537&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0059">
<span class="label">59.</span><cite>
Renzi S., Digiacomo L., Pozzi D., et al., “Structuring Lipid Nanoparticles, DNA, and Protein Corona Into Stealth Bionanoarchitectures for In Vivo Gene Delivery,” Nature Communications
15, no. 1 (2024): 9119, 10.1038/s41467-024-53569-8.</cite> [<a href="https://doi.org/10.1038/s41467-024-53569-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11496629/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39438484/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Structuring%20Lipid%20Nanoparticles,%20DNA,%20and%20Protein%20Corona%20Into%20Stealth%20Bionanoarchitectures%20for%20In%C2%A0Vivo%20Gene%20Delivery&amp;author=S.%20Renzi&amp;author=L.%20Digiacomo&amp;author=D.%20Pozzi&amp;volume=15&amp;issue=1&amp;publication_year=2024&amp;pages=9119&amp;pmid=39438484&amp;doi=10.1038/s41467-024-53569-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0060">
<span class="label">60.</span><cite>
Kowalski P. S., Rudra A., Miao L., and Anderson D. G., “Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery,” Molecular Therapy
27, no. 4 (2019): 710–728, 10.1016/j.ymthe.2019.02.012.
</cite> [<a href="https://doi.org/10.1016/j.ymthe.2019.02.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6453548/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30846391/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy&amp;title=Delivering%20the%20Messenger:%20Advances%20in%20Technologies%20for%20Therapeutic%20mRNA%20Delivery&amp;author=P.%20S.%20Kowalski&amp;author=A.%20Rudra&amp;author=L.%20Miao&amp;author=D.%20G.%20Anderson&amp;volume=27&amp;issue=4&amp;publication_year=2019&amp;pages=710-728&amp;pmid=30846391&amp;doi=10.1016/j.ymthe.2019.02.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0061">
<span class="label">61.</span><cite>
Cheng X. and Lee R. J., “The Role of Helper Lipids in Lipid Nanoparticles (LNPs) Designed for Oligonucleotide Delivery,” Advanced Drug Delivery Reviews
99, no. Pt A (2016): 129–137, 10.1016/j.addr.2016.01.022.
</cite> [<a href="https://doi.org/10.1016/j.addr.2016.01.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26900977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advanced%20Drug%20Delivery%20Reviews&amp;title=The%20Role%20of%20Helper%20Lipids%20in%20Lipid%20Nanoparticles%20(LNPs)%20Designed%20for%20Oligonucleotide%20Delivery&amp;author=X.%20Cheng&amp;author=R.%20J.%20Lee&amp;volume=99&amp;issue=Pt%20A&amp;publication_year=2016&amp;pages=129-137&amp;pmid=26900977&amp;doi=10.1016/j.addr.2016.01.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0062">
<span class="label">62.</span><cite>
Zhang R., El‐Mayta R., Murdoch T. J., et al., “Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,” Biomaterials Science
9, no. 4 (2021): 1449–1463, 10.1039/d0bm01609h.
</cite> [<a href="https://doi.org/10.1039/d0bm01609h" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8753632/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33404020/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomaterials%20Science&amp;title=Helper%20Lipid%20Structure%20Influences%20Protein%20Adsorption%20and%20Delivery%20of%20Lipid%20Nanoparticles%20to%20Spleen%20and%20Liver&amp;author=R.%20Zhang&amp;author=R.%20El%E2%80%90Mayta&amp;author=T.%20J.%20Murdoch&amp;volume=9&amp;issue=4&amp;publication_year=2021&amp;pages=1449-1463&amp;pmid=33404020&amp;doi=10.1039/d0bm01609h&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0063">
<span class="label">63.</span><cite>
Hald Albertsen C., Kulkarni J. A., Witzigmann D., Lind M., Petersson K., and Simonsen J. B., “The Role of Lipid Components in Lipid Nanoparticles for Vaccines and Gene Therapy,” Advanced Drug Delivery Reviews
188 (2022): 114416, 10.1016/j.addr.2022.114416.
</cite> [<a href="https://doi.org/10.1016/j.addr.2022.114416" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9250827/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35787388/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advanced%20Drug%20Delivery%20Reviews&amp;title=The%20Role%20of%20Lipid%20Components%20in%20Lipid%20Nanoparticles%20for%20Vaccines%20and%20Gene%20Therapy&amp;author=C.%20Hald%20Albertsen&amp;author=J.%20A.%20Kulkarni&amp;author=D.%20Witzigmann&amp;author=M.%20Lind&amp;author=K.%20Petersson&amp;volume=188&amp;publication_year=2022&amp;pages=114416&amp;pmid=35787388&amp;doi=10.1016/j.addr.2022.114416&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0064">
<span class="label">64.</span><cite>
Semple S. C., Chonn A., and Cullis P. R., “Influence of Cholesterol on the Association of Plasma Proteins With Liposomes,” Biochemistry
35, no. 8 (1996): 2521–2525, 10.1021/bi950414i.
</cite> [<a href="https://doi.org/10.1021/bi950414i" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8611555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Influence%20of%20Cholesterol%20on%20the%20Association%20of%20Plasma%20Proteins%20With%20Liposomes&amp;author=S.%20C.%20Semple&amp;author=A.%20Chonn&amp;author=P.%20R.%20Cullis&amp;volume=35&amp;issue=8&amp;publication_year=1996&amp;pages=2521-2525&amp;pmid=8611555&amp;doi=10.1021/bi950414i&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0065">
<span class="label">65.</span><cite>
Patel S., Ashwanikumar N., Robinson E., et al., “Naturally‐Occurring Cholesterol Analogues in Lipid Nanoparticles Induce Polymorphic Shape and Enhance Intracellular Delivery of mRNA,” Nature Communications
11, no. 1 (2020): 983, 10.1038/s41467-020-14527-2.</cite> [<a href="https://doi.org/10.1038/s41467-020-14527-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7033178/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32080183/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Naturally%E2%80%90Occurring%20Cholesterol%20Analogues%20in%20Lipid%20Nanoparticles%20Induce%20Polymorphic%20Shape%20and%20Enhance%20Intracellular%20Delivery%20of%20mRNA&amp;author=S.%20Patel&amp;author=N.%20Ashwanikumar&amp;author=E.%20Robinson&amp;volume=11&amp;issue=1&amp;publication_year=2020&amp;pages=983&amp;pmid=32080183&amp;doi=10.1038/s41467-020-14527-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0066">
<span class="label">66.</span><cite>
Rodrigueza W. V., Pritchard P. H., and Hope M. J., “The Influence of Size and Composition on the Cholesterol Mobilizing Properties of Liposomes In Vivo,” Biochimica et Biophysica Acta
1153, no. 1 (1993): 9–19, 10.1016/0005-2736(93)90270-a.
</cite> [<a href="https://doi.org/10.1016/0005-2736(93)90270-a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8241255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochimica%20et%20Biophysica%20Acta&amp;title=The%20Influence%20of%20Size%20and%20Composition%20on%20the%20Cholesterol%20Mobilizing%20Properties%20of%20Liposomes%20In%C2%A0Vivo&amp;author=W.%20V.%20Rodrigueza&amp;author=P.%20H.%20Pritchard&amp;author=M.%20J.%20Hope&amp;volume=1153&amp;issue=1&amp;publication_year=1993&amp;pages=9-19&amp;pmid=8241255&amp;doi=10.1016/0005-2736(93)90270-a&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0067">
<span class="label">67.</span><cite>
Herrera‐Barrera M., Ryals R. C., Gautam M., et al., “Peptide‐Guided Lipid Nanoparticles Deliver mRNA to the Neural Retina of Rodents and Nonhuman Primates,” Science Advances
9, no. 2 (2023): eadd4623, 10.1126/sciadv.add4623.
</cite> [<a href="https://doi.org/10.1126/sciadv.add4623" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9833661/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36630502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science%20Advances&amp;title=Peptide%E2%80%90Guided%20Lipid%20Nanoparticles%20Deliver%20mRNA%20to%20the%20Neural%20Retina%20of%20Rodents%20and%20Nonhuman%20Primates&amp;author=M.%20Herrera%E2%80%90Barrera&amp;author=R.%20C.%20Ryals&amp;author=M.%20Gautam&amp;volume=9&amp;issue=2&amp;publication_year=2023&amp;pages=eadd4623&amp;pmid=36630502&amp;doi=10.1126/sciadv.add4623&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0068">
<span class="label">68.</span><cite>
Dahlman J. E., Kauffman K. J., Xing Y., et al., “Barcoded Nanoparticles for High Throughput In Vivo Discovery of Targeted Therapeutics,” Proceedings of the National Academy of Sciences of the United States of America
114, no. 8 (2017): 2060–2065, 10.1073/pnas.1620874114.
</cite> [<a href="https://doi.org/10.1073/pnas.1620874114" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5338412/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28167778/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20of%20the%20United%20States%20of%20America&amp;title=Barcoded%20Nanoparticles%20for%20High%20Throughput%20In%C2%A0Vivo%20Discovery%20of%20Targeted%20Therapeutics&amp;author=J.%20E.%20Dahlman&amp;author=K.%20J.%20Kauffman&amp;author=Y.%20Xing&amp;volume=114&amp;issue=8&amp;publication_year=2017&amp;pages=2060-2065&amp;pmid=28167778&amp;doi=10.1073/pnas.1620874114&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0069">
<span class="label">69.</span><cite>
Gebhardt R. and Matz‐Soja M., “Liver Zonation: Novel Aspects of Its Regulation and Its Impact on Homeostasis,” World Journal of Gastroenterology
20, no. 26 (2014): 8941, 10.3748/wjg.v20.i26.8491.</cite> [<a href="https://doi.org/10.3748/wjg.v20.i26.8491" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4093700/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25024605/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20Journal%20of%20Gastroenterology&amp;title=Liver%20Zonation:%20Novel%20Aspects%20of%20Its%20Regulation%20and%20Its%20Impact%20on%20Homeostasis&amp;author=R.%20Gebhardt&amp;author=M.%20Matz%E2%80%90Soja&amp;volume=20&amp;issue=26&amp;publication_year=2014&amp;pages=8941&amp;pmid=25024605&amp;doi=10.3748/wjg.v20.i26.8491&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0070">
<span class="label">70.</span><cite>
Yamazaki K., Kubara K., Ishii S., et al., “Lipid Nanoparticle‐Targeted mRNA Formulation as a Treatment for Ornithine‐Transcarbamylase Deficiency Model Mice,” Molecular Therapy ‐ Nucleic Acids
33 (2023): 210–226, 10.1016/j.omtn.2023.06.023.
</cite> [<a href="https://doi.org/10.1016/j.omtn.2023.06.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10372164/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37520683/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy%20%E2%80%90%20Nucleic%20Acids&amp;title=Lipid%20Nanoparticle%E2%80%90Targeted%20mRNA%20Formulation%20as%20a%20Treatment%20for%20Ornithine%E2%80%90Transcarbamylase%20Deficiency%20Model%20Mice&amp;author=K.%20Yamazaki&amp;author=K.%20Kubara&amp;author=S.%20Ishii&amp;volume=33&amp;publication_year=2023&amp;pages=210-226&amp;pmid=37520683&amp;doi=10.1016/j.omtn.2023.06.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0071">
<span class="label">71.</span><cite>
Truong B., Allegri G., Liu X. B., et al., “Lipid Nanoparticle‐Targeted mRNA Therapy as a Treatment for the Inherited Metabolic Liver Disorder Arginase Deficiency,” Proceedings of the National Academy of Sciences of the United States of America
116, no. 42 (2019): 21150–21159, 10.1073/pnas.1906182116.
</cite> [<a href="https://doi.org/10.1073/pnas.1906182116" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6800360/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31501335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20of%20the%20United%20States%20of%20America&amp;title=Lipid%20Nanoparticle%E2%80%90Targeted%20mRNA%20Therapy%20as%20a%20Treatment%20for%20the%20Inherited%20Metabolic%20Liver%20Disorder%20Arginase%20Deficiency&amp;author=B.%20Truong&amp;author=G.%20Allegri&amp;author=X.%20B.%20Liu&amp;volume=116&amp;issue=42&amp;publication_year=2019&amp;pages=21150-21159&amp;pmid=31501335&amp;doi=10.1073/pnas.1906182116&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0072">
<span class="label">72.</span><cite>
Gurung S., Timmermand O. V., Perocheau D., et al., “mRNA Therapy Corrects Defective Glutathione Metabolism and Restores Ureagenesis in Preclinical Argininosuccinic Aciduria,” Science Translational Medicine
16, no. 729 (2024): eadh1334, 10.1126/scitranslmed.adh1334.
</cite> [<a href="https://doi.org/10.1126/scitranslmed.adh1334" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7615535/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38198573/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science%20Translational%20Medicine&amp;title=mRNA%20Therapy%20Corrects%20Defective%20Glutathione%20Metabolism%20and%20Restores%20Ureagenesis%20in%20Preclinical%20Argininosuccinic%20Aciduria&amp;author=S.%20Gurung&amp;author=O.%20V.%20Timmermand&amp;author=D.%20Perocheau&amp;volume=16&amp;issue=729&amp;publication_year=2024&amp;pages=eadh1334&amp;pmid=38198573&amp;doi=10.1126/scitranslmed.adh1334&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0073">
<span class="label">73.</span><cite>
An D., Schneller J. L., Frassetto A., et al., “Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia,” Cell Reports
21, no. 12 (2017): 3548–3558, 10.1016/j.celrep.2017.11.081.
</cite> [<a href="https://doi.org/10.1016/j.celrep.2017.11.081" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9667413/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29262333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Reports&amp;title=Systemic%20Messenger%20RNA%20Therapy%20as%20a%20Treatment%20for%20Methylmalonic%20Acidemia&amp;author=D.%20An&amp;author=J.%20L.%20Schneller&amp;author=A.%20Frassetto&amp;volume=21&amp;issue=12&amp;publication_year=2017&amp;pages=3548-3558&amp;pmid=29262333&amp;doi=10.1016/j.celrep.2017.11.081&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0074">
<span class="label">74.</span><cite>
An D., Frassetto A., Jacquinet E., et al., “Long‐Term Efficacy and Safety of mRNA Therapy in Two Murine Models of Methylmalonic Acidemia,” eBioMedicine
45 (2019): 519–528, 10.1016/j.ebiom.2019.07.003.
</cite> [<a href="https://doi.org/10.1016/j.ebiom.2019.07.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6642332/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31303505/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=eBioMedicine&amp;title=Long%E2%80%90Term%20Efficacy%20and%20Safety%20of%20mRNA%20Therapy%20in%20Two%20Murine%20Models%20of%20Methylmalonic%20Acidemia&amp;author=D.%20An&amp;author=A.%20Frassetto&amp;author=E.%20Jacquinet&amp;volume=45&amp;publication_year=2019&amp;pages=519-528&amp;pmid=31303505&amp;doi=10.1016/j.ebiom.2019.07.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0075">
<span class="label">75.</span><cite>
Coughlan K. A., Eybye M., Henderson N., et al., “Improved Therapeutic Efficacy in Two Mouse Models of Methylmalonic Acidemia (MMA) Using a Second‐Generation mRNA Therapy,” Molecular Genetics and Metabolism
143, no. 1‐2 (2024): 108560, 10.1016/J.YMGME.2024.108560.
</cite> [<a href="https://doi.org/10.1016/J.YMGME.2024.108560" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39121792/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Genetics%20and%20Metabolism&amp;title=Improved%20Therapeutic%20Efficacy%20in%20Two%20Mouse%20Models%20of%20Methylmalonic%20Acidemia%20(MMA)%20Using%20a%20Second%E2%80%90Generation%20mRNA%20Therapy&amp;author=K.%20A.%20Coughlan&amp;author=M.%20Eybye&amp;author=N.%20Henderson&amp;volume=143&amp;issue=1%E2%80%902&amp;publication_year=2024&amp;pages=108560&amp;pmid=39121792&amp;doi=10.1016/J.YMGME.2024.108560&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0076">
<span class="label">76.</span><cite>
Jiang L., Park J. S., Yin L., et al., “Dual mRNA Therapy Restores Metabolic Function in Long‐Term Studies in Mice With Propionic Acidemia,” Nature Communications
11, no. 1 (2020): 3559, 10.1038/s41467-020-19156-3.</cite> [<a href="https://doi.org/10.1038/s41467-020-19156-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7578066/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33087718/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Dual%20mRNA%20Therapy%20Restores%20Metabolic%20Function%20in%20Long%E2%80%90Term%20Studies%20in%20Mice%20With%20Propionic%20Acidemia&amp;author=L.%20Jiang&amp;author=J.%20S.%20Park&amp;author=L.%20Yin&amp;volume=11&amp;issue=1&amp;publication_year=2020&amp;pages=3559&amp;pmid=33087718&amp;doi=10.1038/s41467-020-19156-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0077">
<span class="label">77.</span><cite>
Baek R., Coughlan K., Jiang L., et al., “Characterizing the Mechanism of Action for mRNA Therapeutics for the Treatment of Propionic Acidemia, Methylmalonic Acidemia, and Phenylketonuria,” Nature Communications
15, no. 1 (2024): 3804, 10.1038/s41467-024-47460-9.</cite> [<a href="https://doi.org/10.1038/s41467-024-47460-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11076592/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38714648/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Characterizing%20the%20Mechanism%20of%20Action%20for%20mRNA%20Therapeutics%20for%20the%20Treatment%20of%20Propionic%20Acidemia,%20Methylmalonic%20Acidemia,%20and%20Phenylketonuria&amp;author=R.%20Baek&amp;author=K.%20Coughlan&amp;author=L.%20Jiang&amp;volume=15&amp;issue=1&amp;publication_year=2024&amp;pages=3804&amp;pmid=38714648&amp;doi=10.1038/s41467-024-47460-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0078">
<span class="label">78.</span><cite>
Balakrishnan B., An D., Nguyen V., DeAntonis C., Martini P. G. V., and Lai K., “Novel mRNA‐Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia,” Molecular Therapy
28, no. 1 (2020): 304–312, 10.1016/j.ymthe.2019.09.018.
</cite> [<a href="https://doi.org/10.1016/j.ymthe.2019.09.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6952165/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31604675/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy&amp;title=Novel%20mRNA%E2%80%90Based%20Therapy%20Reduces%20Toxic%20Galactose%20Metabolites%20and%20Overcomes%20Galactose%20Sensitivity%20in%20a%20Mouse%20Model%20of%20Classic%20Galactosemia&amp;author=B.%20Balakrishnan&amp;author=D.%20An&amp;author=V.%20Nguyen&amp;author=C.%20DeAntonis&amp;author=P.%20G.%20V.%20Martini&amp;volume=28&amp;issue=1&amp;publication_year=2020&amp;pages=304-312&amp;pmid=31604675&amp;doi=10.1016/j.ymthe.2019.09.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0079">
<span class="label">79.</span><cite>
Parra‐Guillen Z. P., Fontanellas A., Jiang L., et al., “Disease Pharmacokinetic–Pharmacodynamic Modelling in Acute Intermittent Porphyria to Support the Development of mRNA‐Based Therapies,” British Journal of Pharmacology
177, no. 14 (2020): 3168–3182, 10.1111/bph.15040.
</cite> [<a href="https://doi.org/10.1111/bph.15040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7312321/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32133631/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Pharmacology&amp;title=Disease%20Pharmacokinetic%E2%80%93Pharmacodynamic%20Modelling%20in%20Acute%20Intermittent%20Porphyria%20to%20Support%20the%20Development%20of%20mRNA%E2%80%90Based%20Therapies&amp;author=Z.%20P.%20Parra%E2%80%90Guillen&amp;author=A.%20Fontanellas&amp;author=L.%20Jiang&amp;volume=177&amp;issue=14&amp;publication_year=2020&amp;pages=3168-3182&amp;pmid=32133631&amp;doi=10.1111/bph.15040&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0080">
<span class="label">80.</span><cite>
Jericó D., Córdoba K. M., Jiang L., et al., “mRNA‐Based Therapy in a Rabbit Model of Variegate Porphyria Offers New Insights Into the Pathogenesis of Acute Attacks,” Molecular Therapy ‐ Nucleic Acids
25 (2021): 207–219, 10.1016/j.omtn.2021.05.010.
</cite> [<a href="https://doi.org/10.1016/j.omtn.2021.05.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8368795/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34458006/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy%20%E2%80%90%20Nucleic%20Acids&amp;title=mRNA%E2%80%90Based%20Therapy%20in%20a%20Rabbit%20Model%20of%20Variegate%20Porphyria%20Offers%20New%20Insights%20Into%20the%20Pathogenesis%20of%20Acute%20Attacks&amp;author=D.%20Jeric%C3%B3&amp;author=K.%20M.%20C%C3%B3rdoba&amp;author=L.%20Jiang&amp;volume=25&amp;publication_year=2021&amp;pages=207-219&amp;pmid=34458006&amp;doi=10.1016/j.omtn.2021.05.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0081">
<span class="label">81.</span><cite>
Cao J., Choi M., Guadagnin E., et al., “mRNA Therapy Restores Euglycemia and Prevents Liver Tumors in Murine Model of Glycogen Storage Disease,” Nature Communications
12, no. 1 (2021): 3090, 10.1038/s41467-021-23318-2.</cite> [<a href="https://doi.org/10.1038/s41467-021-23318-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8149455/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34035281/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=mRNA%20Therapy%20Restores%20Euglycemia%20and%20Prevents%20Liver%20Tumors%20in%20Murine%20Model%20of%20Glycogen%20Storage%20Disease&amp;author=J.%20Cao&amp;author=M.%20Choi&amp;author=E.%20Guadagnin&amp;volume=12&amp;issue=1&amp;publication_year=2021&amp;pages=3090&amp;pmid=34035281&amp;doi=10.1038/s41467-021-23318-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0082">
<span class="label">82.</span><cite>
Cao J., An D., Galduroz M., et al., “mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency,” Molecular Therapy
27, no. 7 (2019): 1242–1251, 10.1016/j.ymthe.2019.04.017.
</cite> [<a href="https://doi.org/10.1016/j.ymthe.2019.04.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6612659/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31056400/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy&amp;title=mRNA%20Therapy%20Improves%20Metabolic%20and%20Behavioral%20Abnormalities%20in%20a%20Murine%20Model%20of%20Citrin%20Deficiency&amp;author=J.%20Cao&amp;author=D.%20An&amp;author=M.%20Galduroz&amp;volume=27&amp;issue=7&amp;publication_year=2019&amp;pages=1242-1251&amp;pmid=31056400&amp;doi=10.1016/j.ymthe.2019.04.017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0083">
<span class="label">83.</span><cite>
Prieve M. G., Harvie P., Monahan S. D., et al., “Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency,” Molecular Therapy
26, no. 3 (2018): 801–813, 10.1016/j.ymthe.2017.12.024.
</cite> [<a href="https://doi.org/10.1016/j.ymthe.2017.12.024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5910669/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29433939/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy&amp;title=Targeted%20mRNA%20Therapy%20for%20Ornithine%20Transcarbamylase%20Deficiency&amp;author=M.%20G.%20Prieve&amp;author=P.%20Harvie&amp;author=S.%20D.%20Monahan&amp;volume=26&amp;issue=3&amp;publication_year=2018&amp;pages=801-813&amp;pmid=29433939&amp;doi=10.1016/j.ymthe.2017.12.024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0084">
<span class="label">84.</span><cite>
Gurung S., Karamched S., Perocheau D., et al., “The Incidence of Movement Disorder Increases With Age and Contrasts With Subtle and Limited Neuroimaging Abnormalities in Argininosuccinic Aciduria,” Journal of Inherited Metabolic Disease
47, no. 6 (2023): 1213–1227, 10.1002/jimd.12691.
</cite> [<a href="https://doi.org/10.1002/jimd.12691" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11586606/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38044746/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Inherited%20Metabolic%20Disease&amp;title=The%20Incidence%20of%20Movement%20Disorder%20Increases%20With%20Age%20and%20Contrasts%20With%20Subtle%20and%20Limited%20Neuroimaging%20Abnormalities%20in%20Argininosuccinic%20Aciduria&amp;author=S.%20Gurung&amp;author=S.%20Karamched&amp;author=D.%20Perocheau&amp;volume=47&amp;issue=6&amp;publication_year=2023&amp;pages=1213-1227&amp;pmid=38044746&amp;doi=10.1002/jimd.12691&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0085">
<span class="label">85.</span><cite>
Daly O., Mahiny A. J., Majeski S., et al., “ASL mRNA‐LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model,” Biomedicine
11, no. 6 (2023): 1735, 10.3390/biomedicines11061735.</cite> [<a href="https://doi.org/10.3390/biomedicines11061735" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10296609/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37371829/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicine&amp;title=ASL%20mRNA%E2%80%90LNP%20Therapeutic%20for%20the%20Treatment%20of%20Argininosuccinic%20Aciduria%20Enables%20Survival%20Benefit%20in%20a%20Mouse%20Model&amp;author=O.%20Daly&amp;author=A.%20J.%20Mahiny&amp;author=S.%20Majeski&amp;volume=11&amp;issue=6&amp;publication_year=2023&amp;pages=1735&amp;pmid=37371829&amp;doi=10.3390/biomedicines11061735&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0086">
<span class="label">86.</span><cite>
Perez‐Garcia C. G., Diaz‐Trelles R., Vega J. B., et al., “Development of an mRNA Replacement Therapy for Phenylketonuria,” Molecular Therapy ‐ Nucleic Acids
28 (2022): 87–98, 10.1016/j.omtn.2022.02.020.
</cite> [<a href="https://doi.org/10.1016/j.omtn.2022.02.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8933640/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35356682/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy%20%E2%80%90%20Nucleic%20Acids&amp;title=Development%20of%20an%20mRNA%20Replacement%20Therapy%20for%20Phenylketonuria&amp;author=C.%20G.%20Perez%E2%80%90Garcia&amp;author=R.%20Diaz%E2%80%90Trelles&amp;author=J.%20B.%20Vega&amp;volume=28&amp;publication_year=2022&amp;pages=87-98&amp;pmid=35356682&amp;doi=10.1016/j.omtn.2022.02.020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0087">
<span class="label">87.</span><cite>
Cacicedo M. L., Weinl‐Tenbruck C., Frank D., et al., “mRNA‐Based Therapy Proves Superior to the Standard of Care for Treating Hereditary Tyrosinemia 1 in a Mouse Model,” Molecular Therapy ‐ Methods &amp; Clinical Development
26 (2022): 294–308, 10.1016/j.omtm.2022.07.006.
</cite> [<a href="https://doi.org/10.1016/j.omtm.2022.07.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9357842/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35949297/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy%20%E2%80%90%20Methods%20&amp;%20Clinical%20Development&amp;title=mRNA%E2%80%90Based%20Therapy%20Proves%20Superior%20to%20the%20Standard%20of%20Care%20for%20Treating%20Hereditary%20Tyrosinemia%201%20in%20a%20Mouse%20Model&amp;author=M.%20L.%20Cacicedo&amp;author=C.%20Weinl%E2%80%90Tenbruck&amp;author=D.%20Frank&amp;volume=26&amp;publication_year=2022&amp;pages=294-308&amp;pmid=35949297&amp;doi=10.1016/j.omtm.2022.07.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0088">
<span class="label">88.</span><cite>
Greig J. A., Jennis M., Dandekar A., et al., “Lipid Nanoparticle mRNA Therapy Improves Survival and Reduces Serum Branched‐Chain Amino Acids in Mouse Models of Maple Syrup Urine Disease,” Human Gene Therapy
35, no. 17‐18 (2024): 726–733, 10.1089/hum.2024.047.
</cite> [<a href="https://doi.org/10.1089/hum.2024.047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39001827/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Human%20Gene%20Therapy&amp;title=Lipid%20Nanoparticle%20mRNA%20Therapy%20Improves%20Survival%20and%20Reduces%20Serum%20Branched%E2%80%90Chain%20Amino%20Acids%20in%20Mouse%20Models%20of%20Maple%20Syrup%20Urine%20Disease&amp;author=J.%20A.%20Greig&amp;author=M.%20Jennis&amp;author=A.%20Dandekar&amp;volume=35&amp;issue=17%E2%80%9018&amp;publication_year=2024&amp;pages=726-733&amp;pmid=39001827&amp;doi=10.1089/hum.2024.047&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0089">
<span class="label">89.</span><cite>
Zhao X. J., Mohsen A. W., Mihalik S., et al., “Synthetic mRNA Rescues Very Long‐Chain Acyl‐CoA Dehydrogenase Deficiency in Patient Fibroblasts and a Murine Model,” Molecular Genetics and Metabolism
138, no. 1 (2023): 106982, 10.1016/j.ymgme.2022.106982.
</cite> [<a href="https://doi.org/10.1016/j.ymgme.2022.106982" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9877169/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36580829/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Genetics%20and%20Metabolism&amp;title=Synthetic%20mRNA%20Rescues%20Very%20Long%E2%80%90Chain%20Acyl%E2%80%90CoA%20Dehydrogenase%20Deficiency%20in%20Patient%20Fibroblasts%20and%20a%20Murine%20Model&amp;author=X.%20J.%20Zhao&amp;author=A.%20W.%20Mohsen&amp;author=S.%20Mihalik&amp;volume=138&amp;issue=1&amp;publication_year=2023&amp;pages=106982&amp;pmid=36580829&amp;doi=10.1016/j.ymgme.2022.106982&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0090">
<span class="label">90.</span><cite>
Zhao X. J., Mohsen A. W., Mihalik S., et al., “Messenger RNA Rescues Medium‐Chain Acyl‐CoA Dehydrogenase Deficiency in Fibroblasts From Patients and a Murine Model,” Human Molecular Genetics
32, no. 14 (2023): 2347–2356, 10.1093/hmg/ddad076.
</cite> [<a href="https://doi.org/10.1093/hmg/ddad076" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10321387/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37162351/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Human%20Molecular%20Genetics&amp;title=Messenger%20RNA%20Rescues%20Medium%E2%80%90Chain%20Acyl%E2%80%90CoA%20Dehydrogenase%20Deficiency%20in%20Fibroblasts%20From%20Patients%20and%20a%20Murine%20Model&amp;author=X.%20J.%20Zhao&amp;author=A.%20W.%20Mohsen&amp;author=S.%20Mihalik&amp;volume=32&amp;issue=14&amp;publication_year=2023&amp;pages=2347-2356&amp;pmid=37162351&amp;doi=10.1093/hmg/ddad076&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0091">
<span class="label">91.</span><cite>
Yang T., Ge J., Huang L., et al., “Preclinical Evaluation of AGT mRNA Replacement Therapy for Primary Hyperoxaluria Type I Disease,” Science Advances
11, no. 15 (2025): eadt9694, 10.1126/sciadv.adt9694.
</cite> [<a href="https://doi.org/10.1126/sciadv.adt9694" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11980851/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40203111/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science%20Advances&amp;title=Preclinical%20Evaluation%20of%20AGT%20mRNA%20Replacement%20Therapy%20for%20Primary%20Hyperoxaluria%20Type%20I%20Disease&amp;author=T.%20Yang&amp;author=J.%20Ge&amp;author=L.%20Huang&amp;volume=11&amp;issue=15&amp;publication_year=2025&amp;pages=eadt9694&amp;pmid=40203111&amp;doi=10.1126/sciadv.adt9694&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0092">
<span class="label">92.</span><cite>
Greig J. A., Chorazeczewski J. K., Chowdhary V., et al., “Lipid Nanoparticle‐Encapsulated mRNA Therapy Corrects Serum Total Bilirubin Level in Crigler‐Najjar Syndrome Mouse Model,” Molecular Therapy ‐ Methods &amp; Clinical Development
29 (2023): 32–39, 10.1016/j.omtm.2023.02.007.
</cite> [<a href="https://doi.org/10.1016/j.omtm.2023.02.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10017950/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36936447/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy%20%E2%80%90%20Methods%20&amp;%20Clinical%20Development&amp;title=Lipid%20Nanoparticle%E2%80%90Encapsulated%20mRNA%20Therapy%20Corrects%20Serum%20Total%20Bilirubin%20Level%20in%20Crigler%E2%80%90Najjar%20Syndrome%20Mouse%20Model&amp;author=J.%20A.%20Greig&amp;author=J.%20K.%20Chorazeczewski&amp;author=V.%20Chowdhary&amp;volume=29&amp;publication_year=2023&amp;pages=32-39&amp;pmid=36936447&amp;doi=10.1016/j.omtm.2023.02.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0093">
<span class="label">93.</span><cite>
Karadagi A., Cavedon A. G., Zemack H., et al., “Systemic Modified Messenger RNA for Replacement Therapy in Alpha 1‐Antitrypsin Deficiency,” Scientific Reports
10 (2020): 7052, 10.1038/s41598-020-64017-0.
</cite> [<a href="https://doi.org/10.1038/s41598-020-64017-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7184591/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32341402/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scientific%20Reports&amp;title=Systemic%20Modified%20Messenger%20RNA%20for%20Replacement%20Therapy%20in%20Alpha%201%E2%80%90Antitrypsin%20Deficiency&amp;author=A.%20Karadagi&amp;author=A.%20G.%20Cavedon&amp;author=H.%20Zemack&amp;volume=10&amp;publication_year=2020&amp;pages=7052&amp;pmid=32341402&amp;doi=10.1038/s41598-020-64017-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0094">
<span class="label">94.</span><cite>
Wei G., Cao J., Huang P., et al., “Synthetic Human ABCB4 mRNA Therapy Rescues Severe Liver Disease Phenotype in a BALB/c.Abcb4‐/‐ Mouse Model of PFIC3,” Journal of Hepatology
74, no. 6 (2021): 1416–1428, 10.1016/j.jhep.2020.12.010.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2020.12.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8188846/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33340584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Hepatology&amp;title=Synthetic%20Human%20ABCB4%20mRNA%20Therapy%20Rescues%20Severe%20Liver%20Disease%20Phenotype%20in%20a%20BALB/c.Abcb4%E2%80%90/%E2%80%90%20Mouse%20Model%20of%20PFIC3&amp;author=G.%20Wei&amp;author=J.%20Cao&amp;author=P.%20Huang&amp;volume=74&amp;issue=6&amp;publication_year=2021&amp;pages=1416-1428&amp;pmid=33340584&amp;doi=10.1016/j.jhep.2020.12.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0095">
<span class="label">95.</span><cite>
Zhu X., Yin L., Theisen M., et al., “Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild‐Type Mice, Fabry Mouse Model, and Wild‐Type Non‐Human Primates,” American Journal of Human Genetics
104, no. 4 (2019): 625–637, 10.1016/j.ajhg.2019.02.003.
</cite> [<a href="https://doi.org/10.1016/j.ajhg.2019.02.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6451694/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30879639/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Human%20Genetics&amp;title=Systemic%20mRNA%20Therapy%20for%20the%20Treatment%20of%20Fabry%20Disease:%20Preclinical%20Studies%20in%20Wild%E2%80%90Type%20Mice,%20Fabry%20Mouse%20Model,%20and%20Wild%E2%80%90Type%20Non%E2%80%90Human%20Primates&amp;author=X.%20Zhu&amp;author=L.%20Yin&amp;author=M.%20Theisen&amp;volume=104&amp;issue=4&amp;publication_year=2019&amp;pages=625-637&amp;pmid=30879639&amp;doi=10.1016/j.ajhg.2019.02.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0096">
<span class="label">96.</span><cite>
Córdoba K. M., Jericó D., Jiang L., et al., “Systemic Messenger RNA Replacement Therapy Is Effective in a Novel Clinically Relevant Model of Acute Intermittent Porphyria Developed in Non‐Human Primates,” Gut
74, no. 2 (2024): 270–283, 10.1136/gutjnl-2024-332619.</cite> [<a href="https://doi.org/10.1136/gutjnl-2024-332619" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11874285/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39366725/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=Systemic%20Messenger%20RNA%20Replacement%20Therapy%20Is%20Effective%20in%20a%20Novel%20Clinically%20Relevant%20Model%20of%20Acute%20Intermittent%20Porphyria%20Developed%20in%20Non%E2%80%90Human%20Primates&amp;author=K.%20M.%20C%C3%B3rdoba&amp;author=D.%20Jeric%C3%B3&amp;author=L.%20Jiang&amp;volume=74&amp;issue=2&amp;publication_year=2024&amp;pages=270-283&amp;pmid=39366725&amp;doi=10.1136/gutjnl-2024-332619&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0097">
<span class="label">97.</span><cite>
Yu H., Brewer E., Shields M., et al., “Restoring Ornithine Transcarbamylase (OTC) Activity in an OTC‐Deficient Mouse Model Using LUNAR‐OTC mRNA,” Clinical and Translational Discovery
2, no. 2 (2022): e33, 10.1002/ctd2.33.</cite> [<a href="https://doi.org/10.1002/ctd2.33" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20and%20Translational%20Discovery&amp;title=Restoring%20Ornithine%20Transcarbamylase%20(OTC)%20Activity%20in%20an%20OTC%E2%80%90Deficient%20Mouse%20Model%20Using%20LUNAR%E2%80%90OTC%20mRNA&amp;author=H.%20Yu&amp;author=E.%20Brewer&amp;author=M.%20Shields&amp;volume=2&amp;issue=2&amp;publication_year=2022&amp;pages=e33&amp;doi=10.1002/ctd2.33&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0098">
<span class="label">98.</span><cite>
Khoja S., Liu X. B., Truong B., et al., “Intermittent Lipid Nanoparticle mRNA Administration Prevents Cortical Dysmyelination Associated With Arginase Deficiency,” Molecular Therapy ‐ Nucleic Acids
28 (2022): 859–874, 10.1016/j.omtn.2022.04.012.
</cite> [<a href="https://doi.org/10.1016/j.omtn.2022.04.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9156989/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35694211/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy%20%E2%80%90%20Nucleic%20Acids&amp;title=Intermittent%20Lipid%20Nanoparticle%20mRNA%20Administration%20Prevents%20Cortical%20Dysmyelination%20Associated%20With%20Arginase%20Deficiency&amp;author=S.%20Khoja&amp;author=X.%20B.%20Liu&amp;author=B.%20Truong&amp;volume=28&amp;publication_year=2022&amp;pages=859-874&amp;pmid=35694211&amp;doi=10.1016/j.omtn.2022.04.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0099">
<span class="label">99.</span><cite>
Perocheau D., Gurung S., Touramanidou L., et al., “Ex Vivo Precision‐Cut Liver Slices Model Disease Phenotype and Monitor Therapeutic Response for Liver Monogenic Diseases,” F1000Res
12 (2023): 1580, 10.12688/f1000research.142014.1.
</cite> [<a href="https://doi.org/10.12688/f1000research.142014.1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11016166/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38618017/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=F1000Res&amp;title=Ex%20Vivo%20Precision%E2%80%90Cut%20Liver%20Slices%20Model%20Disease%20Phenotype%20and%20Monitor%20Therapeutic%20Response%20for%20Liver%20Monogenic%20Diseases&amp;author=D.%20Perocheau&amp;author=S.%20Gurung&amp;author=L.%20Touramanidou&amp;volume=12&amp;publication_year=2023&amp;pages=1580&amp;pmid=38618017&amp;doi=10.12688/f1000research.142014.1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0100">
<span class="label">100.</span><cite>
Cheng Q., Wei T., Jia Y., et al., “Dendrimer‐Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I,” Advanced Materials
30, no. 52 (2018): e1805308, 10.1002/adma.201805308.
</cite> [<a href="https://doi.org/10.1002/adma.201805308" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30368954/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advanced%20Materials&amp;title=Dendrimer%E2%80%90Based%20Lipid%20Nanoparticles%20Deliver%20Therapeutic%20FAH%20mRNA%20to%20Normalize%20Liver%20Function%20and%20Extend%20Survival%20in%20a%20Mouse%20Model%20of%20Hepatorenal%20Tyrosinemia%20Type%20I&amp;author=Q.%20Cheng&amp;author=T.%20Wei&amp;author=Y.%20Jia&amp;volume=30&amp;issue=52&amp;publication_year=2018&amp;pages=e1805308&amp;pmid=30368954&amp;doi=10.1002/adma.201805308&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0101">
<span class="label">101.</span><cite>
Phillips J. D., “Heme Biosynthesis and the Porphyrias,” Molecular Genetics and Metabolism
128, no. 3 (2019): 164–177, 10.1016/j.ymgme.2019.04.008.
</cite> [<a href="https://doi.org/10.1016/j.ymgme.2019.04.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7252266/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31326287/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Genetics%20and%20Metabolism&amp;title=Heme%20Biosynthesis%20and%20the%20Porphyrias&amp;author=J.%20D.%20Phillips&amp;volume=128&amp;issue=3&amp;publication_year=2019&amp;pages=164-177&amp;pmid=31326287&amp;doi=10.1016/j.ymgme.2019.04.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0102">
<span class="label">102.</span><cite>
Pischik E. and Kauppinen R., “An Update of Clinical Management of Acute Intermittent Porphyria,” Application of Clinical Genetics
8 (2015): 201–214, 10.2147/TACG.S48605.
</cite> [<a href="https://doi.org/10.2147/TACG.S48605" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4562648/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26366103/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Application%20of%20Clinical%20Genetics&amp;title=An%20Update%20of%20Clinical%20Management%20of%20Acute%20Intermittent%20Porphyria&amp;author=E.%20Pischik&amp;author=R.%20Kauppinen&amp;volume=8&amp;publication_year=2015&amp;pages=201-214&amp;pmid=26366103&amp;doi=10.2147/TACG.S48605&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0103">
<span class="label">103.</span><cite>
Jiang L., Berraondo P., Jericó D., et al., “Systemic Messenger RNA as an Etiological Treatment for Acute Intermittent Porphyria,” Nature Medicine
24, no. 12 (2018): 1899–1909, 10.1038/s41591-018-0199-z.</cite> [<a href="https://doi.org/10.1038/s41591-018-0199-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30297912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Medicine&amp;title=Systemic%20Messenger%20RNA%20as%20an%20Etiological%20Treatment%20for%20Acute%20Intermittent%20Porphyria&amp;author=L.%20Jiang&amp;author=P.%20Berraondo&amp;author=D.%20Jeric%C3%B3&amp;volume=24&amp;issue=12&amp;publication_year=2018&amp;pages=1899-1909&amp;pmid=30297912&amp;doi=10.1038/s41591-018-0199-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0104">
<span class="label">104.</span><cite>
Roseman D. S., Khan T., Rajas F., et al., “G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a,” Molecular Therapy
26, no. 3 (2018): 814–821, 10.1016/j.ymthe.2018.01.006.
</cite> [<a href="https://doi.org/10.1016/j.ymthe.2018.01.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5910675/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29428299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy&amp;title=G6PC%20mRNA%20Therapy%20Positively%20Regulates%20Fasting%20Blood%20Glucose%20and%20Decreases%20Liver%20Abnormalities%20in%20a%20Mouse%20Model%20of%20Glycogen%20Storage%20Disease%201a&amp;author=D.%20S.%20Roseman&amp;author=T.%20Khan&amp;author=F.%20Rajas&amp;volume=26&amp;issue=3&amp;publication_year=2018&amp;pages=814-821&amp;pmid=29428299&amp;doi=10.1016/j.ymthe.2018.01.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0105">
<span class="label">105.</span><cite>
Furtado D., Cortez‐Jugo C., Hung Y. H., Bush A. I., and Caruso F., “mRNA Treatment Rescues Niemann–Pick Disease Type C1 in Patient Fibroblasts,” Molecular Pharmaceutics
19, no. 11 (2022): 3987–3999, 10.1021/acs.molpharmaceut.2c00463.
</cite> [<a href="https://doi.org/10.1021/acs.molpharmaceut.2c00463" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36125338/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Pharmaceutics&amp;title=mRNA%20Treatment%20Rescues%20Niemann%E2%80%93Pick%20Disease%20Type%20C1%20in%20Patient%20Fibroblasts&amp;author=D.%20Furtado&amp;author=C.%20Cortez%E2%80%90Jugo&amp;author=Y.%20H.%20Hung&amp;author=A.%20I.%20Bush&amp;author=F.%20Caruso&amp;volume=19&amp;issue=11&amp;publication_year=2022&amp;pages=3987-3999&amp;pmid=36125338&amp;doi=10.1021/acs.molpharmaceut.2c00463&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0106">
<span class="label">106.</span><cite>
Milliner D. S., Harris P. C., and Sas D. J., “Primary Hyperoxaluria Type 1,” GeneReviews [Internet], 1993–2025.</cite>
</li>
<li id="jimd70078-bib-0107">
<span class="label">107.</span><cite>
Karadagi A., Cavedon A. G., Zemack H., et al., “Systemic Modified Messenger RNA for Replacement Therapy in Alpha 1‐Antitrypsin Deficiency,” Scientific Reports
10 (2020): 7052.
</cite> [<a href="https://doi.org/10.1038/s41598-020-64017-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7184591/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32341402/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scientific%20Reports&amp;title=Systemic%20Modified%20Messenger%20RNA%20for%20Replacement%20Therapy%20in%20Alpha%201%E2%80%90Antitrypsin%20Deficiency&amp;author=A.%20Karadagi&amp;author=A.%20G.%20Cavedon&amp;author=H.%20Zemack&amp;volume=10&amp;publication_year=2020&amp;pages=7052&amp;pmid=32341402&amp;doi=10.1038/s41598-020-64017-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0108">
<span class="label">108.</span><cite>
Forny P., Hörster F., Ballhausen D., et al., “Guidelines for the Diagnosis and Management of Methylmalonic Acidaemia and Propionic Acidaemia: First Revision,” Journal of Inherited Metabolic Disease
44, no. 3 (2021): 566–592, 10.1002/jimd.12370.
</cite> [<a href="https://doi.org/10.1002/jimd.12370" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8252715/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33595124/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Inherited%20Metabolic%20Disease&amp;title=Guidelines%20for%20the%20Diagnosis%20and%20Management%20of%20Methylmalonic%20Acidaemia%20and%20Propionic%20Acidaemia:%20First%20Revision&amp;author=P.%20Forny&amp;author=F.%20H%C3%B6rster&amp;author=D.%20Ballhausen&amp;volume=44&amp;issue=3&amp;publication_year=2021&amp;pages=566-592&amp;pmid=33595124&amp;doi=10.1002/jimd.12370&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0109">
<span class="label">109.</span><cite>
“Moderna Expands the Field of mRNA Medicine With Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease,” Moderna Press Release, (2023), <a href="https://investors.modernatx.com/news/news-details/2023/Moderna-Expands-the-Field-of-mRNA-Medicine-with-Positive-Clinical-Results-Across-Cancer-Rare-Disease-and-Infectious-Disease/default.aspx" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://investors.modernatx.com/news/news‐details/2023/Moderna‐Expands‐the‐Field‐of‐mRNA‐Medicine‐with‐Positive‐Clinical‐Results‐Across‐Cancer‐Rare‐Disease‐and‐Infectious‐Disease/default.aspx</a>.</cite>
</li>
<li id="jimd70078-bib-0110">
<span class="label">110.</span><cite>
“Moderna Announces Positive Clinical Results, Expansion of mRNA Technology,” accessed January 16, 2025, <a href="https://www.uspharmacist.com/article/moderna-announces-positive-clinical-results-expansion-of-mrna-technology" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.uspharmacist.com/article/moderna‐announces‐positive‐clinical‐results‐expansion‐of‐mrna‐technology</a>.</cite>
</li>
<li id="jimd70078-bib-0111">
<span class="label">111.</span><cite>
ClinicalTrials.gov
, “National Library of Medicine (NIH),” accessed April 2025, clinicaltrials.gov.</cite>
</li>
<li id="jimd70078-bib-0112">
<span class="label">112.</span><cite>
“Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra‐Rare Disease, Crigler‐Najjar Syndrome Type 1,” accessed January 16, 2025, <a href="https://investors.modernatx.com/news/news-details/2021/Moderna-and-the-Institute-for-Life-Changing-Medicines-Announce-a-New-Collaboration-to-Develop-an-mRNA-Therapeutic-for-Ultra-Rare-Disease-Crigler-Najjar-Syndrome-Type-one/default.aspx" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://investors.modernatx.com/news/news‐details/2021/Moderna‐and‐the‐Institute‐for‐Life‐Changing‐Medicines‐Announce‐a‐New‐Collaboration‐to‐Develop‐an‐mRNA‐Therapeutic‐for‐Ultra‐Rare‐Disease‐Crigler‐Najjar‐Syndrome‐Type‐one/default.aspx</a>.</cite>
</li>
<li id="jimd70078-bib-0113">
<span class="label">113.</span><cite>
Karikó K., Buckstein M., Ni H., and Weissman D., “Suppression of RNA Recognition by Toll‐Like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA,” Immunity
23, no. 2 (2005): 165–175, 10.1016/j.immuni.2005.06.008.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2005.06.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16111635/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Suppression%20of%20RNA%20Recognition%20by%20Toll%E2%80%90Like%20Receptors:%20The%20Impact%20of%20Nucleoside%20Modification%20and%20the%20Evolutionary%20Origin%20of%20RNA&amp;author=K.%20Karik%C3%B3&amp;author=M.%20Buckstein&amp;author=H.%20Ni&amp;author=D.%20Weissman&amp;volume=23&amp;issue=2&amp;publication_year=2005&amp;pages=165-175&amp;pmid=16111635&amp;doi=10.1016/j.immuni.2005.06.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0114">
<span class="label">114.</span><cite>
Li C., Lee A., Grigoryan L., et al., “Mechanisms of Innate and Adaptive Immunity to the Pfizer‐BioNTech BNT162b2 Vaccine,” Nature Immunology
23, no. 4 (2022): 543–555, 10.1038/s41590-022-01163-9.
</cite> [<a href="https://doi.org/10.1038/s41590-022-01163-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8989677/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35288714/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Immunology&amp;title=Mechanisms%20of%20Innate%20and%20Adaptive%20Immunity%20to%20the%20Pfizer%E2%80%90BioNTech%20BNT162b2%20Vaccine&amp;author=C.%20Li&amp;author=A.%20Lee&amp;author=L.%20Grigoryan&amp;volume=23&amp;issue=4&amp;publication_year=2022&amp;pages=543-555&amp;pmid=35288714&amp;doi=10.1038/s41590-022-01163-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0115">
<span class="label">115.</span><cite>
Lee Y., Jeong M., Park J., Jung H., and Lee H., “Immunogenicity of Lipid Nanoparticles and Its Impact on the Efficacy of mRNA Vaccines and Therapeutics,” Experimental &amp; Molecular Medicine
55, no. 10 (2023): 2085–2096, 10.1038/s12276-023-01086-x.
</cite> [<a href="https://doi.org/10.1038/s12276-023-01086-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10618257/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37779140/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Experimental%20&amp;%20Molecular%20Medicine&amp;title=Immunogenicity%20of%20Lipid%20Nanoparticles%20and%20Its%20Impact%20on%20the%20Efficacy%20of%20mRNA%20Vaccines%20and%20Therapeutics&amp;author=Y.%20Lee&amp;author=M.%20Jeong&amp;author=J.%20Park&amp;author=H.%20Jung&amp;author=H.%20Lee&amp;volume=55&amp;issue=10&amp;publication_year=2023&amp;pages=2085-2096&amp;pmid=37779140&amp;doi=10.1038/s12276-023-01086-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0116">
<span class="label">116.</span><cite>
Tahtinen S., Tong A. J., Himmels P., et al., “IL‐1 and IL‐1ra Are Key Regulators of the Inflammatory Response to RNA Vaccines,” Nature Immunology
23, no. 4 (2022): 532–542, 10.1038/s41590-022-01160-y.
</cite> [<a href="https://doi.org/10.1038/s41590-022-01160-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35332327/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Immunology&amp;title=IL%E2%80%901%20and%20IL%E2%80%901ra%20Are%20Key%20Regulators%20of%20the%20Inflammatory%20Response%20to%20RNA%20Vaccines&amp;author=S.%20Tahtinen&amp;author=A.%20J.%20Tong&amp;author=P.%20Himmels&amp;volume=23&amp;issue=4&amp;publication_year=2022&amp;pages=532-542&amp;pmid=35332327&amp;doi=10.1038/s41590-022-01160-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0117">
<span class="label">117.</span><cite>
Ndeupen S., Qin Z., Jacobsen S., Bouteau A., Estanbouli H., and Igyártó B. Z., “The mRNA‐LNP Platform's Lipid Nanoparticle Component Used in Preclinical Vaccine Studies Is Highly Inflammatory,” iScience
24, no. 12 (2021): 103479, 10.1016/j.isci.2021.103479.
</cite> [<a href="https://doi.org/10.1016/j.isci.2021.103479" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8604799/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34841223/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=iScience&amp;title=The%20mRNA%E2%80%90LNP%20Platform's%20Lipid%20Nanoparticle%20Component%20Used%20in%20Preclinical%20Vaccine%20Studies%20Is%20Highly%20Inflammatory&amp;author=S.%20Ndeupen&amp;author=Z.%20Qin&amp;author=S.%20Jacobsen&amp;author=A.%20Bouteau&amp;author=H.%20Estanbouli&amp;volume=24&amp;issue=12&amp;publication_year=2021&amp;pages=103479&amp;pmid=34841223&amp;doi=10.1016/j.isci.2021.103479&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0118">
<span class="label">118.</span><cite>
Alameh M. G., Tombácz I., Bettini E., et al., “Lipid Nanoparticles Enhance the Efficacy of mRNA and Protein Subunit Vaccines by Inducing Robust T Follicular Helper Cell and Humoral Responses,” Immunity
54, no. 12 (2021): 2877–2892.e7, 10.1016/j.immuni.2021.11.001.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2021.11.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8566475/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34852217/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Lipid%20Nanoparticles%20Enhance%20the%20Efficacy%20of%20mRNA%20and%20Protein%20Subunit%20Vaccines%20by%20Inducing%20Robust%20T%20Follicular%20Helper%20Cell%20and%20Humoral%20Responses&amp;author=M.%20G.%20Alameh&amp;author=I.%20Tomb%C3%A1cz&amp;author=E.%20Bettini&amp;volume=54&amp;issue=12&amp;publication_year=2021&amp;pages=2877-2892.e7&amp;pmid=34852217&amp;doi=10.1016/j.immuni.2021.11.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0119">
<span class="label">119.</span><cite>
Szebeni J., Storm G., Ljubimova J. Y., et al., “Applying Lessons Learned From Nanomedicines to Understand Rare Hypersensitivity Reactions to mRNA‐Based SARS‐CoV‐2 Vaccines,” Nature Nanotechnology
17, no. 4 (2022): 337–346, 10.1038/s41565-022-01071-x.</cite> [<a href="https://doi.org/10.1038/s41565-022-01071-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35393599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Nanotechnology&amp;title=Applying%20Lessons%20Learned%20From%20Nanomedicines%20to%20Understand%20Rare%20Hypersensitivity%20Reactions%20to%20mRNA%E2%80%90Based%20SARS%E2%80%90CoV%E2%80%902%20Vaccines&amp;author=J.%20Szebeni&amp;author=G.%20Storm&amp;author=J.%20Y.%20Ljubimova&amp;volume=17&amp;issue=4&amp;publication_year=2022&amp;pages=337-346&amp;pmid=35393599&amp;doi=10.1038/s41565-022-01071-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0120">
<span class="label">120.</span><cite>
Risma K. A., Edwards K. M., Hummell D. S., et al., “Potential Mechanisms of Anaphylaxis to COVID‐19 mRNA Vaccines,” Journal of Allergy and Clinical Immunology
147, no. 6 (2021): 2075–2082.e2, 10.1016/j.jaci.2021.04.002.
</cite> [<a href="https://doi.org/10.1016/j.jaci.2021.04.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8056854/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33857566/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Allergy%20and%20Clinical%20Immunology&amp;title=Potential%20Mechanisms%20of%20Anaphylaxis%20to%20COVID%E2%80%9019%20mRNA%20Vaccines&amp;author=K.%20A.%20Risma&amp;author=K.%20M.%20Edwards&amp;author=D.%20S.%20Hummell&amp;volume=147&amp;issue=6&amp;publication_year=2021&amp;pages=2075-2082.e2&amp;pmid=33857566&amp;doi=10.1016/j.jaci.2021.04.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0121">
<span class="label">121.</span><cite>
Center for Disease Control and Prevention (CDC)
, “Coronavirus Disease 2019 (COVID‐19) Vaccine Safety | Vaccine Safety | CDC,” accessed January 30, 2025, <a href="https://www.cdc.gov/vaccine-safety/vaccines/covid-19.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Fsafety%2Fallergic-reaction.html" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.cdc.gov/vaccine‐safety/vaccines/covid‐19.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019‐ncov%2Fvaccines%2Fsafety%2Fallergic‐reaction.html</a>.</cite>
</li>
<li id="jimd70078-bib-0122">
<span class="label">122.</span><cite>
Adams D., Gonzalez‐Duarte A., O'Riordan W. D., et al., “Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis,” New England Journal of Medicine
379, no. 1 (2018): 11–21, 10.1056/nejmoa1716153.
</cite> [<a href="https://doi.org/10.1056/nejmoa1716153" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Patisiran,%20an%20RNAi%20Therapeutic,%20for%20Hereditary%20Transthyretin%20Amyloidosis&amp;author=D.%20Adams&amp;author=A.%20Gonzalez%E2%80%90Duarte&amp;author=W.%20D.%20O'Riordan&amp;volume=379&amp;issue=1&amp;publication_year=2018&amp;pages=11-21&amp;pmid=29972753&amp;doi=10.1056/nejmoa1716153&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0123">
<span class="label">123.</span><cite>
Tenchov R., Sasso J. M., and Zhou Q. A., “PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective,” Bioconjugate Chemistry
34, no. 6 (2023): 941–960, 10.1021/acs.bioconjchem.3c00174.
</cite> [<a href="https://doi.org/10.1021/acs.bioconjchem.3c00174" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10190134/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37162501/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioconjugate%20Chemistry&amp;title=PEGylated%20Lipid%20Nanoparticle%20Formulations:%20Immunological%20Safety%20and%20Efficiency%20Perspective&amp;author=R.%20Tenchov&amp;author=J.%20M.%20Sasso&amp;author=Q.%20A.%20Zhou&amp;volume=34&amp;issue=6&amp;publication_year=2023&amp;pages=941-960&amp;pmid=37162501&amp;doi=10.1021/acs.bioconjchem.3c00174&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0124">
<span class="label">124.</span><cite>“Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer‐BioNTech COVID‐19 Vaccine—United States,” MMWR. Morbidity and Mortality Weekly Report
70, no. 2 (2021): 46–51.
</cite> [<a href="https://doi.org/10.15585/mmwr.mm7002e1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7808711/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33444297/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=MMWR.%20Morbidity%20and%20Mortality%20Weekly%20Report&amp;title=Allergic%20Reactions%20Including%20Anaphylaxis%20After%20Receipt%20of%20the%20First%20Dose%20of%20Pfizer%E2%80%90BioNTech%20COVID%E2%80%9019%20Vaccine%E2%80%94United%20States&amp;volume=70&amp;issue=2&amp;publication_year=2021&amp;pages=46-51&amp;pmid=33444297&amp;doi=10.15585/mmwr.mm7002e1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0125">
<span class="label">125.</span><cite>
Food and Drug Administration (FDA)
, “Highlights of Prescribing Information,” (2018), <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">doi:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf</a>.</cite>
</li>
<li id="jimd70078-bib-0126">
<span class="label">126.</span><cite>
Klimek L., Novak N., Cabanillas B., Jutel M., Bousquet J., and Akdis C. A., “Allergenic Components of the mRNA‐1273 Vaccine for COVID‐19: Possible Involvement of Polyethylene Glycol and IgG‐Mediated Complement Activation,” Allergy European Journal of Allergy and Clinical Immunology
76, no. 11 (2021): 3307–3313, 10.1111/all.14794.
</cite> [<a href="https://doi.org/10.1111/all.14794" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8013891/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33657648/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Allergy%20European%20Journal%20of%20Allergy%20and%20Clinical%20Immunology&amp;title=Allergenic%20Components%20of%20the%20mRNA%E2%80%901273%20Vaccine%20for%20COVID%E2%80%9019:%20Possible%20Involvement%20of%20Polyethylene%20Glycol%20and%20IgG%E2%80%90Mediated%20Complement%20Activation&amp;author=L.%20Klimek&amp;author=N.%20Novak&amp;author=B.%20Cabanillas&amp;author=M.%20Jutel&amp;author=J.%20Bousquet&amp;volume=76&amp;issue=11&amp;publication_year=2021&amp;pages=3307-3313&amp;pmid=33657648&amp;doi=10.1111/all.14794&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0127">
<span class="label">127.</span><cite>
Kozma G. T., Mészáros T., Vashegyi I., et al., “Pseudo‐Anaphylaxis to Polyethylene Glycol (PEG)‐Coated Liposomes: Roles of Anti‐PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions,” ACS Nano
13, no. 8 (2019): 9315–9324, 10.1021/acsnano.9b03942.
</cite> [<a href="https://doi.org/10.1021/acsnano.9b03942" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31348638/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ACS%20Nano&amp;title=Pseudo%E2%80%90Anaphylaxis%20to%20Polyethylene%20Glycol%20(PEG)%E2%80%90Coated%20Liposomes:%20Roles%20of%20Anti%E2%80%90PEG%20IgM%20and%20Complement%20Activation%20in%20a%20Porcine%20Model%20of%20Human%20Infusion%20Reactions&amp;author=G.%20T.%20Kozma&amp;author=T.%20M%C3%A9sz%C3%A1ros&amp;author=I.%20Vashegyi&amp;volume=13&amp;issue=8&amp;publication_year=2019&amp;pages=9315-9324&amp;pmid=31348638&amp;doi=10.1021/acsnano.9b03942&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0128">
<span class="label">128.</span><cite>
Dézsi L., Mészáros T., Kozma G., et al., “A Naturally Hypersensitive Porcine Model May Help Understand the Mechanism of COVID‐19 mRNA Vaccine‐Induced Rare (Pseudo) Allergic Reactions: Complement Activation as a Possible Contributing Factor,” Geroscience
44, no. 2 (2022): 597–618, 10.1007/s11357-021-00495-y.
</cite> [<a href="https://doi.org/10.1007/s11357-021-00495-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8831099/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35146583/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Geroscience&amp;title=A%20Naturally%20Hypersensitive%20Porcine%20Model%20May%20Help%20Understand%20the%20Mechanism%20of%20COVID%E2%80%9019%20mRNA%20Vaccine%E2%80%90Induced%20Rare%20(Pseudo)%20Allergic%20Reactions:%20Complement%20Activation%20as%20a%20Possible%20Contributing%20Factor&amp;author=L.%20D%C3%A9zsi&amp;author=T.%20M%C3%A9sz%C3%A1ros&amp;author=G.%20Kozma&amp;volume=44&amp;issue=2&amp;publication_year=2022&amp;pages=597-618&amp;pmid=35146583&amp;doi=10.1007/s11357-021-00495-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0129">
<span class="label">129.</span><cite>
Au H. K. E., Isalan M., and Mielcarek M., “Gene Therapy Advances: A Meta‐Analysis of AAV Usage in Clinical Settings,” Frontiers in Medicine
8 (2022): 809118, 10.3389/fmed.2021.809118.
</cite> [<a href="https://doi.org/10.3389/fmed.2021.809118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8864161/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35223884/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Medicine&amp;title=Gene%20Therapy%20Advances:%20A%20Meta%E2%80%90Analysis%20of%20AAV%20Usage%20in%20Clinical%20Settings&amp;author=H.%20K.%20E.%20Au&amp;author=M.%20Isalan&amp;author=M.%20Mielcarek&amp;volume=8&amp;publication_year=2022&amp;pages=809118&amp;pmid=35223884&amp;doi=10.3389/fmed.2021.809118&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0130">
<span class="label">130.</span><cite>
Bulcha J. T., Wang Y., Ma H., Tai P. W. L., and Gao G., “Viral Vector Platforms Within the Gene Therapy Landscape,” Signal Transduction and Targeted Therapy
6, no. 1 (2021): 53, 10.1038/s41392-021-00487-6.
</cite> [<a href="https://doi.org/10.1038/s41392-021-00487-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7868676/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33558455/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Signal%20Transduction%20and%20Targeted%20Therapy&amp;title=Viral%20Vector%20Platforms%20Within%20the%20Gene%20Therapy%20Landscape&amp;author=J.%20T.%20Bulcha&amp;author=Y.%20Wang&amp;author=H.%20Ma&amp;author=P.%20W.%20L.%20Tai&amp;author=G.%20Gao&amp;volume=6&amp;issue=1&amp;publication_year=2021&amp;pages=53&amp;pmid=33558455&amp;doi=10.1038/s41392-021-00487-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0131">
<span class="label">131.</span><cite>
Counsell J. R., Asgarian Z., Meng J., et al., “Erratum: Lentiviral Vectors Can Be Used for Full‐Length Dystrophin Gene Therapy,” Scientific Reports
7 (2017): 46880, 10.1038/srep46880.
</cite> [<a href="https://doi.org/10.1038/srep46880" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7365309/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28849794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scientific%20Reports&amp;title=Erratum:%20Lentiviral%20Vectors%20Can%20Be%20Used%20for%20Full%E2%80%90Length%20Dystrophin%20Gene%20Therapy&amp;author=J.%20R.%20Counsell&amp;author=Z.%20Asgarian&amp;author=J.%20Meng&amp;volume=7&amp;publication_year=2017&amp;pages=46880&amp;pmid=28849794&amp;doi=10.1038/srep46880&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0132">
<span class="label">132.</span><cite>
Han S., Ronzitti G., Arnson B., et al., “Low‐Dose Liver‐Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction,” Molecular Therapy ‐ Methods &amp; Clinical Development
4 (2017): 126–136, 10.1016/j.omtm.2016.12.010.
</cite> [<a href="https://doi.org/10.1016/j.omtm.2016.12.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5363303/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28344998/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy%20%E2%80%90%20Methods%20&amp;%20Clinical%20Development&amp;title=Low%E2%80%90Dose%20Liver%E2%80%90Targeted%20Gene%20Therapy%20for%20Pompe%20Disease%20Enhances%20Therapeutic%20Efficacy%20of%20ERT%20via%20Immune%20Tolerance%20Induction&amp;author=S.%20Han&amp;author=G.%20Ronzitti&amp;author=B.%20Arnson&amp;volume=4&amp;publication_year=2017&amp;pages=126-136&amp;pmid=28344998&amp;doi=10.1016/j.omtm.2016.12.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0133">
<span class="label">133.</span><cite>
Vavilis T., Stamoula E., Ainatzoglou A., et al., “mRNA in the Context of Protein Replacement Therapy,” Pharmaceutics
15, no. 1 (2023): 166, 10.3390/pharmaceutics15010166.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics15010166" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9866414/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36678793/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceutics&amp;title=mRNA%20in%20the%20Context%20of%20Protein%20Replacement%20Therapy&amp;author=T.%20Vavilis&amp;author=E.%20Stamoula&amp;author=A.%20Ainatzoglou&amp;volume=15&amp;issue=1&amp;publication_year=2023&amp;pages=166&amp;pmid=36678793&amp;doi=10.3390/pharmaceutics15010166&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0134">
<span class="label">134.</span><cite>
Schaible P., “Modifying Enzyme Replacement Therapy – A Perspective,” Journal of Cellular and Molecular Medicine
27, no. 2 (2023): 165–173, 10.1111/jcmm.17653.
</cite> [<a href="https://doi.org/10.1111/jcmm.17653" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9843529/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36566487/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Cellular%20and%20Molecular%20Medicine&amp;title=Modifying%20Enzyme%20Replacement%20Therapy%20%E2%80%93%20A%20Perspective&amp;author=P.%20Schaible&amp;volume=27&amp;issue=2&amp;publication_year=2023&amp;pages=165-173&amp;pmid=36566487&amp;doi=10.1111/jcmm.17653&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0135">
<span class="label">135.</span><cite>
Wong C. H., Li D., Wang N., Gruber J., Lo A. W., and Conti R. M., “The Estimated Annual Financial Impact of Gene Therapy in the United States,” Gene Therapy
30, no. 10‐11 (2023): 761–773, 10.1038/s41434-023-00419-9.
</cite> [<a href="https://doi.org/10.1038/s41434-023-00419-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10678302/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37935855/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gene%20Therapy&amp;title=The%20Estimated%20Annual%20Financial%20Impact%20of%20Gene%20Therapy%20in%20the%20United%20States&amp;author=C.%20H.%20Wong&amp;author=D.%20Li&amp;author=N.%20Wang&amp;author=J.%20Gruber&amp;author=A.%20W.%20Lo&amp;volume=30&amp;issue=10%E2%80%9011&amp;publication_year=2023&amp;pages=761-773&amp;pmid=37935855&amp;doi=10.1038/s41434-023-00419-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0136">
<span class="label">136.</span><cite>
Bretos‐Azcona P. E., Wallace M., Jootun M., Jin G., Agirrezabal I., and Szende A., “An Early Cost‐Utility Model of mRNA‐Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom,” Clinical Drug Investigation
44, no. 6 (2024): 399–412, 10.1007/s40261-024-01363-1.
</cite> [<a href="https://doi.org/10.1007/s40261-024-01363-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38796677/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Drug%20Investigation&amp;title=An%20Early%20Cost%E2%80%90Utility%20Model%20of%20mRNA%E2%80%90Based%20Therapies%20for%20the%20Treatment%20of%20Methylmalonic%20and%20Propionic%20Acidemia%20in%20the%20United%20Kingdom&amp;author=P.%20E.%20Bretos%E2%80%90Azcona&amp;author=M.%20Wallace&amp;author=M.%20Jootun&amp;author=G.%20Jin&amp;author=I.%20Agirrezabal&amp;volume=44&amp;issue=6&amp;publication_year=2024&amp;pages=399-412&amp;pmid=38796677&amp;doi=10.1007/s40261-024-01363-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0137">
<span class="label">137.</span><cite>
Parenti G., Andria G., and Ballabio A., “Lysosomal Storage Diseases: From Pathophysiology to Therapy,” Annual Review of Medicine
66 (2015): 471–486, 10.1146/annurev-med-122313-085916.</cite> [<a href="https://doi.org/10.1146/annurev-med-122313-085916" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25587658/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annual%20Review%20of%20Medicine&amp;title=Lysosomal%20Storage%20Diseases:%20From%20Pathophysiology%20to%20Therapy&amp;author=G.%20Parenti&amp;author=G.%20Andria&amp;author=A.%20Ballabio&amp;volume=66&amp;publication_year=2015&amp;pages=471-486&amp;pmid=25587658&amp;doi=10.1146/annurev-med-122313-085916&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0138">
<span class="label">138.</span><cite>
Webb C., Ip S., Bathula N. V., et al., “Current Status and Future Perspectives on MRNA Drug Manufacturing,” Molecular Pharmaceutics
19, no. 4 (2022): 1047–1058, 10.1021/acs.molpharmaceut.2c00010.
</cite> [<a href="https://doi.org/10.1021/acs.molpharmaceut.2c00010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35238565/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Pharmaceutics&amp;title=Current%20Status%20and%20Future%20Perspectives%20on%20MRNA%20Drug%20Manufacturing&amp;author=C.%20Webb&amp;author=S.%20Ip&amp;author=N.%20V.%20Bathula&amp;volume=19&amp;issue=4&amp;publication_year=2022&amp;pages=1047-1058&amp;pmid=35238565&amp;doi=10.1021/acs.molpharmaceut.2c00010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0139">
<span class="label">139.</span><cite>
Kido J., Makris G., Santra S., and Häberle J., “Clinical Landscape of Citrin Deficiency: A Global Perspective on a Multifaceted Condition,” Journal of Inherited Metabolic Disease
47, no. 6 (2024): 1144–1156, 10.1002/jimd.12722.
</cite> [<a href="https://doi.org/10.1002/jimd.12722" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11586594/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38503330/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Inherited%20Metabolic%20Disease&amp;title=Clinical%20Landscape%20of%20Citrin%20Deficiency:%20A%20Global%20Perspective%20on%20a%20Multifaceted%20Condition&amp;author=J.%20Kido&amp;author=G.%20Makris&amp;author=S.%20Santra&amp;author=J.%20H%C3%A4berle&amp;volume=47&amp;issue=6&amp;publication_year=2024&amp;pages=1144-1156&amp;pmid=38503330&amp;doi=10.1002/jimd.12722&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0140">
<span class="label">140.</span><cite>
Hayasaka K. and Numakura C., “Adult‐Onset Type II Citrullinemia: Current Insights and Therapy,” Application of Clinical Genetics
11 (2018): 163–170, 10.2147/TACG.S162084.
</cite> [<a href="https://doi.org/10.2147/TACG.S162084" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6296197/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30588060/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Application%20of%20Clinical%20Genetics&amp;title=Adult%E2%80%90Onset%20Type%20II%20Citrullinemia:%20Current%20Insights%20and%20Therapy&amp;author=K.%20Hayasaka&amp;author=C.%20Numakura&amp;volume=11&amp;publication_year=2018&amp;pages=163-170&amp;pmid=30588060&amp;doi=10.2147/TACG.S162084&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0141">
<span class="label">141.</span><cite>
Zakas P. M., Cunningham S. C., Doherty A., et al., “Sleeping Beauty mRNA‐LNP Enables Stable rAAV Transgene Expression in Mouse and NHP Hepatocytes and Improves Vector Potency,” Molecular Therapy
2 (2024): 3356–3371, 10.1016/j.ymthe.2024.06.021.</cite> [<a href="https://doi.org/10.1016/j.ymthe.2024.06.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11489535/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38981468/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Therapy&amp;title=Sleeping%20Beauty%20mRNA%E2%80%90LNP%20Enables%20Stable%20rAAV%20Transgene%20Expression%20in%20Mouse%20and%20NHP%20Hepatocytes%20and%20Improves%20Vector%20Potency&amp;author=P.%20M.%20Zakas&amp;author=S.%20C.%20Cunningham&amp;author=A.%20Doherty&amp;volume=2&amp;publication_year=2024&amp;pages=3356-3371&amp;pmid=38981468&amp;doi=10.1016/j.ymthe.2024.06.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0142">
<span class="label">142.</span><cite>
Jalil S., Keskinen T., Juutila J., et al., “Genetic and Functional Correction of Argininosuccinate Lyase Deficiency Using CRISPR Adenine Base Editors,” American Journal of Human Genetics
111, no. 4 (2024): 714–728, 10.1016/j.ajhg.2024.03.004.
</cite> [<a href="https://doi.org/10.1016/j.ajhg.2024.03.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11023919/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38579669/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Human%20Genetics&amp;title=Genetic%20and%20Functional%20Correction%20of%20Argininosuccinate%20Lyase%20Deficiency%20Using%20CRISPR%20Adenine%20Base%20Editors&amp;author=S.%20Jalil&amp;author=T.%20Keskinen&amp;author=J.%20Juutila&amp;volume=111&amp;issue=4&amp;publication_year=2024&amp;pages=714-728&amp;pmid=38579669&amp;doi=10.1016/j.ajhg.2024.03.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0143">
<span class="label">143.</span><cite>
Musunuru K., Grandinette S. A., Wang X., et al., “Patient‐Specific In Vivo Gene Editing to Treat a Rare Genetic Disease,” New England Journal of Medicine
15 (2025): 2235–2243, 10.1056/NEJMoa2504747.</cite> [<a href="https://doi.org/10.1056/NEJMoa2504747" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40373211/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Patient%E2%80%90Specific%20In%C2%A0Vivo%20Gene%20Editing%20to%20Treat%20a%20Rare%20Genetic%20Disease&amp;author=K.%20Musunuru&amp;author=S.%20A.%20Grandinette&amp;author=X.%20Wang&amp;volume=15&amp;publication_year=2025&amp;pages=2235-2243&amp;pmid=40373211&amp;doi=10.1056/NEJMoa2504747&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0144">
<span class="label">144.</span><cite>
Rothgangl T., Ioannidi E. I., Weber Y., et al., “Treatment of a Genetic Liver Disease in Mice Through Transient Prime Expression,” bioRxiv, (2024), 575834, 10.1101/2024.01.22.575834.</cite> [<a href="https://doi.org/10.1101/2024.01.22.575834" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>]</li>
<li id="jimd70078-bib-0145">
<span class="label">145.</span><cite>
Qiu M., Tang Y., Chen J., et al., “Lung‐Selective mRNA Delivery of Synthetic Lipid Nanoparticles for the Treatment of Pulmonary Lymphangioleiomyomatosis,” Proceedings of the National Academy of Sciences of the United States of America
119, no. 8 (2022): e2116271119, 10.1073/pnas.2116271119.
</cite> [<a href="https://doi.org/10.1073/pnas.2116271119" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8872770/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35173043/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20of%20the%20United%20States%20of%20America&amp;title=Lung%E2%80%90Selective%20mRNA%20Delivery%20of%20Synthetic%20Lipid%20Nanoparticles%20for%20the%20Treatment%20of%20Pulmonary%20Lymphangioleiomyomatosis&amp;author=M.%20Qiu&amp;author=Y.%20Tang&amp;author=J.%20Chen&amp;volume=119&amp;issue=8&amp;publication_year=2022&amp;pages=e2116271119&amp;pmid=35173043&amp;doi=10.1073/pnas.2116271119&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0146">
<span class="label">146.</span><cite>
Żak M. M., Kaur K., Yoo J., et al., “Modified mRNA Formulation and Stability for Cardiac and Skeletal Muscle Delivery,” Pharmaceutics
15, no. 9 (2023): 2176, 10.3390/pharmaceutics15092176.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics15092176" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10535735/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37765147/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceutics&amp;title=Modified%20mRNA%20Formulation%20and%20Stability%20for%20Cardiac%20and%20Skeletal%20Muscle%20Delivery&amp;author=M.%20M.%20%C5%BBak&amp;author=K.%20Kaur&amp;author=J.%20Yoo&amp;volume=15&amp;issue=9&amp;publication_year=2023&amp;pages=2176&amp;pmid=37765147&amp;doi=10.3390/pharmaceutics15092176&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0147">
<span class="label">147.</span><cite>
Breda L., Papp T. E., Triebwasser M. P., et al., “In Vivo Hematopoietic Stem Cell Modification by mRNA Delivery,” Science (1979)
381, no. 6656 (2023): 436–443, 10.1126/science.ade6967.</cite> [<a href="https://doi.org/10.1126/science.ade6967" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10567133/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37499029/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science%20(1979)&amp;title=In%20Vivo%20Hematopoietic%20Stem%20Cell%20Modification%20by%20mRNA%20Delivery&amp;author=L.%20Breda&amp;author=T.%20E.%20Papp&amp;author=M.%20P.%20Triebwasser&amp;volume=381&amp;issue=6656&amp;publication_year=2023&amp;pages=436-443&amp;pmid=37499029&amp;doi=10.1126/science.ade6967&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0148">
<span class="label">148.</span><cite>
Kenjo E., Hozumi H., Makita Y., et al., “Low Immunogenicity of LNP Allows Repeated Administrations of CRISPR‐Cas9 mRNA Into Skeletal Muscle in Mice,” Nature Communications
12, no. 1 (2021): 7101, 10.1038/s41467-021-26714-w.</cite> [<a href="https://doi.org/10.1038/s41467-021-26714-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8654819/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34880218/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Low%20Immunogenicity%20of%20LNP%20Allows%20Repeated%20Administrations%20of%20CRISPR%E2%80%90Cas9%20mRNA%20Into%20Skeletal%20Muscle%20in%20Mice&amp;author=E.%20Kenjo&amp;author=H.%20Hozumi&amp;author=Y.%20Makita&amp;volume=12&amp;issue=1&amp;publication_year=2021&amp;pages=7101&amp;pmid=34880218&amp;doi=10.1038/s41467-021-26714-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0149">
<span class="label">149.</span><cite>
Melamed J. R., Yerneni S. S., Arral M. L., et al., “Ionizable Lipid Nanoparticles Deliver mRNA to Pancreatic β Cells via Macrophage‐Mediated Gene Transfer,” Science Advances
9, no. 4 (2023): eade1444, 10.1126/sciadv.ade1444.
</cite> [<a href="https://doi.org/10.1126/sciadv.ade1444" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9882987/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36706177/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science%20Advances&amp;title=Ionizable%20Lipid%20Nanoparticles%20Deliver%20mRNA%20to%20Pancreatic%20%CE%B2%20Cells%20via%20Macrophage%E2%80%90Mediated%20Gene%20Transfer&amp;author=J.%20R.%20Melamed&amp;author=S.%20S.%20Yerneni&amp;author=M.%20L.%20Arral&amp;volume=9&amp;issue=4&amp;publication_year=2023&amp;pages=eade1444&amp;pmid=36706177&amp;doi=10.1126/sciadv.ade1444&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0150">
<span class="label">150.</span><cite>
Schachner‐Nedherer A. L., Fuchs J., Vidakovic I., et al., “Lipid Nanoparticles as a Shuttle for Anti‐Adipogenic miRNAs to Human Adipocytes,” Pharmaceutics
15, no. 7 (2023): 1983, 10.3390/pharmaceutics15071983.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics15071983" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10384627/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37514169/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceutics&amp;title=Lipid%20Nanoparticles%20as%20a%20Shuttle%20for%20Anti%E2%80%90Adipogenic%20miRNAs%20to%20Human%20Adipocytes&amp;author=A.%20L.%20Schachner%E2%80%90Nedherer&amp;author=J.%20Fuchs&amp;author=I.%20Vidakovic&amp;volume=15&amp;issue=7&amp;publication_year=2023&amp;pages=1983&amp;pmid=37514169&amp;doi=10.3390/pharmaceutics15071983&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0151">
<span class="label">151.</span><cite>
Swingle K. L., Safford H. C., Geisler H. C., et al., “Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta During Pregnancy,” Journal of the American Chemical Society
145, no. 8 (2023): 4691–4706, 10.1021/jacs.2c12893.
</cite> [<a href="https://doi.org/10.1021/jacs.2c12893" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9992266/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36789893/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20the%20American%20Chemical%20Society&amp;title=Ionizable%20Lipid%20Nanoparticles%20for%20In%C2%A0Vivo%20mRNA%20Delivery%20to%20the%20Placenta%20During%20Pregnancy&amp;author=K.%20L.%20Swingle&amp;author=H.%20C.%20Safford&amp;author=H.%20C.%20Geisler&amp;volume=145&amp;issue=8&amp;publication_year=2023&amp;pages=4691-4706&amp;pmid=36789893&amp;doi=10.1021/jacs.2c12893&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0152">
<span class="label">152.</span><cite>
Kim M., Jeong M., Hur S., et al., “Engineered Ionizable Lipid Nanoparticles for Targeted Delivery of RNA Therapeutics Into Different Types of Cells in the Liver,” Science Advances
7, no. 9 (2021): eabf4398, 10.1126/sciadv.abf4398.
</cite> [<a href="https://doi.org/10.1126/sciadv.abf4398" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7909888/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33637537/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science%20Advances&amp;title=Engineered%20Ionizable%20Lipid%20Nanoparticles%20for%20Targeted%20Delivery%20of%20RNA%20Therapeutics%20Into%20Different%20Types%20of%20Cells%20in%20the%20Liver&amp;author=M.%20Kim&amp;author=M.%20Jeong&amp;author=S.%20Hur&amp;volume=7&amp;issue=9&amp;publication_year=2021&amp;pages=eabf4398&amp;pmid=33637537&amp;doi=10.1126/sciadv.abf4398&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0153">
<span class="label">153.</span><cite>
Palanki R., Riley J. S., Bose S. K., et al., “In Utero Delivery of Targeted Ionizable Lipid Nanoparticles Facilitates In Vivo Gene Editing of Hematopoietic Stem Cells,” Proceedings of the National Academy of Sciences of the United States of America
121, no. 32 (2024): e2400783121, 10.1073/pnas.2400783121.
</cite> [<a href="https://doi.org/10.1073/pnas.2400783121" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11317576/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39078677/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20of%20the%20United%20States%20of%20America&amp;title=In%20Utero%20Delivery%20of%20Targeted%20Ionizable%20Lipid%20Nanoparticles%20Facilitates%20In%C2%A0Vivo%20Gene%20Editing%20of%20Hematopoietic%20Stem%20Cells&amp;author=R.%20Palanki&amp;author=J.%20S.%20Riley&amp;author=S.%20K.%20Bose&amp;volume=121&amp;issue=32&amp;publication_year=2024&amp;pages=e2400783121&amp;pmid=39078677&amp;doi=10.1073/pnas.2400783121&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0154">
<span class="label">154.</span><cite>
Ruan W., Jiao M., Xu S., et al., “Brain‐Targeted CRISPR/Cas9 Nanomedicine for Effective Glioblastoma Therapy,” Journal of Controlled Release
351 (2022): 739–751, 10.1016/j.jconrel.2022.09.046.
</cite> [<a href="https://doi.org/10.1016/j.jconrel.2022.09.046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36174804/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Controlled%20Release&amp;title=Brain%E2%80%90Targeted%20CRISPR/Cas9%20Nanomedicine%20for%20Effective%20Glioblastoma%20Therapy&amp;author=W.%20Ruan&amp;author=M.%20Jiao&amp;author=S.%20Xu&amp;volume=351&amp;publication_year=2022&amp;pages=739-751&amp;pmid=36174804&amp;doi=10.1016/j.jconrel.2022.09.046&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0155">
<span class="label">155.</span><cite>
Johnsen K. B., Burkhart A., Thomsen L. B., Andresen T. L., and Moos T., “Targeting the Transferrin Receptor for Brain Drug Delivery,” Progress in Neurobiology
181 (2019): 101665, 10.1016/j.pneurobio.2019.101665.
</cite> [<a href="https://doi.org/10.1016/j.pneurobio.2019.101665" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31376426/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Progress%20in%20Neurobiology&amp;title=Targeting%20the%20Transferrin%20Receptor%20for%20Brain%20Drug%20Delivery&amp;author=K.%20B.%20Johnsen&amp;author=A.%20Burkhart&amp;author=L.%20B.%20Thomsen&amp;author=T.%20L.%20Andresen&amp;author=T.%20Moos&amp;volume=181&amp;publication_year=2019&amp;pages=101665&amp;pmid=31376426&amp;doi=10.1016/j.pneurobio.2019.101665&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0156">
<span class="label">156.</span><cite>
Won Y. W., Adhikary P. P., Lim K. S., Kim H. J., Kim J. K., and Kim Y. H., “Oligopeptide Complex for Targeted Non‐Viral Gene Delivery to Adipocytes,” Nature Materials
13, no. 12 (2014): 1157–1164, 10.1038/nmat4092.
</cite> [<a href="https://doi.org/10.1038/nmat4092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25282508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Materials&amp;title=Oligopeptide%20Complex%20for%20Targeted%20Non%E2%80%90Viral%20Gene%20Delivery%20to%20Adipocytes&amp;author=Y.%20W.%20Won&amp;author=P.%20P.%20Adhikary&amp;author=K.%20S.%20Lim&amp;author=H.%20J.%20Kim&amp;author=J.%20K.%20Kim&amp;volume=13&amp;issue=12&amp;publication_year=2014&amp;pages=1157-1164&amp;pmid=25282508&amp;doi=10.1038/nmat4092&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0157">
<span class="label">157.</span><cite>
Zhang B., Chen Z., Han J., Li M., Nayak N. R., and Fan X., “Comprehensive Evaluation of the Effectiveness and Safety of Placenta‐Targeted Drug Delivery Using Three Complementary Methods,” Journal of Visualized Experiments
2018, no. 139 (2018): 58219, 10.3791/58219.</cite> [<a href="https://doi.org/10.3791/58219" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6235115/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30247484/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Visualized%20Experiments&amp;title=Comprehensive%20Evaluation%20of%20the%20Effectiveness%20and%20Safety%20of%20Placenta%E2%80%90Targeted%20Drug%20Delivery%20Using%20Three%20Complementary%20Methods&amp;author=B.%20Zhang&amp;author=Z.%20Chen&amp;author=J.%20Han&amp;author=M.%20Li&amp;author=N.%20R.%20Nayak&amp;volume=2018&amp;issue=139&amp;publication_year=2018&amp;pages=58219&amp;pmid=30247484&amp;doi=10.3791/58219&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0158">
<span class="label">158.</span><cite>
Dilliard S. A., Cheng Q., and Siegwart D. J., “On the Mechanism of Tissue‐Specific mRNA Delivery by Selective Organ Targeting Nanoparticles,” Proceedings of the National Academy of Sciences of the United States of America
118, no. 52 (2021): e2109256118, 10.1073/pnas.2109256118.
</cite> [<a href="https://doi.org/10.1073/pnas.2109256118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8719871/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34933999/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20of%20the%20United%20States%20of%20America&amp;title=On%20the%20Mechanism%20of%20Tissue%E2%80%90Specific%20mRNA%20Delivery%20by%20Selective%20Organ%20Targeting%20Nanoparticles&amp;author=S.%20A.%20Dilliard&amp;author=Q.%20Cheng&amp;author=D.%20J.%20Siegwart&amp;volume=118&amp;issue=52&amp;publication_year=2021&amp;pages=e2109256118&amp;pmid=34933999&amp;doi=10.1073/pnas.2109256118&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0159">
<span class="label">159.</span><cite>
Li Q., Chan C., Peterson N., et al., “Engineering Caveolae‐Targeted Lipid Nanoparticles to Deliver mRNA to the Lungs,” ACS Chemical Biology
15, no. 4 (2020): 830–836, 10.1021/acschembio.0c00003.
</cite> [<a href="https://doi.org/10.1021/acschembio.0c00003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32155049/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ACS%20Chemical%20Biology&amp;title=Engineering%20Caveolae%E2%80%90Targeted%20Lipid%20Nanoparticles%20to%20Deliver%20mRNA%20to%20the%20Lungs&amp;author=Q.%20Li&amp;author=C.%20Chan&amp;author=N.%20Peterson&amp;volume=15&amp;issue=4&amp;publication_year=2020&amp;pages=830-836&amp;pmid=32155049&amp;doi=10.1021/acschembio.0c00003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0160">
<span class="label">160.</span><cite>
Gao K., Li J., Song H., et al., “In Utero Delivery of mRNA to the Heart, Diaphragm and Muscle With Lipid Nanoparticles,” Bioactive Materials
25 (2023): 387–398, 10.1016/j.bioactmat.2023.02.011.
</cite> [<a href="https://doi.org/10.1016/j.bioactmat.2023.02.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9950423/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36844366/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioactive%20Materials&amp;title=In%20Utero%20Delivery%20of%20mRNA%20to%20the%20Heart,%20Diaphragm%20and%20Muscle%20With%20Lipid%20Nanoparticles&amp;author=K.%20Gao&amp;author=J.%20Li&amp;author=H.%20Song&amp;volume=25&amp;publication_year=2023&amp;pages=387-398&amp;pmid=36844366&amp;doi=10.1016/j.bioactmat.2023.02.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0161">
<span class="label">161.</span><cite>
Isaac I., Patel L., Tran N., et al., “Reengineering mRNA Lipid Nanoparticles for Systemic Delivery to Pancreas,” bioRxiv, (2024), 10.1101/2024.10.30.621163.</cite> [<a href="https://doi.org/10.1101/2024.10.30.621163" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>]</li>
<li id="jimd70078-bib-0162">
<span class="label">162.</span><cite>
Kularatne R. N., Crist R. M., and Stern S. T., “The Future of Tissue‐Targeted Lipid Nanoparticle‐Mediated Nucleic Acid Delivery,” Pharmaceuticals
15, no. 7 (2022): 897, 10.3390/ph15070897.
</cite> [<a href="https://doi.org/10.3390/ph15070897" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9322927/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35890195/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceuticals&amp;title=The%20Future%20of%20Tissue%E2%80%90Targeted%20Lipid%20Nanoparticle%E2%80%90Mediated%20Nucleic%20Acid%20Delivery&amp;author=R.%20N.%20Kularatne&amp;author=R.%20M.%20Crist&amp;author=S.%20T.%20Stern&amp;volume=15&amp;issue=7&amp;publication_year=2022&amp;pages=897&amp;pmid=35890195&amp;doi=10.3390/ph15070897&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jimd70078-bib-0163">
<span class="label">163.</span><cite>
Saunders N. R. M., Paolini M. S., Fenton O. S., et al., “A Nanoprimer to Improve the Systemic Delivery of siRNA and mRNA,” Nano Letters
20, no. 6 (2020): 4264–4269, 10.1021/acs.nanolett.0c00752.
</cite> [<a href="https://doi.org/10.1021/acs.nanolett.0c00752" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32357299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nano%20Letters&amp;title=A%20Nanoprimer%20to%20Improve%20the%20Systemic%20Delivery%20of%20siRNA%20and%20mRNA&amp;author=N.%20R.%20M.%20Saunders&amp;author=M.%20S.%20Paolini&amp;author=O.%20S.%20Fenton&amp;volume=20&amp;issue=6&amp;publication_year=2020&amp;pages=4264-4269&amp;pmid=32357299&amp;doi=10.1021/acs.nanolett.0c00752&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Inherited Metabolic Disease are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/jimd.70078"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/JIMD-48-0.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12361847/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12361847/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12361847%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361847/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12361847/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12361847/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40826824/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12361847/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40826824/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12361847/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12361847/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="dWsJPxRDYRY3qkhGHZZwBGlYna19uCtjHn7vHusHMlImMAjh56C3hUEeJkd44VbO">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
